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Aim and general outline
1
Melanin, a pigment that colors the skin, hair, and iris, is produced by specialized cells 
called melanocytes. These melanocytes are derived from the neural crest (1). During 
embryonic development they colonize the skin, the uveal tract of the eye and, to a 
lesser extent, multiple other tissues throughout the body such as the meninges and 
the anogenital tract (2). Melanocytes at these different sites can give rise to different 
types of neoplasms, which can be benign (melanocytic nevi, melanocytomas) or 
malignant (melanomas) (3-7). Cutaneous melanoma is the most common malignant 
melanocytic tumor (~95%), while mucosal melanoma, uveal melanoma (UM), and 
primary melanoma of the central nervous system account for approximately 1.3%, 
3% and 1% of all melanoma cases respectively (8-10). 
While the molecular underpinnings of the most frequent cutaneous melanocytic 
neoplasms (melanomas, melanocytic nevi) have been extensively studied, elucidation 
of the molecular pathogenesis of the more rare melanocytic tumors is lagging behind. 
The aim of the research described in this thesis was to reduce this knowledge gap, in 
order to facilitate the diagnosis and to discover potential therapeutic targets in these 
less frequent melanocytic neoplasms. 
The review on the molecular pathology in melanocytic tumors we present in chapter 2 
serves as an introduction to the rest of the thesis. The first part of this review focuses 
on the three subgroups of spitzoid melanocytic tumors and their specific phenotypical 
and genetic characteristics: the HRAS-mutated spitzoid tumors, the melanocytic 
BAP1-associated intradermal tumors (MBAITs), and the spitzoid lesions with genomic 
rearrangements involving kinases. Subsequently, the molecular background of 
congenital melanocytic nevi and neurocutaneous melanosis is described. Melanomas 
from different origin have been shown to contain different mutation types and 
mutation frequencies, which can be of aid in the differential diagnosis of a melanoma 
or a melanoma metastasis. The last part of the review focuses on targeted therapy for 
metastatic melanoma.
The HRAS-mutated spitzoid tumors are described in chapter 3. This type of spitzoid 
tumors is characterized by a typical phenotype. They are predominantly located in 
the dermis, have a wedged shape, relatively low cellularity, show desmoplasia and 
have an infiltrating base. Recognition of this subgroup is important since they have a 
favorable prognosis and can be easily overdiagnosed as a melanoma. 
The results of whole genome copy-number analysis of twenty-five UMs as well as 
mutation and MLPA analysis of these tumors are described in chapter 4. Our findings 
point to both genetic changes that may play a role in the initiation of UM, as well as to 
chromosomal areas that may indicate metastatic behavior.
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Mutation analysis of twenty primary leptomeningeal melanocytic neoplasms (LMNs) 
showed that these harbor oncogenic mutations in GNAQ and GNA11 as is presented 
in chapter 5. This knowledge can be of help in the differential diagnosis between 
a primary LMN and a metastasis to the central nervous system of a cutaneous 
melanoma, which has implications for treatment and prognosis. Based on the 
presence of GNAQ and GNA11 mutations in both LMNs as well as in uveal melanomas 
(UMs), we also hypothesized that they might share gross chromosomal aberrations. 
The LMNs were tested for copy number aberrations frequently present in UMs by 
multiplex ligation-dependent probe amplification (MLPA) and OncoScan analysis. 
We demonstrate how GNAQ mutation analysis can also be of aid in the histological 
challenging differential diagnosis of melanotic schwannoma with LMNs in chapter 6. 
GNAQ mutations were highly specific for LMNs compared to melanotic schwannoma. 
Correct diagnosis of the latter is important to identify those patients who need further 
evaluation for possible underlying Carney Complex (an autosomal dominant syndrome 
associated with spotty pigmentation of the skin, endocrinopathy, and endocrine and 
non endocrine tumors (for example myxomas of the heart)). 
Chapter 7 describes whole genome copy-number variation analysis as well as mutation 
analysis in five central nervous system melanocytic tumors and three congenital 
melanocytic nevi of five patients with the rare syndrome of neurocutaneous melanosis. 
The findings might have implications for diagnosis, prognosis, and therapy.
In chapter 8, mutation analysis in a series of twenty-four female urogenital tract 
melanomas is presented. Our finding that NRAS mutations were more prevalent than 
KIT mutations has potential implications for therapy in the advanced setting.
A summary, general conclusions, and future perspectives related to the work described 
in this thesis are provided in chapter 9. 
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Chapter 2
ABSTRACT
In this article we give an update on recent findings regarding molecular pathology in 
cutaneous melanocytic tumours. 
The focus lies on use of genetics in the diagnosis of distinct subtypes of spitzoid 
tumours that are often characterized by specific phenotypic-genotypic alterations 
that can frequently be recognized by adequate histological examination. Typical 
illustrating cases are given in order to increase recognition of these lesions in daily 
dermatopathology practice. New molecular findings in the pathogenesis of congenital 
melanocytic tumours and neurocutaneous melanosis are reviewed. In addition use of 
mutation analysis in the differential diagnosis of melanoma metastasis is discussed. 
Finally application of mutation analysis in targeted therapy in advanced melanoma 
with advantages of new techniques such as next generation sequencing is described.
17
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INTRODUCTION
During the past 20 years, there has been a rapid development of molecular techniques 
increasing the possibilities of genetic testing in all kinds of tumors including melanocytic 
tumors. This has led to a rapid gain in our knowledge on the development of melanocytic 
tumors, which can help in diagnosis, prognosis, and treatment of melanocytic tumors. 
In 2010, we wrote a review on the molecular pathology of these tumors (1). Since 
developments in the field are fast, we will address in this paper relevant new findings 
from the recent years within the field of molecular pathology in melanocytic lesions. 
The first part has a focus on new findings with respect to diagnosis and pathogenesis. 
The focus will be on new molecular findings in spitzoid tumors, in congenital melanocytic 
nevi (CMN) and neurocutaneous melanocytosis, and the use of molecular tests in the 
(differential) diagnosis of melanoma. 
The second part will will be devoted to application of molecular pathology in the 
treatment of melanoma, and will briefly address new technological developments 
such as next generation sequencing (NGS) techniques in this setting.
PART 1.  MOLECULAR PATHOLOGY IN THE DIAGNOSIS AND 
PATHOGENESIS OF MELANOCYTIC TUMOURS
Early events in the development of melanocytic tumours are often hotspot mutations 
in genes involved in the MAPK pathway, which is one of the most important pathways 
involved in melanocytic tumor development (Figure 1). Important oncogenes in this 
pathway are BRAF (7q34), NRAS (1p13), HRAS (11p15), GNAQ (9p21), GNA11 (19p13), 
and KIT (4q12) (2-5). Mutations in these genes are mostly mutually exclusive, by themselves 
do not cause malignant progression, stay present with malignant progression, and activate 
the MAPK pathway. Different subtypes of benign and malignant melanocytic tumours 
are characterized by different mutations in these genes of the MAPK pathway.
In common nevi for instance, BRAF and NRAS mutations are present in 60-87.5% (6, 
7) and 20%, respectively. In large congenital nevi upto 80% NRAS mutations are 
reported (7, 8). In blue nevi, mainly GNAQ (83%) and GNA11 (7%) mutations are found 
(9), and in Spitz nevi HRAS mutations are reported in 20-29% (7, 10). 
Especially in Spitz tumors several new data indicate that these tumors are genetically 
more diverse than was previously thought. We will discuss these new findings below 
in part 1, together with new insights in the pathogenesis of CMN and the rare disease 
of neurocutaneous melanocytosis. We will also address the role of molecular pathology 
in the differential diagnosis of (metastatic) melanoma.
The distinct mutations in different melanoma types will be discussed later in part 2 
(see also Table 1).
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1.1. What is new in spitzoid melanocytic tumors?
At present roughly three subgroups of spitzoid melanocytic tumors can be identified 
based on distinct genetic alterations. The first one is the group of the HRAS-mutated 
spitzoid tumors (11). The second group is the one of the BAP1-mutated “spitzoid lesions” 
(12, 13), and the third group consists of spitzoid tumors with kinase fusion (14).
The first two groups seem to be characterized mostly by a typical phenotype that can 
be recognized or at least suspected upon histological evaluation. 
Most of the HRAS-mutated spitzoid tumors are typically wedge shaped, dermal-based 
lesions, with an infiltrative margin, consisting of mostly spindle shaped cells, and 
showing marked desmoplasia (11, 15). This group is relevant to discriminate because 
of the favorable prognosis and to prevent melanoma overdiagnosis.
Figure 1 This figure depicts two important pathways involved in the development of melanocytic 
tumours and melanoma: the MAPK-pathway and the AKT/PI3K-pathway. Activation of both 
routes leads to proliferation. NRAS plays an important role in both pathways. Mutations in GNAQ, 
GNA11, and BRAF all lead to activation of the MAPK-pathway only, while mutations in KIT and 
NRAS can activate both pathways. Different inhibitors can be applied in targeted therapy of 
advanced melanoma patients, and their points of action are indicated also. This figure shows 
that MEK-inhibitors can be effective in case of several different gene mutations in the MAPK- 
pathway, because they exert their effect in the distal part of the pathway.
KIT
Tyrosinase
Kinase
inhibitor
GNAQ
GNA11
BRAFBRAFi
P13K/AKT
MEKi
ERK
PROLIFERATION
RAS
MEK
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Several studies have reported the presence of HRAS mutations in spitzoid tumors 
with benign behavior, and absence in clear-cut spitzoid melanomas (10, 15, 16). 
There is only one recent paper mentioning the occurrence of HRAS mutations in upto 
10% (2/20 cases examined) of primary cutaneous melanomas (17). In this paper no 
histology of the lesions is shown or described, therefore whether these lesions were 
spitzoid or not remains unclear, and no follow-up data of the patients are included to 
confirm the proposed diagnosis of melanoma by the authors. Furthermore, this 
paper also gives mutation frequencies of BRAF (25%) and NRAS (10%) that are quite 
different from most studies in the melanoma field.
In 2010, we described a series of 24 HRAS mutated spitzoid melanocytic tumors (11). 
In 7/24 (29%) of these lesions the initial diagnosis or important differential diagnosis 
had been melanoma based upon histological examination alone. These were mainly 
cases in adults that displayed rather frequent or deep mitotic activity. In five cases, 
more than 2 mitoses/1mm2 or deep mitoses were present. In this series with a mean 
and median follow-up of 10.5 years, no recurrences or metastases occurred. An 
example of a HRAS-mutated spitzoid lesion is depicted in Figure 2.  
The second group, which we preferentially call MBAITs (melanocytic BAP1- associated 
intradermal tumors, but are also called Wiesner tumor or BAPoma) are often polypoid, 
dermal based, consisting of large epitheloid “spitzoid-looking” cells, that can have a 
small common nevus component at the margin (especially in BAP1-germline mutated 
lesions), and in one third of cases there are prominent tumour-infiltrating lymphocytes 
(TILs).  
These BAP1-mutated melanocytic lesions were first described by Wiesner et al.. They 
described two families, one in Australia and one in Germany, in which a total of sixteen 
individuals were affected by atypical cutaneous melanocytic tumours, in association 
with cutaneous and uveal melanomas (12). The affected family members were found 
to have a BAP1 germline mutation. Subsequently, it was found that these spitzoid 
looking MBAITs besides a BAP1 mutation also contained a BRAF mutation. Later, 
these lesions were also described in a sporadic setting in so-called atypical spitzoid 
tumors (ASTs), without having an underlying BAP1 germline mutation (13, 18). In 2012, 
Wiesner et al. described a series of 32 ASTs (18). Nine cases (28%) showed BAP 1 
protein expression loss while BRAF protein expression was present.  In 8/9 cases (89%) 
a BRAFV600E mutation was found, and in 5/9 cases (55%) a somatic BAP1 mutation 
was present. No HRAS mutations were found. Histology was comparable to the 
BAP1-germline mutation associated MBAITs, demonstrating a dermal based lesion, 
plump epithelioid cells, giant cells, with in 1/3 cases prominent TILs, and absence of 
prominent fibrosis. These cases were not described to contain a small nevoid 
component in contrast to the germline BAP1-associated cases.
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Yeh et al. recently described genomic loss, determined with array CGH, of >1Mbp of 
chromosome 3 in a region containing the BAP1 locus in a series of 29 cases  out of 
436 ambiguous melanocytic tumours (6.7%) (19): 22 cases showed partial loss of 
chromosome 3, while 7 cases demonstrated monosomy of chromosome 3. In 11 
Figure 2  HRAS-mutated spitzoid tumour in a female patient of 47 years of age. 
The lesion was located on the right lower arm and measured 0.8 cm in diameter. The lesion was 
diagnosed elsewhere as STUMP (spitzoid tumor of uncertain malignant potential). 
A, B: The lesion was symmetrical, wedge shaped, mainly dermal located, with epithelioid spitzoid 
looking cells in an eosinophilic hyalinised stroma ( A HE 25x, B HE 400x ). There were 2 mitoses 
present per 1mm2.  Deep mitoses were absent.  
C: Sequence plot of the mutation HRAS c.182A>T(p.(Gln61Leu)) with 44% of mutant alleles. The 
genomic sequence of the gene investigated is marked in green bars and the protein sequence 
information is on top of the gene sequence. The combined (forward and reverse) gene 
sequence information is highlighted in light green and the expected protein sequence is placed 
on top. The forward sequence information is indicated as light blue bars and reverse sequence 
information as purple bars. The square box shows the number and percentage of the different 
nucleotides at the variant position; the red vertical bar indicates the HRAS hotspot mutation 
position. The sequence plots are generated in SeqNext (from JSI medical systems GmbH). 
Note; the HRAS RefSeq is NM_005343.2.
A
C
HRAS exon 3
B
A
C HRAS exon 3
B
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cases BAP1 mutation analysis was performed with in 10 cases a loss of function 
mutation of BAP1, and in the remaining single case with wild-type BAP1, BAP1 protein 
expression was lost on the immunohistochemical level. In the cases with loss of 1 
copy of BAP1, the BAP1 protein expression was always lost. So immunohistochemistry 
for the BAP1 protein seems to correlate well with the genetic findings. Reported follow-up 
in their series was good, although short (median 17 months), with no recurrences, 
and in one patient a negative sentinel lymph node. Morphology of 17 lesions with 
biallelic loss of BAP1 that looked spitzoid was as described previously by others, with 
TILs being present in 50% of cases, and 31% having a small nevoid component at 
the margin. In these cases, a junctional component was present composed of 
the common nevus component. In one case without a common nevus component, 
a junctional spitzoid component was present. In 12/17 cases a BRAFV600E mutation 
was present, 4 cases were wildtype BRAF, and 1 case showed an NRASQ61R mutation. 
The latter is rarely reported at present, but we have also encountered such a case 
ourselves recently (paper submitted). In our patient no underlying BAP1 mutation 
was found. The other reported NRAS-mutated case (19) in literature was not tested for 
a germline mutation in BAP1. Most of the MBAIT cases reported thusfar do not seem 
to be tested  for the presence of NRAS mutations, so the number of NRAS mutated 
cases may be larger, and the genetic make-up of these BAP1 associated melanocytic 
lesions could be broader than currently thought.
The fact that the combined MBAIT lesions show only BAP1 loss in the epithelioid 
component suggests that they probably develop from a common nevus (that is 
mostly BRAF- and seldom NRAS-mutated) (7).
MBAITs probably have a low risk of developing into melanoma, but at present, data 
about behaviour are insufficient to draw definite conclusions. 
In the two largest series thusfar by Pouryazdanparast et al. (20) and Yeh et al. (19), 
reporting 28 and 29 cases respectively, follow-up was favourable without recurrences. 
Follow-up was relatively short with a mean of 21 months and median of 17 months 
respectively. Pouryazdanparast performed FISH (using probes targeting chromosome 
6p25 (RREB1), chromosome 6q23 (MYB), chromosome 11q13 (CCND1), and the 
centromeric portion of chromosome 6 (CEP 6)) on these lesions, which was negative 
in all cases. 
The difference in outcome between the uveal lesions and the skin lesions with a 
BAP1 mutation may be related to the presence of different oncogenic driver mutations 
in uveal lesions, which harbor GNAQ or GNA11 mutations (21) instead of BRAF or 
NRAS mutations. 
The suggested progression-promoting effect of mutated BAP1 is in line with the 
tumor suppressive function of intact BAP1 as a deubiquitylase required for efficient 
assembly of the homologous recombination (HR) factors BRCA1 and RAD51 after 
DNA double strand breaks (DSBs) (22) (23). BAP1 is recruited to DNA damage sites 
23
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together with ASXL1 and deubiquitilates Ub-H2AK119 at sites of DNA damage (22, 
23). In this way,  it promotes error-free repair of these lesions. Defective HR and 
increased sensitivity to radiation due to BAP1 deficiency may, therefore, lead to 
genomic instability, a hallmark of cancer (22, 23). Moreover, BAP1 prevents 
proteasomal degradation of the conserved epigenetic regulator host cell factor-1 
(HCF-1) and, consistent with this, Dey et al. showed that BAP1 KO splenocytes 
contained far less HCF-1 than their wild type counterparts (24). It is thought that BAP1 
regulates gene expression via stabilization of HCF-1(24). These two examined 
functions of BAP1 could explain tumor-progression due to altered BAP1 expression. 
The most important reason for recognition of MBAITs at present is that they can be a 
marker of an underlying BAP1-associated germline mutation/cancer syndrome. 
Individuals with a BAP1 germline mutation have an increased risk to develop 
cutaneous and ocular melanoma and mesothelioma, apart from the risk to develop 
multiple MBAITs (25).  
Management of MBAIT lesions should consist of complete removal of the lesion and 
advise for genetic counseling to exclude a potential underlying cancer syndrome.
Typical BRAF-mutated MBAIT cases from our own practice are shown in Figures 3 
and 4 (Courtesy Dr. R. Kornegoor, Department of Pathology, Gelre Hospitals, Apeldoorn, 
The Netherlands). 
In case of suspicion of a MBAIT lesion, we recommend at least a BRAF and BAP1 
immunostaining, but preferentially BRAF, NRAS, HRAS, and BAP1 mutation analysis 
is performed. In case a laboratory cannot perform these, we recommend consultation 
because of the important implications of a correct diagnosis. Mutation analysis of the 
BAP1 gene is difficult, since it is a complex gene and mutations can be present along 
all of the 17 exons of the gene. A low tumour percentage due to the small size of a 
lesion or small size of the spitzoid component, or the presence of a lot of TILs, can all 
hamper BAP1 mutation analysis in this setting. 
The third group of spitzoid lesions, those with kinase fusions has only recently been 
described. Wiesner et al. described the presence of alterations in ROS1, NTRK1, ALK, 
BRAF, and RET in respectively 17%, 16%, 10%, 5% and 3% of spitzoid tumours. These 
alterations were present along the entire spectrum of the spitzoid tumours (55% in 
Spitz nevi, 56% in AST, and 39% in spitzoid melanoma) and these alterations therefore 
seem early events, and are not useful (yet) for differentiating benign from malignant 
spitzoid lesions. No clear distinct phenotypes were described at this time.
Recently Busam et al. described 17 cases of Spitz tumors with ALK–fusion, including 
5 Spitz nevi and 12 AST (26). Clinically, these lesions were often polypoid. Histology 
showed a compound, mostly dermal located lesions with a plexiform growth, and 
consisting of fusiform melanocytes. In only 2 cases the lesional cells contained 
pigment. 
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Figure 3  BRAF-mutated MBAIT in a 31-years old female located on the lower back (Courtesy 
Dr. R. Kornegoor, Gelre Hospitals, Apeldoorn, The Netherlands).  
A: overview (HE 25x), showing a polypoid lesion above the skin surface. The central part, B (HE 
400x) consists of large epithelioid cells with intermingled lymphocytes. The margin, C (HE 
100x), shows a common compound nevus. 
D: Molecular analysis showed a BRAFV600E mutation. In D Sequence plot of the mutation BRAF 
c.1799_1800TG>AA (p.(Val600Glu) alias p.V600E) with 7% mutant allel (very low load). Note; 
the BRAF RefSeq is NM_004333.4.
The sequence plots are visualized as described under Fig. 2. 
Immunohistochemistry demonstrated positive BRAF protein expression, and loss of BAP1 
protein expression in the large epithelioid cells (not shown).
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Figure 4  BRAF-mutated MBAIT-lesion located on the posterior side of the ear in a 55-year-old 
female (Courtesy Dr. R. Kornegoor, Gelre Hospitals, Apeldoorn, The Netherlands). 
A: overview showing a nodular dermal based lesion with lymphocytes at the lateral margin. In this 
case no common nevus component was present (HE, 25x). B: a higher magnification 
demonstrates the large epithelioid aspect of the cells (HE, 200x). In C absence of BAP1 protein 
expression is seen in the large epithelioid melanocytes. Nuclei in the keratinocytes in the 
epidermis stain positive, serving as a positive internal control (400x). In D, BRAF protein is 
expressed by the large epithelioid melanocytes (400x). 
E: Sequence plots of the mutation BRAF c.1799T>A (p.(Val600Glu) alias p.V600E) with 23% 
mutant alleles and of the BAP1 (RefSeq NM_004656.2) c.581-1G>A splice site mutation with 
34% mutant alleles. The sequence plots are visualized as described under Fig. 2. In the BAP1 
plot the intron-exon boundary is represented as grey-white parts.
1mm
B
A
B C D
E
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All cases showed ALK protein expression. ALK FISH was positive in all cases (using 
a commercially available break-apart probe, Abbott Molecular, Des Plaines, IL): in 
11/17 cases the fusion partner was tropomyosin 3 (TPM-3), in 6/17 cases the fusion 
partner was dynactin 1 (DCTN-1). FISH for copy number alterations did not met the 
criteria for melanoma diagnosis in any case. Array-CGH revealed no chromosomal 
gains or losses. In 2 cases a sentinel node procedure was performed and in both 
cases showed small nests in the subcapsular sinus. Both patients were alive and well 
after <1 year and after 4 years of follow-up. At present the follow-up time and number 
of cases is too limited to draw definite conclusions about the prognosis of this group 
of Spitz tumors with  ALK-fusions.
An ALK-positive Spitz tumor is presented in Figure 5. (Courtesy Prof. Dr. J. van den 
Oord, KU Leuven, Belgium). 
The anaplastic lymphoma kinase (ALK) gene, located on chromosome 2p23, is a 
receptor tyrosinase kinase protein and is capable of causing diverse tumour types of 
different lineages through a variety of molecular mechanisms (27). The most common 
mechanism of ALK activation is a genomic rearrangement involving the ALK locus, 
with a breakpoint in the 3’ end of the ALK gene, with the other breakpoint involving 
a diverse group of genes leading to formation of a fusion oncogene that encodes 
for a fusion oncoprotein that is able to self-associate (27). Another way of ALK 
activation is by gain-of-function point mutations, but these are less frequent than ALK 
rearrangements. Also, ALK amplifications have been described in several tumor 
types, leading to the presence of multiple copies of the wild-type full-lenght ALK 
gene. But the way this contributes to tumor development is poorly understood (27).
As mentioned above, in spitzoid tumours at present, only ALK rearrangements have 
been tested and described, and present in upto 19% of cases (14), with TPM-3 and 
DCTN-1 as fusion partners (14, 26). ALK rearrangements leading to TPM3-ALK fusion 
have also been reported in anaplastic large cell lymphoma and papillary thyroid 
carcinoma, and result in a constitutive tyrosinase kinase activity, in this way causing 
tumor development (27). 
Relevance of diagnosis of Spitz tumors with kinase fusions at the moment is mainly 
for treatment in malignant lesions (eg ALK, RET, ROS 1 alterations can be targeted 
with kinase inhibitors, such as crizotinib, cabozantinib, vandetanib).
Table 2 summarises the characteristic features of the three above-described subtypes 
of spitzoid melanocytic lesions, including the most common histological findings, 
and genetic and prognostic features, with clinical relevance of recognition of these 
subtypes.
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1.2  Molecular background of congenital melanocytic nevi (CMN) 
and neurocutaneous melanosis (NCM)
Congenital melanocytic nevi (CMN) are pigmented moles present at birth or shortly 
thereafter (28). They vary in size from small to very large or “giant’’ and hundreds of 
CMN can be present in one patient (29). CMN are considered to be a sporadic event 
with the exception of a few familial cases (30, 31). Especially giant CMN (> 40cm in 
size) are associated with an increased risk for cutaneous melanoma (up to 10–15% 
life-time risk) (32). 
Figure 5  ALK-positive spitzoid tumour diagnosed as spitzoid tumour of uncertain malignant 
potential (STUMP).
This lesion was seen in consultation elsewere (Courtesy Prof. Dr. J. van den Oord, KU Leuven, 
Belgium). The lesion was clinically polypoid and presented on the arm of a 4-year old girl. There 
were 11 mitoses/1mm2 present. Follow-up data are not available yet.  In A HE overview (25x); 
in B and C larger maginification (HE 200-400x resp.) showing spindle shaped cells and some 
lymphocytes intermingled; in D PHH3 staining demonstrating mitoses (400x); in E mitf (250x); 
and in F ALK (250x). 
A B
C D
E F
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Both NRAS and BRAF mutations have been detected in CMN in a mutually exclusive 
pattern, and there is a genotype-phenotype correlation between the size of CMN and 
type of mutation. Especially, large and giant CMN harbor somatic NRAS mutations 
(> 75%) in contrast to medium-sized CMN that are less frequently NRAS-mutated 
and especially small CMN and acquired melanocytic nevi that frequently carry 
BRAFV600E mutations (up to 80% in acquired nevi) (33). Activating BRAFV600E mutations 
Table 2   Overview of frequencies of gene mutations in different melanoma subtypes 
derived from different locations
Subtypes spitzoid 
melanocytic tumours
HRAS-mutated 
spitzoid tumours
BAP 1-mutated 
spitzoid tumours
(MBAIT)
Spitzoid tumours with 
kinase fusions
Histological 
characteristics 
(phenotype)
- dermal based lesions
- wedge shaped
- desmoplasia
- often spindle shaped 
cells
- mostly dermal based
- often polypoid
- often TILs
- epithelioid cells, 
a common nevus 
component can be 
present
- no distinct 
phenotypes identified 
yet.
- ST with ALK fusions 
recently reported as 
often polypoid with 
plexiform growth of 
fusiform melanocytes 
(26)
Genetic alterations - HRAS mutations or 
amplification
- single 11p gain can 
be present
- BAP1 mutation
- often  with combined 
BRAFV600E mutation. 
Rare cases with 
combined NRAS 
mutation reported
- loss of (a part of ) 
chromosome 3 can 
be present
- specific fusion of 
certain genes (ROS1 
17%, NTRK1 16%, 
ALK 10%, BRAF 5%, 
RET 3%)
-in ALK fused STs no 
chromosomal gains 
or losses reported  
thusfar (26)
Relevance of 
diagnosis
-favourable prognosis 
(prevention of 
overdiagnosis of 
melanoma).
-can be a marker 
of a BAP1 cancer 
syndrome.
-genetic counceling 
should be advised.
-behaviour not clear yet.
-in case of malignant/
metastatic cases 
targeted treatment is 
an option (ALK, ROS, 
and RET alterations 
can be targeted by 
kinase inhibitors 
like crizotinib, 
cabozantinib, 
vandetanib).
-behaviour not clear yet.
Abbreviations: TILs=tumour-infiltrating lymphocytes; ST=Spitz tumour; MBAIT=melanocytic BAP1 associated 
intradermal tumour.
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in large CMN are rare (approximately 15 %) (6). A few cases of large CMN were shown 
to harbor a chromosomal translocation involving BRAF resulting in gain-of-function, 
and this could represent an alternative mechanism of BRAF activation in BRAF- or 
NRAS-wild-type CMN (34).   
Recently, using several highly sensitive techniques, Charbel et al. showed that large 
and giant CMN contain NRASQ61 mutations (Q61R or Q61K) in up to 94.7% of cases 
(35). In addition, using whole-exome sequencing they found no other coding mutations in 
five large/giant CMN implying that at present NRAS mutations are the sole recurrent 
mutation in these lesions. Somatic NRAS mutations, therefore, seem to be sufficient 
to drive melanocytic proliferations in utero. In addition, identical NRASQ61 mutations 
were recently demonstrated in multiple CMN samples from the same patient (36). 
This finding suggests that multiple CMN are clonal proliferations caused by a single, 
postzygotic NRAS mutation in a neuro-ectodermal precursor cell rather than de novo 
proliferations arising from different mutations. 
Kinsler et al. recently proposed the term “CMN syndrome” as they observed that 
patients with CMN often have characteristic facial features (such as wide or prominent 
forehead and apparent hypertelorism) (37). The osteocartilageneous structures of the 
face are neuro-ectodermal in origin and can be affected by mutations in components 
of the RAS/RAF/MEK/ERK pathway in patients with germ-line RASopathies who have 
characteristic facial features (38). Kinsler et al. hypothesized that the occurrence of a 
postzygotic, somatic NRAS mutation in early neuro-ectodermal precursors might be 
responsible for the characteristic facial features in patients with CMN as well (36). In 
addition, as they observed a high prevalence of red hair in families of children with 
CMN, a germline predisposition for the development of the “CMN syndrome” was 
hypothesized. Indeed, they showed that certain germ-line allele variants of the mela-
nocortin-1-receptor (MC1R), known to be responsible for the red hair/fair skin/freckling 
phenotype, are associated with the presence of CMN (as well as with more extensive 
CMN) (39).
CMN can be associated with a spectrum of neurological abnormalities, including 
malformations (for instance Dandy-Walker malformation), communicating hydrocephalus, 
arachnoid cysts, CNS tumors (for instance astrocytoma and choroid plexus papilloma) 
but also melanotic abnormalities (36). The latter is called neurocutaneous melanosis 
(NCM) and refers to the presence of large of multiple CMN in association with melanin 
depositions in the brain parenchym (visible on T1-weighted MRI) or melanocytic tumors 
like leptomeningeal melanocytosis or melanoma (40). Leptomeningeal melanocytosis 
consists of a diffuse proliferaton of histological benign appearing melanocytes in the 
leptomeninges, without CNS invasion, and carries a poor prognosis once symptomatic 
(40).
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Recently, it was shown that postzygotic, somatic NRAS mutations contribute to the 
pathogenesis of NCM. Identical, somatic NRASQ61 mutations were detected in 
multiple CMN as well as in the CNS melanocytic tumor in the same NCM patients 
(41). Kinsler et al. also detected a somatic NRASQ61 mutation in three non–melanocytic 
CNS tumors occuring in patients with CMN (including choroid plexus papilloma, 
neurocristic hamartoma, meningioma) (36). The presence of identical, somatic 
NRASQ61 mutations in both CMN as well as in CNS melanocytic (and non-melano-
cytic) neoplasms in the same patients suggests that these mutations occur in the 
developing neuro-ectoderm early during embryogenesis. In fact, this pathogenetic 
mechanism fits the spectrum of mosaic RASopathies that are characterized by 
postzygotic mutations resulting in the presence of at least two genetically distinct cell 
populations in the same organism (42). For instance, postzygotic, somatic RAS 
mutations (HRAS, KRAS) were recently shown to be present in distinct lesions of the 
keratinocytic epidermal nevus syndrome, a mosaic RASopathy characterized by the 
presence of epidermal nevi in association with extra-cutaneous abnormalities (CNS, 
ocular, skeletal, cardiovascular, and genitourinary system) (42). The phenotype in the 
spectrum of mosaic RASopathies is most likely determined by type of mutation, the 
timing of the mutation, and affected cell type (42, 43).
A mouse model has demonstrated a role for postzygotic, early embryonic NRAS 
mutations in the pathogenesis of NCM. By using the Cre-loxP technology, Pedersen 
et al. showed that expression of oncogenic NRASG12D in melanocytes early during 
embryogenesis resulted in a mouse phenotype strongly resembling NCM in human 
beings (41). As NRAS mutations occur in benign lesions such as CMN, they are in 
itself insufficient for malignant transformation of melanocytes, and better insight in 
the genetic aberrations eventually leading to melanoma is needed. NRAS mutations 
are a therapeutic target for treatment with MEK inhibitors. In a Phase II trial, treatment 
with MEK162 was shown to have effect in some patients with advanced NRAS-mutated 
melanoma and a Phase III trial is ongoing (44). For patients with NRAS-mutated CNS 
melanocytic tumors treatment with MEK162 might be of benefit as well (45). 
1.3.  Molecular diagnostics in the differential diagnosis of melanoma 
(metastasis)
Melanomas are known for their wide range of cytomorphologic features and 
architectural patterns and may mimic various non-melanocytic tumors (reviewed by 
Banerjee et al. (46, 47)). In most cases a diagnosis can be rendered by careful 
examination of the histomorphology and by sometimes adding immunohistochemical 
stains. In some cases, however, especially in recurrences and metastases, melanomas 
can show an aberrant immunophenotype with loss of lineage-specific markers. In part 
of these cases, molecular analysis of genes in the MAPK pathway and CDKN2A (7) 
mutation analysis can be useful in the differential diagnosis. In addition, molecular 
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analysis can be of help in determining the site of the primary melanoma in case of 
metastasis with an unknown primary since melanomas from different locations have 
different mutation types (see Table 1). Furthermore, molecular analysis can help to 
discriminate between a melanoma metastasis and a second primary melanoma.
One of the lesions that can be hard to distinguish from melanoma is clear cell 
sarcoma (CCS) as they share histopathological features and cannot be distinguished 
by immunohistochemistry (48). Classically, CCS is a deep soft tissue tumor associated 
with tendons and aponeuroses (49), but it can also present as a cutaneous lesion 
(50), and then has to be differentiated from metastatic or primary nodular melanoma. 
While most cutaneous melanomas harbor a BRAF or NRAS mutation (see Table 1), 
CCS in approximately 75% have a t(12;22)(a13;q12) or less commonly a t(2;22)
(q34;q12) translocation leading to the EWSR1/ATF1 or EWSR1/CREB1 fusion transcripts 
(51, 52). Yang et al. (53) performed BRAF and NRAS mutation analysis, as well as 
FISH analysis for the EWST1/ATF1 fusion gene in 31 melanoma cases and 16 CCSs. 
They found the translocation in 78.6 % of the CCSs but in none of the melanomas, 
whereas BRAF and NRAS mutations were present in, respectively, 51.6% and 12.9% 
of the melanomas and not in any of the CCSs. Hantschke et al. (50) describe twelve 
cases of cutaneous CCS in which FISH analysis for the t(12;22)(a13;q12) translocation 
contributed in the differential diagnosis with melanoma. This implicates that this type of 
analysis can be of great aid in the differential diagnosis between CCS and melanoma.
Recently, we described two cases in which mutation analysis lead to the correct 
diagnosis of (dedifferentiated) metastatic melanoma (54). Both patients had a history 
of melanoma and presented several years after their primary diagnosis with a lesion 
histologically and immunohistochemically different from the primary melanoma and 
mimicking a solitary fibrous tumor (SFT). Using BRAF and NRAS mutation analysis, it 
could be proven that both lesions were melanoma metastases instead of SFT. Many 
other soft tissue tumors can mimick melanoma or melanoma metastasis like derma-
tofibrosarcoma protuberans, malignant peripheral nerve sheath tumors (MPNST) 
(55) and sarcomas (46, 56-58).
Although CDKN2A mutation frequency in sporadic melanomas as well as consistency 
in melanoma metastasis are reported to be low (reported CDKN2A mutation 
frequency in upto 25% of primary melanomas, 0-14% in melanoma metasases, with 
a 31% consistency being reported between a primary and the metastasis (59, 60)), 
CDKN2A mutation analysis can be an alternative way to confirm a diagnosis of 
metastatic melanoma by showing a clonal relationship between a primary melanoma 
and a metastasis (after exclusion of a CDKN2A germline mutation (61)), as is illustrated 
by a recent case from our own practice. A 36-year-old woman with a history of a 
superficial spreading melanoma of the back 16 years earlier, presented with a large 
lung mass which was thought to be a non-small cell lesion, probably squamous cell 
carcinoma based on fine needle aspiration (EUS-FNA): melanoma markers HMB45 
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and MART were negative while the squamous cell marker - p63- was weakly positive. 
Evaluation of the pneumonectomy specimen, however, led to a differential diagnosis 
with metastatic melanoma, since immunohistochemical stainings on the complete 
tumor now available for histological evaluation showed in part features consistent 
with melanocytic differentiation. Vimentin, tyrosinase and mitf were weakly positive, 
however S100 and SOX10 were both negative. Therefore additional BRAF and 
CDKN2A mutation analysis was performed. Identical mutations in both genes were 
present in the primary cutaneous melanoma and the lung mass -in absence of a 
germline CDKN2A mutation- confirming that the lung mass was a late metastasis of 
the cutaneous melanoma. This case is illustrated in Figure 6.
In a patient with a history of melanoma, it can occasionally be difficult to differentiate 
between a second primary cutaneous melanoma or a melanoma metastasis based 
on histomorphology, especially when there is epidermotropism (62). If the first 
melanoma was not a cutaneous melanoma, the problem can often be solved by 
mutation analysis since different types of melanomas have mutations in different 
genes of the MAPK pathway as mentioned in Table 1. If the primary melanoma was 
a cutaneous melanoma, mutation analysis of NRAS and BRAF can be of help, but 
since these mutations are hotspot mutations, it’s of limited use. Usage is additionally 
hampered by frequent occurrence of heterogeneity in melanoma with respect to 
NRAS and BRAF status, leading to a substantial discordance in mutation status in 
these genes in a primary compared to the metastases (59, 63).
CDKN2A mutation analysis can sometimes be helpful as we have published before 
(64), and is illustrated by the case above, to differentiate between a new primary and 
a melanoma metastassis. The advantage of using CDKN2A mutations for clonality is 
that CDKN2A mutations are unique mutations instead of hot spot mutations. Although 
CDKN2A mutation frequency in sporadic melanomas is low, CDKN2A mutation 
analysis to our opinion is worth trying, as there is a substantial difference in the 
prognosis between a second primary melanoma and a melanoma metastasis.
PART 2. MOLECULAR PATHOLOGY IN MELANOMA TREATMENT
Metastatic melanoma treatment got a great impulse after the discovery that the (hot 
spot) mutations in genes involved in the MAPK pathway in melanoma, as well as in 
GNAQ and GNA11, proved targetable on the protein level by specific inhibitors. GNAQ 
and GNA11 mutations are mainly present in uveal and primary brain melanomas, and 
combinations of MEK inhibitors with either PI3K or mTOR inhibitors have show 
efficacy in GNAQ- and GNA11-mutant melanomas (65, 66). A simplified scheme of 
the most important pathways involved in melanoma pathogenesis, and points of 
action of specific inhibitors are depicted in Figure 1.
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Figure 6  Case of a superficial spreading melanoma of the back with lung metastasis sixteen 
years later in a female patient.
In A an overview of the primary cutaneous melanoma showing centrally an asymmetrical 
melanocytic lesion (HE, 25x). In B, a more detailed picture showing clear atypia with loss of 
maturation and ascension in the epidermis (HE, 100x). In C, D, and E, the lung lesion at different 
magnifications (HE C 25x, D and E 100x) showing a nodular proliferation of atypical partly 
plasmacytoid cells resembling the primary cutaneous melanoma. Immunohistochemical S100 
stain however was negative (F S100 immunostaining, 100x). Internal and external controles 
were positive. 
G: Sequence plots demonstrated an identical c.168_170delinsTG(p.(Arg58fs)) in the  CDKN2A 
gene in both the skin melanoma and the lung tumour, which was absent  in normal tissue of 
the patient. This confirmed that the lung tumour was a metastasis of the previous melanoma. 
The sequence plots are visualized as described under Fig. 2.
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Melanomas from distinct locations have been shown to contain different mutation 
types and frequencies (5, 67, 68). An overview of the most frequent mutations in the 
distinct melanoma subtypes and their frequencies, as well as the different therapeutic 
options, are depicted in Table 1. 
The most frequently tested genes at present in melanoma are BRAF and NRAS, 
because these mutations are most prevalent in melanoma, especially in those arising 
from the skin. Testing for targeted treatment in melanoma should be guided by the 
localization of the primary tumor. Nowadays this issue becomes less important 
because several molecular labs use platforms that detect various regions from 
multiple genes within one test.
In case of molecular testing for targeted therapy in metastatic melanoma there are 
several important issues. 
Molecular testing for therapy requires a close collaboration between clinician, 
pathologist, and molecular biologist. Testing for treatment should only be performed 
when targeted therapy is considered as a therapeutic option. This can be judged 
best by the clinician. In most cases, testing is only indicated in inoperable stage 3 or 
stage 4 melanoma patients.
Tests need to be performed in an accredited -molecular laboratory that guarantees 
that the laboratory techniques and processes are performed standardized and yield 
high quality results which implies that only validated tests are used. 
The role of the pathologist is to confirm the diagnosis of melanoma metastasis, to 
check representativity of the tumor tissue to be examined, to indicate the area for 
macrodissection (if needed) by the technician for DNA extraction, to indicate possible 
tumor heterogeneity and to estimate the neoplastic cell percentage within the tested 
sample.
The knowledge and the expertise of trained molecular biologists is used to come to 
optimal test-results and adequate interpretation and reporting of molecular test 
results. The molecular report should contain information on the specific tissue block 
tested, the percentage of neoplastic cells, the type of molecular test used and the 
sensitivity of the test, the type of genes and exons or mutations thereof which are 
tested, and an accurate description of the mutation present according to the Human 
Genome Variation Society nomenclature. The molecular biologist, together with the 
pathologist, is responsible for proper integration and interpretation of the molecular 
results in the pathology report.
The molecular test is preferentially performed on a recent metastasis. Reason for this 
is firstly confirmation of the diagnosis of melanoma metastasis. Secondly, there is 
considerable tumour heterogeneity with a reported discrepancy by Colombino et al. 
of 7.5-29% in the BRAF and NRAS mutation status of the metastatic melanoma when 
compared to the primary (59, 63). Concordance seems dependent on the location of 
the metastases and is highest for visceral (92.5%) and nodal metastases (91%), but 
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relatively low for brain (79%) and skin metastases (71%). Especially in the latter 
therefore testing should be performed on the metastasis.
Saint-Jean et al. (69) also reported discordant BRAF results. They performed multiple 
tests in a subgroup of 74 patients: in 10/74 (13.5%) of these patients BRAF status was 
discordant between distinct samples of a patient. In two patients, the discordance 
was present between the primary and a metastasis. In six patients the discordance 
was present between two distinct metastases. The authors state that without repeated 
testing, five patients would unjustly have been excluded from treatment with the 
BRAF-inhibitor, vemurafenib. They advocate to test other samples in case no BRAF 
mutation has been detected. We can agree with this especially in selected cases, 
when the primary location is likely to be associated with a BRAF mutation and when 
no mutation in other targetable genes (like NRAS or KIT) has been identified.  
A molecular test should be able to detect all relevant and targetable mutations in a 
gene. The most frequently tested gene for melanoma treatment at present is BRAF.
The most frequent BRAF mutation is a mononucleotide point mutation in codon 600 
(CTG) of exon 15, c.1799T>A (p.(Val600Glu), in which the valine (V) of codon 600 is 
replaced by glutamine (E). This mutation is therefore known as the BRAFV600E mutation 
and is present in about 70-75% of all BRAF-mutated melanomas (67, 70, 71). In a 
recent study in which 1112 primary and metastatic melanomas from different locations 
were analysed for BRAF mutations (774 skin melanomas, 111 acral melanomas, 26 
mucosal melanomas, 23 uveal melanomas, 1 leptomeningeal melanoma, and 177 
metastases), 44.9% of the cases harbored a BRAF mutation: 75.4% of the cases, 
mutations were BRAFV600E either deriving from the c.1799T>A or from a c.1799 
1800delinsAA mutation. Of the remaining BRAFnon-V600E cases (24.6%), the most 
frequently seen mutation was the BRAFV600K (17.2%); BRAFV600R  or BRAFV600D mutated 
cases were found in low percentages (4.6% ). BRAF exon 11 mutations were also 
observed in a low percentage (0.4%).
There are several studies that have reported that all melanomas with BRAF codon 
600 mutations are sensitive to BRAF inhibitors such as vemurafenib (Zelboraf®, 
Roche Molecular Systems Inc.) and dabrafenib (GSK2118436)(72, 73). This implicates 
that a BRAF test needs to be able to detect not only the BRAFc.1799T>A(p.
(Val600Glu)/ BRAFV600E mutation, but the other codon 600 mutations as well.
A test must be able to detect BRAF mutations that have been reported to be insensitive 
to BRAF inhibitor treatment, like the kinase dead mutation BRAFD594 (74, 75).
The molecular test for therapy should be performed within a short turn-around time 
since mostly this kind of targeted therapy will be given in rapidly progressive metastatic 
melanoma patients. A turn around time of 5 working days is feasible within our hands.
At present we perform NGS-based mutation testing using Ion Torrent Personal 
Genome Machine (IT-PGM) from life Technologies for analysis of gene-panels for 
diagnostic purposes. 
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At the moment there is a tendency towards testing with NGS methods for targeted 
treatment in diverse cancer types. The sensitivity of NGS is higher than Sanger 
sequencing (detection of 2-10% versus 15-25% allele frequency). Moreover, the 
amount of DNA that is needed for the analysis of gene panels is very low, only 10 ng 
for all amplicons for instance when using the Ion Torrent Personal Genome Machine 
(IT-PGM) from life Technologies versus 10ng needed per amplicon for Sanger 
sequencing. 
The turnaround time and costs of NGS methods can be competitive with respect to 
low throughput technologies in centers that have sufficient numbers of samples. 
For diagnostic requests in melanoma in our department a custom-designed gene 
panel for amplicon-sequencing of BRAF (NM_004333.4) exon 15, NRAS (NM_002524.4) 
exon 2 and 3, HRAS (NM_005343.2) exon 2 and 3, AKT1 (NM_005163.2) exon 3, 
GNAQ (NM_002072.2) exon 4 and 5, GNA11 (NM_002067.2) exon 4 and 5, KIT 
NM_000222.2) exon 8, 9, 11, 13, 14 and PDGFRA (NM_006206.4) exon 12, 14, 18 is 
performed. 
The use of small, dedicated gene panels and efficient loading of the chips for IT-PGM 
also significantly reduce costs per case. 
The major benefit of (targeted) NGS is that it uncovers all kinds of mutations in 
selected genomic regions instead of only mutations at predefined positions. 
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ABSTRACT
It is often very difficult to confidently distinguish benign and malignant Spitz lesions, 
and a diagnosis of Spitz tumor of unknown malignant potential (STUMP) is rendered. 
To address this problem, we performed molecular genetic analysis in a large group 
of Spitz tumors (93 Spitz nevi and 77 STUMPs) and identified a subgroup of 24 
lesions harboring a HRAS mutation. This subgroup lay predominantly in the dermis, 
had a relatively low cellularity, showed desmoplasia (with single cells interspersed 
between the collagen bundles) and had an infiltrating base. In 7 of these 24 cases 
(29%) melanoma had been the initial diagnosis, or an important differential diagnostic 
consideration, mainly based on the presence of multiple or deeply located mitotic 
figures, especially in adult patients. In our series none of the patients with the HRAS 
mutated lesions developed recurrences or metastases (mean and median follow-up: 
10.5 years). This was in accordance with the literature: review showed that no HRAS 
mutations had so far been reported in Spitzoid melanomas. We therefore conclude 
that HRAS mutation analysis may be a useful diagnostic tool to help differentiate 
between Spitz nevus and Spitzoid melanoma, thereby reducing the frequency of 
overdiagnosis of melanoma, and to help predict the biological behavior of a STUMP. 
Moreover, this might be a first step towards a more reproducible classification of Spitz 
tumors combining histological and genetic data.
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INTRODUCTION
Spitz tumors are notoriously difficult to classify. They form a diagnostic challenge for 
pathologists and are frequently submitted for consultation to expert dermatopatholo-
gists. Because of similarities with melanoma, Spitz nevus is not uncommonly 
misdiagnosed as melanoma, and vice versa (1).
There have been many attempts to define diagnostic criteria to correctly classify Spitz 
tumors, but this has failed to lead to consensus on diagnostic criteria even among 
expert dermatopathologists (2-9). Moreover, even consensus on the diagnosis does 
not guarantee a correct prediction of outcome (4, 9). 
The lack of objective histological criteria in Spitz tumors illustrates the need for 
additional parameters to aid in this distinction. There are other tumor types (lymphoma, 
breast cancer) where integration of genetic and clinical data besides morphology 
and immunophenotype has resulted in an improved and more reproducible tumor 
classification and has even led to the discovery of new entities within the spectrum, 
and to new therapeutical approaches.
For Spitz tumors the demonstration of HRAS mutations in benign lesions seems a 
first break-through in an improved classification combining histopathology and 
mutation analysis (10). About 15% of Spitz nevi harbor an activating mutation 
(1, 10-12) of this oncogene which is part of the MAPK signaling transduction pathway 
(13, 14).  
Until now, no HRAS mutations have been found in spitzoid melanomas (1, 10-12) and 
so far no malignant progression of a Spitz tumor with a HRAS mutation has been 
described. Presence of a HRAS mutation in a Spitz tumor therefore seems to point to 
a good prognosis and/or a good clinical outcome (10, 11). HRAS mutation analysis 
therefore seems a prime candidate as an adjunct in the differential diagnosis of 
benign versus malignant Spitz tumor.  
The use of molecular techniques for the diagnosis of Spitz tumors is not yet widely 
used in common daily practice. In the past years, we have performed HRAS, BRAF, 
and NRAS mutation analysis on a large group of Spitz lesions (93 Spitz nevi and 77 
STUMPs). After integration of histological and molecular data and review of all HRAS 
mutated cases in our series, we noticed remarkable histomorphological similarities 
between all HRAS mutated Spitz tumors. Although this was previously briefly 
described by Bastian et al. (10), in our opinion most pathologists are unfamiliar with 
these rather distinct features in HRAS mutated Spitz tumors. Improved recognition 
and increased knowledge of these features may significantly improve the accuracy of 
the diagnosis. Therefore, in this article we will first highlight these features in a group 
of 24 HRAS mutated Spitz tumors. Secondly, we hope to point to the role direct 
molecular genetic testing could play in reaching a correct diagnosis and a sound 
prediction of outcome for the individual patient. 
48
Chapter 3
MATERIALS AND METHODS
Patients and histopathology
For this retrospective study, formalin fixed and paraffin embedded (FFPE) tissues of 
24 HRAS mutated Spitz tumors were reviewed.
The larger part of the material from our consultation practice had come from several 
pathology departments in The Netherlands. In the majority of cases the initial diagnosis 
had been made by a general pathologist, but in a few cases it had been reported by 
another expert dermatopathologist (cases 4, 11 and 15). The final histological diagnosis 
was made by a panel of three expert dermatopathologists (WB, MvD, DR), blinded to 
the initial diagnosis and to the results of mutation analysis.
Molecular analysis
DNA extraction 
About three manually dissected sections of 10 µm FFPE tissue with an estimated tumor 
cell percentage of at least 70% were used for DNA extraction. After deparaffinization 
and rehydration, the tissue sections were incubated in proteinase K, followed by 
subsequent affinity-purification of the DNA (QIAGEN GmbH, Germany). DNA sample 
concentration and quality were assessed spectrophotometrically (260/280 nm using 
a NanoDrop spectrophotometer, Peqlab Biotechnologies, Erlangen, Germany) and 
by PCR-amplification using the BIOMED-2 control gene primer set (15). All extracted 
DNAs allowed amplification of at least the 200 bp amplicon of the control gene PCR.
Mutation analysis
Direct sequence analysis of the HRAS gene was performed on all samples. For the 
BRAF and NRAS genes this was performed on 22 of the samples. For 2 lesions this 
could not be performed, due to lack of tissue. Exon 3 of HRAS and NRAS and exon 
15 of BRAF were sequenced. These are known hotspot regions for oncogenic 
mutations in melanocytic lesions of the skin (1, 16-19). The sequences of the primers 
Table 1  Primers used for mutation analyses
Gene Exon Forward (Fw) Reverse (Rv) Primer sequence 5’- 3’
BRAF 15 Fw CCTTTACTTACTACACCTCAG
Rv AAAAATAGCCTCAATTCTTAC
NRAS 3 Fw GATTCTTACAGAAAACAAGTGG
Rv TAATGCTCCTAGTACCTGTAGAG
HRAS 3 Fw CTGCAGGATTCCTACCGGA
Rv ACTTGGTGTTGTTGATGGCA
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used are listed in Table 1. All primers contained a M13 forward or reverse consensus 
sequence for sequencing the different exons. PCR amplification of exon 15 of BRAF 
and exon 3 of NRAS and HRAS was performed in a total volume of 20 µL. PCR mix 
containing 50 ng DNA, buffer IV (Integro), 3 mM MgCl2, 200 µM of each deoxynucleo-
tide triphospate, 30 µg bovine serum albumin (Sigma), 10 pmol of each primer and 
0.25 units of thermostable DNA polymerase (Sigma). DNA amplification was 
performed in a PTC 200 Thermal Cycler (MJ Research). The PCR was started with 
5 min at 94 °C and followed with 30 cycles of denaturation 45 seconds at 94 °C, 
annealing at 60 °C for 45 seconds and extension at 72 °C for 45 seconds, with a final 
extension at 72 °C for 5 minutes. All PCR products were purified with MinElute plates 
(Qiagen). One µl of the PCR product was used for the sequence reaction on an ABI 
PRISM 3700 DNA analyzer (Applied Biosystems). Both strands were sequenced using 
the M13 primers. 
RESULTS
Clinical features
Of the 24 patients, 14 were females and 10 were males. There was no predilection site 
(6 lesions were localized in the head and neck region, 2 on the trunk, 1 on the buttock, 
5 on the upper leg, 5 on the lower leg/foot and 3 on the distal forearm/hand. From two 
patients we could not retrieve information regarding the exact location). The ages 
ranged from 8 to 59 years (mean age: 25 years, median age: 22.5 years).  
At our referral center we classified 17 cases based on histopathological features 
alone as a Spitz nevus, and 7 cases as a STUMP. The initial diagnosis made by the 
original pathologist however was in 3 cases melanoma (cases 4, 11, and 15), and in 
4 cases melanoma was included in the differential diagnosis (cases 6, 14, 16, and 23). 
In the majority of  cases these initial diagnoses were made by general pathologists, 
but a few cases (cases 4, 11 and 15) had already been sent for consultation to an 
expert dermatopathologist. Patient characteristics are given in Table 2. 
Histological features
All lesions had both architectural and cellular features consistent with a diagnosis of 
a Spitz tumor. The lesions were symmetrical and sharply demarcated at the margins 
and all consisted largely of spindle and/or epithelioid cells with large vesicular nuclei 
containing prominent eosinophilic nucleoli and abundant compact, eosinophilic 
cytoplasm. 
The most important criterion for diagnosing STUMP (i.e., refraining from making a 
confident diagnosis of Spitz nevus) or for diagnosing melanoma was the presence of 
more than 2 mitoses /1 mm2 and the presence of deep mitoses, especially in patients 
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Table 1  Patient characteristics
Pat Sex Age Location Size 
(mm)
Clark
level
Mitoses• Mitoses/ 
2 mm2 
Initial 
diagnosis
Final
Diagnosis
Follow-up 
(years)
HRAS 
mutation
(type)
1 F 19 head/ neck < 10* 4 3 + Spitz N Spitz N 11 1
2 F 18 buttock < 12* 3 1 - Spitz N Spitz N 11 3
3 M 17 trunk NA 4 3 ++ Spitz N STUMP 10 1
4 F 12 lower leg/ foot 15 4 3 + Spitzoid melanoma STUMP 9 1
5 F 42 lower leg/ foot < 14* 4 1 - Spitz N STUMP 8 2
6 F 22 head/ neck NA§ NA 1 - STUMP dd Spitz N and melanoma Spitz N 7 2
7 M 10 head/ neck 9 4 2 + Spitz N Spitz N 18 4
8 M 13 NA 4 4 2 + Spitz N Spitz N 13 1
9 M 11 NA 7 4 1 - Spitz N Spitz N 11 2
10 F 8 head/ neck NA§ 4 3 + Spitz N Spitz N 12 5
11 M 39 upper leg 10 4 3 +++ Spitzoid melanoma STUMP 9 2
12 F 22 distal forearm/ hand NA 4 3 +++ Spitz N dd STUMP STUMP NA 1
13 F 16 upper leg NA 4 1 - No diagnosis Spitz N 4 1
14 M 34 lower leg/ foot NA 4 1 - Spitz N dd melanoma Spitz N 4 2
15 F 26 lower leg/ foot 10 4 1 - Spitzoid melanoma Spitz N 8 2
16 M 59 upper arm NA 4 3 ++ Spitz N dd nevoid melanoma STUMP 3 2
17 M 28 upper  leg 10 4 3 ++ Spitz N STUMP 20 6
18 M 8 head/ neck < 10* 5 1 - Spitz N Spitz N 18 1
19 F 27 distal forearm/ hand NA 3 1 - Spitz N Spitz N 16 1
20 F 47 upper  leg NA 4 1 - Spitz N Spitz N NA 1
21 M 29 head/ neck 4 4 1 - Spitz N Spitz N 2 1
22 F 32 trunk 4 4 2 + Spitz N Spitz N 16 1
23 F 32 upper  leg 8 4 1 - Spitz N dd melanoma Spitz N 9 1
24 F 23 lower leg 3 4 2 + Spitz N Spitz N 13 1
NA= not available; Sex: F= female, M= male;  •: 1= no mitoses, 2= only superficial and not atypical,  
3= atypical and/or deep; : dermal number of mitotic figures per 2 mm2: - = no mitoses, += < 2, ++= 2-5, 
+++= > 5; * size of the excision; § : biopsy; dd= differential diagnosis; Spitz N= Spitz nevus, STUMP= 
Spitz tumor of unknown malignant potential; HRAS mutation: 1=  c.181A>T (p.Gln61Leu), 2= c.181A>G 
(p.Gln61Arg), 3= c.182_183 delins TA CAG>CTA, 4= Gln61His c.183 G>T CAG>CAT, 5= c.181_182 delins 
AG CAG>AGG, 6= c.182_183 delins GA CAG>CGA
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1 F 19 head/ neck < 10* 4 3 + Spitz N Spitz N 11 1
2 F 18 buttock < 12* 3 1 - Spitz N Spitz N 11 3
3 M 17 trunk NA 4 3 ++ Spitz N STUMP 10 1
4 F 12 lower leg/ foot 15 4 3 + Spitzoid melanoma STUMP 9 1
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15 F 26 lower leg/ foot 10 4 1 - Spitzoid melanoma Spitz N 8 2
16 M 59 upper arm NA 4 3 ++ Spitz N dd nevoid melanoma STUMP 3 2
17 M 28 upper  leg 10 4 3 ++ Spitz N STUMP 20 6
18 M 8 head/ neck < 10* 5 1 - Spitz N Spitz N 18 1
19 F 27 distal forearm/ hand NA 3 1 - Spitz N Spitz N 16 1
20 F 47 upper  leg NA 4 1 - Spitz N Spitz N NA 1
21 M 29 head/ neck 4 4 1 - Spitz N Spitz N 2 1
22 F 32 trunk 4 4 2 + Spitz N Spitz N 16 1
23 F 32 upper  leg 8 4 1 - Spitz N dd melanoma Spitz N 9 1
24 F 23 lower leg 3 4 2 + Spitz N Spitz N 13 1
NA= not available; Sex: F= female, M= male;  •: 1= no mitoses, 2= only superficial and not atypical,  
3= atypical and/or deep; : dermal number of mitotic figures per 2 mm2: - = no mitoses, += < 2, ++= 2-5, 
+++= > 5; * size of the excision; § : biopsy; dd= differential diagnosis; Spitz N= Spitz nevus, STUMP= 
Spitz tumor of unknown malignant potential; HRAS mutation: 1=  c.181A>T (p.Gln61Leu), 2= c.181A>G 
(p.Gln61Arg), 3= c.182_183 delins TA CAG>CTA, 4= Gln61His c.183 G>T CAG>CAT, 5= c.181_182 delins 
AG CAG>AGG, 6= c.182_183 delins GA CAG>CGA
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over 17 years of age. Deep mitoses were defined as mitoses in the deep half and/or 
at the base of the lesion. Mitoses were quantified by searching for a hotspot in the 
dermis and counting 1 mm2.
The tumors were all predominantly intradermal with no or very little epidermal 
involvement, had a relatively low cellularity and showed desmoplasia with single 
melanocytic cells interspersed between the dermal collagen bundles. Where this 
growth pattern continued into the base of the lesion, the term “infiltrative growth pattern” 
was applied. An overview of the distinctive histologic features is given in Table 3. It is 
illustrated in Figure 1. Finally, the lesions contained very little or no melanin pigment 
and cells had vesicular nuclei: these features were not considered distinctive since 
they are quite common in Spitz tumors of all types. 
Molecular findings 
Six different mutations were found in exon 3 of HRAS. There was no correlation 
between the type of mutation and the phenotype of the lesion; the different types of 
mutation were associated with the same histomorphologic changes. In 21 of the lesions 
BRAF exon 15 and NRAS exon 3 were also tested, but no mutations were found.
Follow-up
Follow-up data was retrieved from the Dutch nationwide histopathology and 
cytopathology data network and archive (PALGA) (20).  Follow-up data was available 
in 22 of the 24 cases; median and mean follow-up were both 10.5 years (range 2 to 
20 years). All patients had remained free of disease. 
Table 3   Histologic features of HRAS mutated Spitz tumors
Histologic feature Number of lesions
Predominantly intradermal localization n= 24 (24/24= 100%)
Relatively low cellularity n= 10 (10/24= 42%)
Single cells between collagen bundles n= 23 (23/24= 96%)
Desmoplasia n= 21 (21/24= 88%)
Infiltrative base n= 22 (22/23*= 96%)
* in one case the base could not be examined  due to extensive positive resection margins
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Figure 1  Four HRAS mutated Spitz tumors. 
Note the architectural similarities with the mainly intradermal localisation and the relatively low 
cellularity. A, B: case 2; Spitz nevus. B shows the desmoplasia with single cells between the 
collagen bundles. C, D: case 14; Spitz nevus, initial differential diagnosis melanoma. D shows 
the infiltrative base of the lesion. E, F: case 5; spitzoid tumor of unknown malignant potential 
(STUMP). F shows the desmoplasia. G, H: case 11; STUMP, the initial diagnosis was spitzoid 
melanoma. There are multiple dermal mitoses (H, arrows).
A B
C D
E F
G H
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DISCUSSION
In this article we describe the distinct histological features of HRAS exon 3 mutated 
Spitz tumors. Meticulous evaluation of the histomorphological features of these 
lesions remains of great importance to help avoid misdiagnosis. Awareness of the 
characteristic features described in this article and mutation analysis may contribute 
to this. This is especially important since it is in general hard to predict the outcome 
of an atypical Spitz tumor in an individual patient (4). However, the presence of a 
HRAS mutation seems to be associated with a favorable prognosis: so far, none of 
the patients with HRAS mutated Spitz tumors developed recurrent disease, and no 
HRAS mutations have been found, or previously reported, in spitzoid melanomas 
with distant metastases or fatal outcome. Follow-up over 6-8 years of the 12 cases 
with 11p copy number increase that Bastian et al. (10) described, showed no evidence 
of metastases. Da Forno et al. (11) performed HRAS mutation analysis in 21 Spitzoid 
melanomas and no mutations were found. In addition, these workers did not find 
HRAS mutations in 22 non-spitzoid melanomas. They stated that, based on the 
known HRAS mutation frequency of approximately 15% in Spitz nevi and the absence 
of HRAS mutations in spitzoid melanomas, it  would seem unlikely that HRAS mutated 
Spitz nevi should progress into spitzoid melanomas. In a series of 36 Spitzoid 
melanomas Van Dijk et al. (1) found no HRAS mutations.  They identified HRAS 
mutations in 4/14 (29%) cases of Spitz nevi, and in 3/22 (14%) cases  of atypical Spitz 
nevi. Follow-up of 7.8 years and 6 years, respectively, showed no evidence of 
recurrence or metastases in lesions harboring a HRAS mutation. Takata et al. (21) 
found no HRAS mutations in 22 non-spitzoid melanomas. However, they did not find 
any HRAS mutations in 11 typical Spitz nevi and 16 atypical Spitz tumors, either, 
which is in contrast to the other studies referred to here. All the studies that have 
determined the HRAS mutation status are consistent that no HRAS mutations are 
found in spitzoid melanomas and so far no metastases have been reported for Spitz 
tumors with a HRAS mutation. This was also the case in our series, in which none of 
the patients developed metastases, even after many years of follow-up. Detection of a 
HRAS mutation therefore seems to correlate with benign biological behavior. An overview 
of the mentioned studies is provided in Table 4.
In older patients especially, where the a priori chance of a melanoma is higher, Spitz 
nevi are at risk of being misdiagnosed as a melanoma. In the present series of 24 
cases of HRAS mutated Spitz tumors, in 7 cases (29%) the initial diagnosis was 
melanoma or melanoma was an important differential diagnostic consideration. 
We’ve illustrated that in the HRAS mutated Spitz tumors, even in higher age groups, 
mitoses are frequently seen; in 5 cases (1, 11, 12, 16, 17) more than 2 dermal mitoses/ 
mm2 and/or deep mitoses were seen (21% of cases). Deep mitoses were defined as 
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mitoses present in the lower half and/or at the base of a lesion. If one is unfamiliar with 
the distinct histopathological features of HRAS mutated Spitz tumors, characterized 
by a predominantly intradermal localization, a relatively low cellularity, desmoplasia 
and single cells between the collagen bundles, an infiltrative base and no or very little 
melanin pigment, the risk of misdiagnosis is probably very significant. Bastian et al. 
(10) already described the characteristic histopathological appearance in 12 Spitz 
nevi with 11p copy number increase involving the HRAS gene. In 8 of these 12 lesions 
a HRAS mutation was found. Consistent with their data we found that these lesions 
were mainly intradermal, showed single cells, often with vesicular nuclei, lying 
between the collagen bundles and desmoplasia. Bastian and colleagues described 
eosinophilic membranes and marked nuclear pleomorphism. Although we could not 
identify such eosinophilic membranes, some cells were surrounded by eosinophilic 
material, which we interpreted as the presence of a small amount of collagen around 
the cells. We also did not consider the nuclear pleomorphism to exceed that normally 
seen in Spitz nevi. 
The reported mutation frequencies in Spitz tumors vary considerably between 
different studies, not only for HRAS, but also for BRAF and NRAS as reviewed by Da 
Forno et al. (17). Possible explanations are lack of consistency of the diagnostic 
criteria and variations in age distribution. Moreover, there might have been a difference 
in the percentage of tumor cells in the lesions used for DNA isolation.  In most of the 
studies this is not specified, while a reliable PCR and mutation analysis requires a 
tumor cell percentage of at least 50%; a lower percentage might lead to false negative 
Table 4   Comparison of HRAS mutation data and follow-up in published studies  
of Spitz tumors
Study Spitz N Atypical 
Spitz N
STUMP Spitzoid 
melanoma
Follow-up 
(years)*
Bastian et al  2000 (10) 8/102 - - - 6-8 
Van Dijk et al 2005 (15) - - - 0/36 -
4/14 - - - 7.8
- 3/22 - - 6
Takata et al 2007 (21) 0/11 0/16 - 0/22 -
Da Forno et al
2009 (11)
- - - 0/21 -
Present study 17 - 7 - 10.4
Spitz N= Spitz nevus; STUMP= Spitz tumor of unknown malignant potential. 
* Follow up in years. No recurrences or metastases were reported.
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results. This requirement of a high tumor percentage is at present an important 
limitation for the diagnostic use of HRAS and BRAF mutation analysis by traditional 
PCR and sequence analysis in melanocytic tumors. A practical consequence for the 
general pathologist is that there should be enough tumor material left when a case is 
sent for consultation. Another limitation is the relative low frequency of HRAS 
mutations in Spitz tumors. Therefore only a small proportion of the lesions can be 
classified based on the HRAS mutation status. Perhaps more sensitive techniques, 
such as high resolution melting assay (HRMA), may allow an increase in the number 
of Spitz tumors that can be analyzed and reveal that more Spitz tumors contain 
mutations than presently thought. We expect that, in the near future, classification of 
melanocytic tumors and more specifically of Spitz tumors will combine morphology 
and genetic data, and that this integrated classification will allow for a more objective 
approach to predict the biological behavior of individual tumors. Despite the 
limitations of the present technique of HRAS mutation analysis by PCR and 
sequencing, it does seem a most rewarding step towards a more reproducible and 
objective classification in a subset of Spitz tumors. We therefore advocate that 
mutation analysis for HRAS be performed, preferentially together with BRAF in case a 
diagnosis of STUMP is considered since this is more common in spitzoid melanomas 
and very rarely found in Spitz nevi (22).
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ABSTRACT  
To further elucidate the genetic underpinnings of uveal melanoma (UM) and identify 
new markers that correlate with disease outcome, archival formalin-fixed paraffin 
embedded enucleation specimens from 25 patients with UM and a mean follow-up 
of 14 years were analyzed for whole genome copy number alterations using 
OncoScan analysis. Copy-number alterations of chromosomes 1, 3, 6 and 8 were 
also analyzed in these tumors using multiplex ligation-dependent probe amplification, 
and mutations in GNAQ, GNA11 and BAP1 were searched for by Sanger sequencing. 
Our study confirms the previously reported GNAQ and GNA11 mutation frequencies 
in UMs as well as the presence of monosomy 3 as a factor strongly indicating poor 
prognosis. Two cases with metastatic disease, but without monosomy of chromosome 
3, showed loss of a small region in the distal part of chromosome 2p. Also, UMs 
leading to metastatic disease had more chromosomal aberrations than those without 
metastases. Three UMs lacking a GNAQ or GNA11 mutation showed a gain of 
chromosome 8q; one of these cases demonstrated extensive chromothripsis. 
Another case (with suspect lung metastasis) showed focal chromothripsis. Our whole 
genome copy-number analysis shows that focal loss of chromosome 2p may be 
involved in metastatic spread of UMs without monosomy 3; metastatic UMs carry 
more chromosomal aberrations than those without metastases; and chromothripsis 
may play a role in the oncogenesis of Ums, but does not necessarily indicate a poor 
prognosis. The clinical and particularly diagnostic utility of these findings needs to be 
corroborated in a larger set of patients with UM.
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INTRODUCTION
Uveal melanomas (UMs) are the most common primary intraocular malignancy in 
adults, with an incidence of 6 per million population in the USA (1). Approximately 
50% are fatal, usually as a result of metastatic disease (2) for which, even nowadays, 
there is no effective treatment. In the past, prognostic factors employed to indicate 
patients at risk of metastatic disease included clinical and histological features, such 
as tumor diameter and location (2,3), cell type, closed connective tissue loops, and 
mitotic rate (3,4). Like in other neoplasms, genetic alterations have been proven to play 
an important role in the development and progression of UM. Over the past 15 years, 
it has become clear that these genetic alterations are better predictors of prognosis 
than the traditional clinicopathological factors (5,6). 
Recently, gene expression profiling has shown that UMs can be divided into two 
distinct molecular subgroups with different prognoses: class 1 lesions, with a low risk 
of metastasis, and class 2 lesions, with a high risk of metastatis (5,7). In most of 
the cases with metastasis (84%), there is a monosomy of chromosome 3, which is 
often associated with an inactivating mutation in the tumor-suppressor gene BRCA1- 
associated protein-1 (BAP1, a ubiquitin carboxyterminal hydrolase) (8) located on the 
remaining chromosome 3 (9).
BAP1 mutations are considered to be late events that coincide with the onset of 
metastatic behavior (9). In contrast, GNAQ and GNA11 mutations at codon 209 
(Q209) or 183 (R183) are thought to occur early in the pathogenesis of UMs (10). 
GNAQ and GNA11 mutations have been described in 45% and 32% of UMs, 
respectively (10-14). Both GNAQ and GNA11 encode for heterotrimeric guanine nu-
cleotide-binding protein (G protein) αq subunits that mediate signals between G-pro-
tein-coupled receptors and their downstream pathways (15) and are involved in 
determining skin and hair pigmentation (16,17). Mutations result in constitutive mito-
gen-activated protein (MAP) kinase activation, turning them into oncogenes. The 
GNAQ and GNA11 mutational status is not significantly correlated with disease-free 
or overall survival (11,14).
However, not all UMs harbor a GNAQ or GNA11 mutation. In earlier studies, in 17% (14) 
and 9% (18) of UMs, respectively, no GNAQ or GNA11 mutation was found. In addition, 
not all cases of metastatic UM carry mutations in BAP1 (9) or show monosomy 3, 
suggesting that additional oncogenic events are involved in UM initiation and 
progression. 
In the present study, we performed a whole-genome screen of copy-number 
alterations using OncoScan analysis. This platform allows for analysis of over 335,000 
probes with a 50- to 100-kb copy-number resolution in ~900 cancer genes and a 
300-kb genome-wide copy-number resolution outside these cancer genes. In addition, 
we applied multiplex ligation-dependent probe amplification (MLPA) analysis. MLPA 
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is a more targeted approach and routinely used in many pathology laboratories. In the 
present study, in particular, chromosomes 1p, 3, 6, and 8 were analyzed by MLPA. 
Both OncoScan and MLPA analysis can theoretically be exploited for assessment of 
DNA obtained from formalin-fixed paraffin-embedded (FFPE) tissue blocks. Finally, we 
also performed mutation analysis of GNAQ, GNA11, and BAP1 by Sanger sequencing 
in 25 primary UM cases.
Results of the genomic analysis were correlated with clinicopathological characteristics 
and follow-up. We confirmed existing prognostic chromosomal aberrations and identified 
potential new mechanisms for UM initiation and chromosomal areas that may 
correlate with metastatic behavior.
MATERIALS AND METHODS
Patients and material
For this retrospective study, FFPE enucleation specimens from 25 patients treated for 
primary UM between 1992 and 2007 at the Department of Ophthalmology of the 
Radboud University Medical Center in Nijmegen, the Netherlands, were included. 
Mean follow-up was 14 years. Follow-up data were available for 19 of the patients, as 
shown in Table 1. For four patients, follow-up was unknown, and for two patients, 
follow-up was uncertain (possible metastasis but not proven). As far as we know, 
none of the patients had a family history of UM. The FFPE samples were retrieved 
from our archives and the tissue blocks stored at room temperature. Hematoxylin and 
eosin-stained sections of all cases were reviewed (ACvEvG, PW) and all cases were 
scored with respect to important pathological factors, such as tumor location and 
size and cell type. The diagnosis of melanoma was made on hematoxylin and 
eosin-stained sections. Anonymized patient information and follow-up data until 2011 
were obtained, and data assessment was performed according to the Human tissue 
and medical research: code of conduct for responsible use (http://www.federa.org/
sites/default/files/digital_version_first_part_code_of_conduct_in_uk_2011_12092012.
pdf). 
DNA extraction and sequence analysis 
DNA extraction and sequence analysis were performed as previously described (19). 
The DNA quality of the samples was tested using the BIOMED-2 gene control 
polymerase chain reaction (PCR) (see Table 1). Mutation detection was performed 
for hotspot mutations in exon 5 (codon Q209) and exon 4 (codon R183) in GNAQ and 
GNA11 (accession number (no.) NT_011255.14 and NG_027904.1, respectively) and 
for all exons of BAP1 (accession no.: NC_000003.11) for all cases. In selected cases, 
exon 15 of BRAF (accession no.: NG_007873.1) and exons 2 and 3 of NRAS (accession 
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no.: NG_007572.1) were analyzed for hotspot mutations. Primer sequences are listed 
in supplementary Table 1. In one of the cases with a BAP1 mutation (case UM 23), 
the presence of a germline mutation was excluded by testing normal DNA. In the 
other BAP1-mutated cases this could not be performed as the patients did not give 
permission for testing for germline mutations and/or there was a lack of normal DNA. 
GNAQ and GNA11 mutation analysis has only been performed in tumor material 
since no germline mutations have been described in these genes in patients with UM 
(20). 
Analysis of copy-number variations 
OncoScan analysis
Copy-number alterations were determined by OncoScan array analysis (molecular 
inversion probe (MIP) technology) (essentially as described by Wang et al. (21)). This 
array consists of more than 335,000 markers, which cover the entire genome with 
high resolution of cancer genes. DNA extracted from the lesions was processed by 
the Affymetrix Research Services Laboratory (ARSL, Santa Clara, CA, USA). The 
normalized OncoScan data were analyzed with the Nexus copy-number software 
version 5.1 (Biodiscovery, Inc, El Segundo, CA, USA) for detection and analysis of 
copy-number variation. 
MLPA procedure and data analysis
To evaluate copy-number changes, we used MLPA kit P027-B1 (MRC-Holland, 
Amsterdam, The Netherlands) containing probes on chromosomes 1p (seven probes), 
3p (nine probes) and 3q (four probes), 6p (four probes) and 6q (two probes), and 8p 
(one probe) and 8q (four probes). Twelve other probes were used as reference probes 
(http://www.mlpa.com). Immortalized cell lines of healthy controls were used as normal 
control samples. MLPA was performed according to the manufacturer’s instructions.
RESULTS
Patients and material
Patient and tumor characteristics are listed in Table 1. Of the 25 patients, 12 were 
female and 13 male. Mean age of the patients was 59 years. Twenty tumors were 
located at the choroid, four at the ciliary body, and one was ciliochoroidal. The mean 
diameter of the tumors was 1.3 cm. Cell type was either epithelioid (four cases), 
spindle (nine cases) or mixed (twelve cases). 
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Chapter 4
Mutation analysis 
All 25 primary UMs were tested for hotspot mutations in GNAQ and GNA11. The 
results are summarized in Table 1. Twenty-two cases (88%) had either a GNAQ or 
GNA11 mutation (n = 11 for GNAQ as well as for GNA11). These mutations were 
mutually exclusive and included only exon 5 (Q209) mutations. The three UMs without 
GNAQ or GNA11 hotspot mutations were analyzed for mutations in the entire exons 4 
and 5 of GNAQ and GNA11 by Sanger sequencing, as well as for mutations in exon 
15 of BRAF, and exons 2 and 3 of NRAS. However, no mutations in these exons were 
observed. 
BAP1-mutation analysis was performed on all samples. Unfortunately, the DNA 
extracted was suboptimal for proper Sanger sequencing of BAP1: appropriate 
evaluation of all 17 exons of BAP1 in these FFPE-derived DNA specimens would 
require design and analysis of small (<100 bp) amplicons for sequence analysis and 
a substantial amount of DNA per sample, which was not feasible. We therefore 
proceeded with our routine BAP1-Sanger sequencing protocol, which uses amplicons 
of 150–250 bp, to analyze the BAP1 mutational status. The percentage of the exons 
that could be properly evaluated is given in Table 1. The majority of the BAP1 coding 
sequence could be evaluated by sequence analysis in the DNA specimens that 
could amplify 200 or 300 bp of the control gene PCR, while part of the BAP1 coding 
sequence could be evaluated in highly degraded cases that could only amplify 100 
bp or less of the control gene PCR (see Table 1). We identified BAP1 mutations in four 
of the 15 UMs with monosomy 3 (26%).
Copy-number variations by OncoScan analysis
OncoScan analysis was successfully performed on all cases. Due to the technology 
of the molecular inversion probes that hybridize to a DNA target in two locations 
spanning a 40-bp “footprint” (21), even the suboptimal DNAs extracted from the 
relatively old FFPE samples were suitable for this analysis. The analysis gave a 
complete overview of copy-number variations of the entire genome. We found a 
difference in the number of copy-number variations between patients with and 
without metastatic disease. As illustrated in Figure 1, the 12 patients with known 
metastases (cases 1, 2, 4, 5, 7, 8, 9, 10, 15, 19, 23, and 24) had more chromosomal 
aberrations than the six cases without metastases (cases 13, 14, 16, 20, 21, and 22).
The occurrence of aberrations of chromosome 1, 3, 6, and 8 were separately analyzed 
in relation to metastases. Seven cases were excluded from this analysis: five because 
of unknown or uncertain follow-up data (cases 3, 6, 11, 12, 17, and 18) (see Table 1) 
and one case (case 25) because a typical pattern of chromosomal imbalance was 
shown (chromothripsis; to be discussed later), which precludes appropriate analysis 
of the chromosomal copy-number alterations. Ten of the 12 patients with a metastasis 
showed monosomy of chromosome 3 (83%). In all of these cases, the entire 
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chromosome 3 was lost. Furthermore, this loss was correlated with a loss of 
chromosome 1p and a gain of chromosome 8q, as is shown in Figure 1B. The six 
patients without metastases did not show monosomy 3, but all of these patients did 
have a gain of chromosome 6p (such a gain being present in four of the 12 patients 
with metastastic disease). Furthermore, loss of chromosome 6q was quite common 
in both groups (half of the cases in both the non-metastastic and the metastatic 
tumors), as well as a chromosome 8q gain (three and 11 cases in non-metastastic 
metastatic tumors, respectively). The minimal common overlapping regions in the 
non-metastatic and the metastatic tumors are indicated in Figure 1C.
Two patients (cases 15 and 19) had metastatic disease, but no monosomy of 
chromosome 3. An overview of the OncoScan data of these two patients is shown in 
Figure 2. The tumors of both these patients showed loss of a small region on the 
distal part of chromosome 2p (2Mb, chr2: 1-2,356,641), which is only found in these 
two cases. Furthermore, in both UMs, a high copy-number gain of chromosome 8q, 
loss of chromosome 1p, gain of chromosome 6p, and loss of chromosome 6q were 
found, but this was also seen in other cases. As can be seen in Table 1, one of these 
cases had a GNAQ mutation and the other had a GNA11 mutation. In addition, these 
two patients differed substantially in age, the tumors had different locations and cell 
types, but otherwise these two tumors did not show any specific histological charac-
teristics.
The three cases in our series without a GNAQ or GNA11 mutation (and without hotspot 
BRAF or NRAS mutations) all showed a gain of chromosome 8q. Interestingly, one of 
these cases (case 25) showed alternating small gains and deletions that is typical of 
chromothripsis (21) in multiple chromosomes, notably chromosomes 1, 3, 6, and 8. 
The chromothripsis of chromosome 3 had been interpreted as a partial loss on the 
MLPA. Another case (case 11, with a GNAQ mutation) also showed chromothripsis, 
but only of chromosome 13 (see Figure 3).
Besides the chromosomal changes described above, the OncoScan analysis 
showed that no other chromosomal abnormalities were shared in a large percentage 
of the patients.
Our MLPA analysis revealed monosomy of chromosome 3 in 15 of the UMs, which is 
completely concordant with the results obtained by OncoScan analysis. Of note, in 
the MLPA platform we used, chromosome 3 is represented by 13 probes, allowing for 
relatively robust testing of chromosome 3 status. In contrast, MLPA analysis of 
copy-number variations in chromosomes 1p (seven probes), 6p (four probes), 6q 
(two probes), 8p (one probe) and 8q (four probes) in ‘old archival’ FFPE material, as 
used in our study, often showed discordant results in flanking probes and was 
therefore considered to be insufficiently robust.
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Figure 2  OncoScan data of the two cases (UM15 (A) and UM19 (B)) with metastasis, but without 
monosomy 3, and the 10 cases with metastasis and monosomy 3 (C). 
The different chromosomes are shown with the location of the gains (in blue) and losses (in 
red). The two cases without monosomy 3 share chromosome 6 aberrations, loss of chromosome 
1, and a high copy-number gain of  chromosome 8q, aberrations also seen in cases with 
monosomy 3. Loss of a small region at the distal part of chromosome 2p (indicated by an 
arrow) is seen in both uveal melanomas without monosomy 3 (A and B) but not in those with 
monosomy 3 (C). The shorter region of loss of chromosome 2 in case UM19 (B) may narrow 
down the region of interest with regard to the location of a putative tumor-suppressor gene.
A
B
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The present study was performed to further unravel genetic alterations involved in the 
initiation and progression of UM by performing a whole-genome screen of 
copy-number alterations by using OncoScan analysis, MLPA, and mutation analysis. 
Of the 25 UM cases included in this study, 11 (44%) had a GNA11Q209 hotspot mutation 
and another 11 (44%) a GNAQQ209 hotspot mutation. The three cases (12%) without 
GNAQ or GNA11 mutations (and without hotspot BRAF and NRAS mutations), all 
showed a gain of 8q. In addition, one of these cases (case 25) showed a very typical 
pattern of alternating small gains and deletions in multiple chromosomes that is 
typical of chromothripsis (22) (see Figure 3). To the best of our knowledge, 
chromothripsis has not been described in UM before. In chromothripsis, a single 
catastrophic event leads to fragmentation of specific regions of the genome, after 
which DNA repair mechanisms piece the fragments together in the wrong order. This 
results in a genomic landscape with multiple chromosomal rearrangements, which is 
thought to promote cancer development (23). It has been observed in various cancer 
types (22) and has been associated with a poor prognosis in multiple myeloma (24), 
acute myeloid leukemia (25), medulloblastoma (25,26), and recently in cutaneous 
melanoma (27). Interestingly, the chromosomes affected in this tumor are 
chromosomes 1, 3, 6, and 8, which also frequently show other aberrations in UMs. 
Furthermore, a GNAQ or GNA11 mutation was lacking in case 25 and the patient had 
not developed metastases after 17 years of follow-up. Less extensive chromothripsis 
involving only chromosome 13 (a chromosome not known to play a part in UM 
development or progression) was found in another case. We did not find any 
copy-number variations in chromosome 13 in the other cases. The role of chromo-
Figure 2  Continued.
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Figure 3  OncoScan data of the two cases (UM11 (A) and UM25 (B)) with chromothripsis. 
The graphs show the typical pattern of many small deletions and gains. A shows chromothripsis 
of chromosome 3 in case UM25 (which showed chromothripsis of chromosomes 1 and 6 as 
well). B shows chromothripsis of chromosome 13 in case UM11 (i.e. the only chromosome 
affected by chromothripsis in this case).
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thripsis in UMs is intruiging, but not yet understood, and (as demonstrated by one of 
our cases) its presence does not necessarily signify a grim prognosis.
The GNAQ and GNA11 mutation frequencies we found are in accordance with those 
reported in the literature. Van Raamsdonk et al. (14) reported GNA11Q209 hotspot 
mutations in 32% of UMs and GNAQQ209 hotspot mutations in 45%, whereas no GNAQ 
or GNA11 hotspot mutations were found in 17%. Daniels et al. (18) found GNA11Q209 
hotspot mutations in 43% of UMs and GNAQQ209 hotspot mutations in 44%, and no 
GNAQ or GNA11 hotspot mutations in 9%. In these studies, R183 exon 4 hotspot 
mutations were reported in 6% and 4% of the cases, respectively. In our relatively 
small series, we did not find exon 4 hotspot mutations. Metastasis occurred in 27% of 
the patients with a GNAQ mutation and in 73% of the patients with a GNA11 mutation, 
corroborating the suggestion of previous studies that GNA11 mutations are correlated 
with a higher chance of metastatic disease (17,27,28,29).
UMs with metastases showed more chromosomal aberrations, as assessed by 
OncoScan analysis, than those without (Figure 1). An association between the 
degree of chromosomal instability and disease outcome has also recently been 
described in cutaneous melanoma (30). However, in our series, there were, individual 
metastatic cases with relatively few aberrations and cases without metastases with 
relatively many aberrations, indicating that the number of aberrations cannot be used 
for determination of the prognosis in an individual case. Monosomy 3 was seen in 15 of 
the cases, which is in concordance with the literature. In all cases with monosomy 3 
in our series, the whole chromosome 3 was lost. Loss of the 1p chromosomal region 
was seen in 65% of our cases with metastatic disease, but not in those without. Many 
genes are located on this chromosome arm, which makes it difficult to determine if a 
specific gene located here might be important for metastatic behavior. A gain of 
chromosome 8q was previously reported to be correlated with metastatic disease 
(31), but this aberration also occurred in patients without metastatic disease (see 
Figure 1). A gain of chromosome 6p has been associated with a good prognosis 
(32,33), and this is confirmed by our results. All patients without metastasis showed 
a gain of chromosome 6, while such a gain was only found in 33% (four out of 12) of 
the patients with metastatic disease. Two patients with metastatic disease, but without 
monosomy 3, showed, besides aberrations on chromosomes 1, 6, and 8, loss of an 
overlapping small region on the distal part of chromosome arm 2p. Interestingly, 
these are the only tumors with this loss. To our knowledge, no (tumor-suppressor) 
genes located on this specific part of chromosome 2 have yet been reported that 
could be involved in the development or progression of UMs. Recently, the presence 
of somatic mutations in SF3B1 (34) and EIF1AX (35) has been described in UM with 
disomy 3 in particular (48% and 29%, respectively, in a series of 31 UM cases with 
disomy 3 vs 5.7% in 35 UM cases with monosomy 3 (35)). Mutations in these genes 
are associated with a good prognosis, and are mutually exclusive with BAP1 
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mutations. The SF3B1 gene is located at chromosome 2q33.1. EIF1AX is located at 
Xp22.1 (35). The knowledge of mutations in SF3B1 and EIF1AX can enhance patient 
prognosis beyond that determined by tumor characteristics, chromosome 3 status, 
and BAP1 mutation status (36). 
As discussed above, the combination of archival FFPE material (that had been stored 
for at least 14 years and of which often only PCR-amplicons of less than 100 bp could 
be retrieved) and the fact that for adequate assessment of BAP1 mutations, the 17 
exons comprising of 2190 nt need to be interrogated allowed us to identify BAP1 
mutations in only three of our cases with monosomy 3 (25%). Of note, it has been 
reported that 84% of UMs carry a BAP1 mutation (9). 
It should also be mentioned that, in this study, only enucleation specimens were 
used, which implies we have studied a subgroup of relatively large UMs since large 
UMs, in particular, are treated with enucleation. There might be tumor heterogeneity. 
Maat et al. (37) have studied the heterogeneity of monosomy 3 status in UMs and 
have shown that large tumors can have intratumor heterogeneity. Onken et al. (38), 
however, performed transcriptomic profiling of fine-needle biopsies from UMs and 
showed that there was little or no intratumor heterogeneity. In the present study, 
tumor heterogeneity was not addressed due to the lack of availability of multiple 
samples from the tumors. 
In conclusion, our mutation analysis of FFPE material from 25 primary UM cases 
confirmed previously reported results on GNAQ and GNA11 mutation frequencies in 
UM as well as on the presence of monosomy 3 as a factor strongly indicating poor 
prognosis. Additionally, whole-genome (OncoScan) copy-number analysis revealed 
that cases with metastases generally have more chromosomal aberrations than 
those without, and identified chromothripsis and chromosome 8q gain as potential 
mechanisms for initiation of UM. Furthermore, our results indicate that loss of a small 
region on chromosome 2p may be involved in the development of metastatic disease. 
The exact role of these genetic aberrations in the oncogenesis and/or metastatic 
spread of UMs needs to be further investigated in a larger study. 
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Supplementary Table 1   Primers used for mutational analysis
Gene Exon Forward (Fw)  
Reverse (Rv)
Primer sequence 5’- 3’
BAP1 1 Fw TGTAAAACGACGGCCAGT  CTGGACATGGCGCTGAG
Rv CAGGAAACAGCTATGACC  GGTGATGGTCAGGCAGG
BAP1 2 Fw TGTAAAACGACGGCCAGT  AGAGCGACCCAGGTGAG
Rv CAGGAAACAGCTATGACC  GCAGTAGGGAAGGACAGC
BAP1 3 Fw TGTAAAACGACGGCCAGT  CTCACTCATCAGGGGCTG
Rv CAGGAAACAGCTATGACC  CTGTTCTCTGGGACCTTCC
BAP1 4 Fw TGTAAAACGACGGCCAGT  TGATTGTCTTCTCCCCTTTG
Rv CAGGAAACAGCTATGACC  CAAAAACATGGCAGCATCC
BAP1 5 Fw TGTAAAACGACGGCCAGT  GCTTGCAGTGAGGGGTG
Rv CAGGAAACAGCTATGACC  GGTCAGATCTGCCCAGTTG
BAP1 6 Fw TGTAAAACGACGGCCAGT  CATAGTCCTACCTGAGGAG
Rv CAGGAAACAGCTATGACC  ATGATACTCCCCCTACTCC
BAP1 7 Fw TGTAAAACGACGGCCAGT  TGGGAGTAGGGGGAGTATC
Rv CAGGAAACAGCTATGACC CCTAGGAGGTAGGCAGAG
BAP1 8 Fw TGTAAAACGACGGCCAGT CCAAACTCAGGGTTTCCTTC
Rv CAGGAAACAGCTATGACC  CTCTCTGTCCCTCCCAAAG
BAP1 9 Fw TGTAAAACGACGGCCAGT  TATCTGCCTCAACCTGATG
Rv CAGGAAACAGCTATGACC  GAGGAGGAATGCAGGGAG
BAP1 10 Fw TGTAAAACGACGGCCAGT  AGCCCGGGTCTACCCTTTC
Rv CAGGAAACAGCTATGACC  TGTCAGACATTAGCGGGTG
BAP1 11a Fw TGTAAAACGACGGCCAGT  GGGAGACTGTGAGCTTTTC
Rv CAGGAAACAGCTATGACC ATTGTCTAGAAAGGCCGGC
BAP1 11b Fw TGTAAAACGACGGCCAGT  GGTTCATGCGCACAAGC
Rv CAGGAAACAGCTATGACC  TTGCCTGTTGCAGCCTC
BAP1 12 Fw TGTAAAACGACGGCCAGT  CCGAGCAGCACTTGTTTG
Rv CAGGAAACAGCTATGACC  CAGGATGGGATCCGAAG
BAP1 13a Fw TGTAAAACGACGGCCAGT  ATGGTCACCTGGCCCGTTC
Rv CAGGAAACAGCTATGACC  TGAGGGCTGCGAGTGTG
BAP1 13b Fw TGTAAAACGACGGCCAGT  ACCTCTCAATTCCTCTGTCC
Rv CAGGAAACAGCTATGACC  CAGGCTGTCATCCTCTCC
BAP1 13c Fw TGTAAAACGACGGCCAGT  CTCGCCTATCCGCTCAG
Rv CAGGAAACAGCTATGACC  CTCCTGGGTGCACCAAG
BAP1 14 Fw TGTAAAACGACGGCCAGT  CAAAGTGTCCTGCACTCTG
Rv CAGGAAACAGCTATGACC  CCCTCTGCCAGGATTAAAG
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Supplementary Table 1   Continued
Gene Exon Forward (Fw)  
Reverse (Rv)
Primer sequence 5’- 3’
BAP1 15 Fw TGTAAAACGACGGCCAGT  TAGCTGCCTATTGCTCGTG
Rv CAGGAAACAGCTATGACC  CAGTGGACCTCGGGAGAG
BAP1 16 Fw TGTAAAACGACGGCCAGT  CTGCTCTGGCAAGATTGG
Rv CAGGAAACAGCTATGACC  AGGGGAGCTGAAGGACAC
BAP1 17 Fw TGTAAAACGACGGCCAGT  CTCAGCTCCTGGCCTGAG
Rv CAGGAAACAGCTATGACC  GGCCACACGGCAAGAGTG
GNAQ 4 Fw TGTAAAACGACGGCCAGT TTCTCATTGTGTCTTCCCTCCT
Rv CAGGAAACAGCTATGACC  AAGGCATAAAAGCTGG-
GAAAT
GNAQ 5 Fw TTCCCTAAGTTTGTAAGTAGTGC
Rv TCCATTTTCTTCTCTCTGACC
GNA11 4 Fw TGTAAAACGACGGCCAGT  GTGCTGTGTCCCTGTCCTG
Rv CAGGAAACAGCTATGACC  GGCAAATGAGCCTCTCAGTG
GNA11 5 Fw GGTGGGAGCCGTCCTGGGATTGC
Rv CCCACCTCGTTGTCCGAC
GNAQ 4a Fw TGTAAAACGACGGCCAGT  GTCACTGACATTCTCATTGT-
GTCTT
Rv CAGGAAACAGCTATGACC  GTGGTGGGGACTCGAACTCT
GNAQ 4b Fw TGTAAAACGACGGCCAGT  ACCTGCCTACGCAACAAGAT
Rv CAGGAAACAGCTATGACC  AAGGCATAAAAGCTGG-
GAAAT
GNAQ 5a Fw TGTAAAACGACGGCCAGT  TTTCCCTAAGTTTGTAAG-
TAGTGCT
Rv CAGGAAACAGCTATGACC  GGTGACATTTTCAAAG-
CAGTG
GNAQ 5b Fw TGTAAAACGACGGCCAGT  AAGGTCAGA-
GAGAAGAAAATGGA
Rv CAGGAAACAGCTATGACC  AGTTCACTCCATTCCCCACA
GNA11 4a Fw TGTAAAACGACGGCCAGT  GTGCTGTGTCCCTGTCCTG
Rv CAGGAAACAGCTATGACC  GTGGGCAGGTAGCCCAAG
GNA11 4b Fw TGTAAAACGACGGCCAGT  ACCGCTGTGTTGCAGCTA
Rv CAGGAAACAGCTATGACC  TGATGTTCTCCAGGTCGAAA
GNA11 4c Fw TGTAAAACGACGGCCAGT  ACCGGCATCATCGAGTACC
Rv CAGGAAACAGCTATGACC  GGCAAATGAGCCTCTCAGTG
GNA11 5a Fw TGTAAAACGACGGCCAGT  CCAGGTGGCTGAGTCCTG
Rv CAGGAAACAGCTATGACC  CGACGAGAAACATGATGGAT
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Supplementary Table 1   Continued
Gene Exon Forward (Fw)  
Reverse (Rv)
Primer sequence 5’- 3’
GNA11 5b Fw TGTAAAACGACGGCCAGT  CCACTGCTTTGAGAACGTGA
Rv CAGGAAACAGCTATGACC  CACTGCACACAGCCCAAG
BRAF 15 Fw TGTAAAACGACGGCCAGT  TTCATGAAGACCTCACAG-
TAAAAA
Rv CAGGAAACAGCTATGACC  AGCCTCAATTCTTACCATCCA
NRAS 2 Fw TGTAAAACGACGGCCAGT  ATTACTGGTTTCCAACAGG
Rv CAGGAAACAGCTATGACC  CTGGATTGTCAGTGCGCTTT
NRAS 3 Fw TGTAAAACGACGGCCAGT  CCCCAGGATTCTTA-
CAGAAAA
Rv CAGGAAACAGCTATGACC  TCGCCTGTCCTCATGTATTG
BRAF 15 Fw TGTAAAACGACGGCCAGT  ACTTACTACACCTCAGA-
TATATTTCTTCAT
Rv CAGGAAACAGCTATGACC  GATGGGACCCACTCCATC
NRAS 2 Fw TGTAAAACGACGGCCAGT  ATTACTGGTTTCCAACAGG
Rv CAGGAAACAGCTATGACC  TGGGTAAAGATGATCCGACA
NRAS 3 Fw TGTAAAACGACGGCCAGT  GGTTATAGATGGTGAAACC
Rv CAGGAAACAGCTATGACC  TAATGCTCCTAGTACCTGTA-
GAG
For some genes different primers with amplicons of different sizes were used.

Mutations in G protein  
encoding genes and chromosomal 
alterations in primary leptomeningeal 
melanocytic neoplasms
Heidi V.N. Küsters-Vandevelde, MD 1, Ilse A.C.H. van Engen-van Grunsven, MD 2, 
Sarah E. Coupland, MBBS, PhD 3, Sarah L. Lake PhD 3,  Jos Rijntjes 2, 
Rolph Pfundt PhD 4, Benno Küsters MD, PhD 2,5, Pieter Wesseling MD, PhD 1,2,6, 
Willeke A.M. Blokx MD, PhD2, Patricia J.T.A.Groenen PhD 2 
1Department of Pathology, Canisius Wilhelmina Hospital, Nijmegen, 2Department of Pathology,  
Radboud University Medical Center, Nijmegen, 3Pathology, Department of Molecular and Clinical Cancer 
Medicine, University of Liverpool, 4Department of Human Genetics, Radboud University Medical Center, 
Nijmegen, 5Department of Pathology, Maastricht University Medical Center, Maastricht,  
6Department of Pathology, VU University Medical Center, Amsterdam
Pathol Oncol Res 2015;21:439-447.
5
84
Chapter 5
ABSTRACT  
Limited data is available on the genetic features of primary leptomeningeal melanocytic 
neoplasms (LMNs). Similarities with uveal melanoma were recently suggested as 
both entities harbor oncogenic mutations in GNAQ and GNA11. Whether primary 
LMNs share additional genetic alterations with uveal melanoma including copy 
number variations is unknown.
Twenty primary LMNs ranging from benign and intermediate-grade melanocytomas 
to melanomas were tested by direct sequencing for hotspot mutations in the genes 
GNA11, GNAQ, BRAF, NRAS and HRAS. Furthermore, the lesions were tested for 
copy number variations of chromosomes frequently present in uveal melanoma 
(1p, 3, 6 and 8q) by multiplex ligation-dependent probe amplification (MLPA). Genome- 
wide analyses of copy number alterations of two leptomeningeal melanocytic neoplasms 
were performed using the OncoScan SNP-array.
GNAQQ209 mutations were present in eleven LMNs, while two of 20 cases carried a 
GNA11Q209 mutation. No BRAF, HRAS or NRAS hotspot mutations were detected. 
Monosomy 3 and gain of 8q were present in one leptomeningeal melanoma, and one 
intermediate-grade melanocytoma harbored a gain of chromosome 6. With MLPA, 
the melanocytomas did not show any further gross chromosomal variations.
Our data shows that primary LMNs, like uveal melanoma, harbor oncogenic mutations 
in GNAQ and GNA11 but lack mutations in BRAF, NRAS and HRAS. This finding may 
help in the differential diagnosis between a primary LMN and a metastasis from a 
cutaneous melanoma to the central nervous system. Copy number variations in 
some aggressive LMNs resemble those present in uveal melanoma but their 
prognostic significance is unclear.  
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INTRODUCTION
Primary leptomeningeal melanocytic neoplasms (LMNs) comprise a spectrum of 
neoplasms ranging from benign melanocytoma to melanoma (1). Melanocytomas 
(MCs) are slow-growing neoplasms generally characterized by a benign clinical 
course, although local recurrence and malignant transformation can occur (2-5). 
 Intermediate-grade melanocytomas (IMCs) show histological features that are 
suggestive of more aggressive behavior, and their clinical behavior is unpredictable 
(1, 6). Primary leptomeningeal melanomas (LMMs) are histological similar to 
melanomas arising in other sites but rarely metastasize to remote organs (7, 8).
Systematic study of LMNs is hampered by their very low incidence, and the genetic 
events underlying the oncogenesis of these tumors are largely unknown. Several 
recent studies, including our previous study, reported the presence of activating 
GNAQQ209 mutations in a substantial proportion of LMNs (37%) (9-11). Identical 
GNAQQ209 mutations are present in uveal melanomas (UMs) and blue nevi, but they 
are very rare in cutaneous melanomas (CMs) (12-15). The GNAQ gene encodes the 
α-subunit of G-proteins (Gαq) that are associated with G protein coupled receptors 
on the cell surface (16). Substitution of the critical glutamine (Q at codon 209) or 
arginine (R at codon 183) of Gαq leads to decreased GTPase activity, preventing 
hydrolysis of GTP and locking GNAQ in its active, GTP-bound state. This results 
eventually in constitutive activation of the MAPK pathway (12, 14, 16-18). Activating 
mutations in R183 of GNAQ are very rare in UMs and blue nevi, and little is known 
about its incidence in LMNs (19).
Activating mutations in GNA11, a homologue of GNAQ located on chromosome 
19p13, are present in UMs and blue nevi, and were more recently demonstrated in 
some cases of LMNs as well (10, 14, 19, 20).
The gross chromosomal alterations present in LMNs are yet to be investigated. In 
UMs, monosomy 3 is a frequent event and strongly associated with metastatic 
disease (50%) (21, 22). Other frequent chromosomal aberrations in UMs include gain 
of chromosome 8q that is also associated with metastasis, and loss of chromosome 
6p, that is associated with good prognosis (21). Based on the presence of GNAQ and 
GNA11 mutations in both LMNs and UMs, we hypothesized that LMNs might also 
share some gross chromosomal alterations with UMs as well.   
In this study, we investigated a series of twenty LMNs for mutations in Q209 and R183 
of both GNA11 and GNAQ, as well as for other well-known “hotspot” mutations in 
BRAF, NRAS and HRAS. Additionally, lesions were tested for copy number variations 
of chromosomes frequently present in UMs (1p, 3, 6, 8q) using MLPA and two LMN 
cases were selected for in depth investigation of copy number alterations across 
the genome using the OncoScan SNP-array. Genetic changes were correlated with 
clinicopathological characteristics and patient follow-up data.
86
Chapter 5
MATERIALS AND METHODS 
Patients and histopathology
For this retrospective study, we collected formalin-fixed, paraffin-embedded tissues of 
20 LMNs, including 14 cases from our previously published series (9). The diagnosis 
of ‘melanocytoma’ (MC) (n=11), ‘intermediate-grade melanocytoma’ (IMC) (n=5) or 
‘leptomeningeal melanoma’ (LMM) (n=4) was based on the criteria previously 
described (1, 6, 9). None of these patients had clinical evidence of primary melanoma 
outside the central nervous system (CNS).
DNA extraction and mutational analysis
DNA extraction and assessment of DNA quality by the BIOMED-2 control gene PCR 
were performed as previously described (9). All but seven DNA samples allowed 
amplification of the 200bp amplicon, minimally (23). The remaining cases (n=7) 
allowed amplification of the 100bp-amplicon only, and still could be evaluated by 
mutational analysis (Table 1).                                                                                                                    
Twenty LMNs were investigated for “hotspot” mutations: Q209 mutations in exon 5 
and R183 mutations of exon 4 in GNAQ and GNA11; V600 mutations in BRAF; G12, 
G13, G15 mutations in exon 2 and Q61 mutations in exon 3 of the NRAS gene; and 
Q61 mutations in exon 3 of HRAS. Primer sequences are listed in supplementary 
table 1. PCR conditions as well as assessment on the ABI PRISM 3730 DNA analyzer 
were standardized and described previously (9). PCR for direct sequence analysis of 
exon 4 of GNAQ and GNA11 were performed using the Amplitaq Gold 360 Master Mix 
(Applied Biosystems) with standardized cycling conditions and duplicate PCRs were 
submitted for Sanger sequencing on an ABI PRISM 3730 DNA analyzer (Life 
Technologies, Foster City, USA).
Determination of copy number variations
1. MLPA procedure 
We used the MLPA P027-B1 assay prepared by MRC-Holland (Amsterdam, the 
Netherlands) containing probes on chromosomes 1p, 3, 6, and 8q (as the MLPA 
assay contains only one probe for chromosome arm 8p we did not include 8p 
analysis in our study).
A further twelve probes were used as reference probes (details available at; http://
www.mlpa.com). Immortalized cell lines of healthy controls were used as baseline 
control samples. MLPA was performed according to the manufacturer’s instructions, 
and as previously described (21). Samples were analyzed on an ABI 3730 DNA 
analyzer using the Genescan software (Life Technologies, Foster City, USA). Details 
on data analysis can be found in Online Resource 2.
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2. OncoScan analysis 
One LMM and one IMC (Table 1), selected due to the presence of copy number 
variations (CNVs) detected by MLPA, were further investigated for CNVs across the 
whole genome by OncoScan analysis (molecular inversion probe technology), as 
described by Wang et al. (24). This array consists of ~335,000 probes of which the 
majority (~283,000) are SNP based. DNA was processed by the Affymetrix Research 
Services Laboratory (ARSL, Santa Clara, California, USA). The normalized OncoScan 
data (2Log(test/reference)-ratios and B-allele frequency plots) were analyzed with the 
Nexus copy number software version 5.1 (Biodiscovery, Inc, El Segundo, California, 
USA) for copy number calling.
Statistical analysis
Fisher’s exact test was used to test whether significant associations were present 
between mutational status and cell type; location of the lesion (spinal versus 
intracranial); disease-related death; and clinical behavior of the lesion (stable versus 
progressive lesions, the latter including local recurrence, leptomeningeal seeding 
and/or distant metastasis). Statistical analyses were performed using SPSS 16.0 for 
Windows (IBM Statistics 20, IBM Corporation, Armonk, New York, United States).
RESULTS
Patients and histopathological characteristics
Our study group consisted of 11 MCs, five IMCs and four LMMs (Table 1). Most 
lesions were located around the spinal cord (13/20). MC recurred in four patients and 
aggressive behavior with leptomeningeal seeding or locoregional disease 
progression was present in three MC patients (#3, #5, #7). One IMC recurred with 
leptomeningeal seeding (patient #14), while two IMCs had stable disease (patients 
#12 and #13). Follow-up data was available for three of four LMM patients and all had 
succumbed to their disease. One LMM patient presented with a melanoma in the 
sacral region and developed distant metastases in the bone and lungs two years 
after initial diagnosis (patient #18). The late manifestation of other melanoma 
locations in this patient is supportive of the sacral lesion being the primary tumor. The 
other two LMM patients demonstrated subsequent leptomeningeal seeding but did 
not develop distant metastases (patients #19 and #20).  
Mutational analysis
A summary of the mutational analyses is provided in Table 1. Briefly, mutations in 
codon 209 of GNAQ in were detected in 11 neoplasms (55%), while in two other LMNs 
a mutation in codon 209 of GNA11 was observed (10%). In this series, GNA11Q209 and 
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Table 1  Patient characteristics, histopathology and results of mutational analysis  
and copy number changes detected by MLPA
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
1* F 27 MC right CPA E no Local recurrence. 
No distant metastases.
wt wt wt wt - - - - - -
2 *, # M 41 MC C0-C3 E 3+ Local recurrence. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - -
3 *, #, + M 27 MC cerebellar 
tentorium
Mx 2+ LM seeding. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
4* M 55  MC C3-6 Mx 2+ Local recurrence. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - - 
5 *, #, + na na MC C5-6 E 3+ Tumor spread in 
neck and vertebra. 
Deceased.
wt wt wt wt na na na na na na
6 *, #, + M 41 MC Th6 S 3+ Local recurrence. na na c.626A>T 
(p.(Gln209Leu))
na na na na na na na
7 *, #, + F 45 MC L3-4 Mx 3+ LM seeding. 
No distant metastases. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt na na na na na na
8 * na na MC Th11 S 1+ na wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
9 *, + na na MC cerebellar S 2+ na wt wt wt wt na na na na na na
10 *, #, + na na MC na S 3+ na wt wt wt wt na na na na na na
11 na na MC EM, ID E 3+ No recurrence. 
Stable. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
12 na na IMC IM Mx 3+ No recurrence. 
Stable. 
Alive.
wt wt wt wt - - - - na na
13 na na IMC cauda S 2+ No recurrence. 
Stable. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
14 & M na IMC IM E 1+ Local recurrence. 
LM seeding. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - gain& gain& na
15 *, + na na IMC LM E 3+ na na na wt na na na na na na na
16 * F 68 IMC cerebellar 
tentorium
E 1+ Deceased 
(not disease related)
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - - - -
17 *, # na na LMM LM E no na wt na wt wt - na na na na -
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Table 1  Patient characteristics, histopathology and results of mutational analysis  
and copy number changes detected by MLPA
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
1* F 27 MC right CPA E no Local recurrence. 
No distant metastases.
wt wt wt wt - - - - - -
2 *, # M 41 MC C0-C3 E 3+ Local recurrence. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - -
3 *, #, + M 27 MC cerebellar 
tentorium
Mx 2+ LM seeding. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
4* M 55  MC C3-6 Mx 2+ Local recurrence. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - - 
5 *, #, + na na MC C5-6 E 3+ Tumor spread in 
neck and vertebra. 
Deceased.
wt wt wt wt na na na na na na
6 *, #, + M 41 MC Th6 S 3+ Local recurrence. na na c.626A>T 
(p.(Gln209Leu))
na na na na na na na
7 *, #, + F 45 MC L3-4 Mx 3+ LM seeding. 
No distant metastases. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt na na na na na na
8 * na na MC Th11 S 1+ na wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
9 *, + na na MC cerebellar S 2+ na wt wt wt wt na na na na na na
10 *, #, + na na MC na S 3+ na wt wt wt wt na na na na na na
11 na na MC EM, ID E 3+ No recurrence. 
Stable. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
12 na na IMC IM Mx 3+ No recurrence. 
Stable. 
Alive.
wt wt wt wt - - - - na na
13 na na IMC cauda S 2+ No recurrence. 
Stable. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
14 & M na IMC IM E 1+ Local recurrence. 
LM seeding. 
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - gain& gain& na
15 *, + na na IMC LM E 3+ na na na wt na na na na na na na
16 * F 68 IMC cerebellar 
tentorium
E 1+ Deceased 
(not disease related)
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - - - -
17 *, # na na LMM LM E no na wt na wt wt - na na na na -
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GNAQQ209 mutations were mutually exclusive. Both GNA11Q209 mutations resulted in 
substitution of glutamine at position 209 by leucine c.626A>T (p.(Gln209Leu)) alias 
Q209L (Figure 1a), and were present in an IMC and LMM (patients #16 and #19) 
(Figure 1b, c). GNAQQ209 mutations were present in seven of 11 MCs (64%), two of 
five IMCs (40%) and two of four LMMs (50%). These GNAQQ209 mutations resulted in 
substitution of glutamine to leucine in 64% (7/11) and to proline in 36% of cases (4/11). 
In all samples, “hotspot” mutations in exon 4 of GNAQ and GNA11, and in BRAF, 
HRAS or NRAS were absent. 
There was no significant association between GNAQ/GNA11 mutational status and 
cell type, location of the lesion, disease-related death, or clinical behavior (Fisher’s 
exact, P>0.05).      
Copy number variations
MLPA results for eleven cases were of sufficient quality for further analysis (Table 1). 
Five MC cases did not harbor gross CNVs for the chromosome regions investigated 
(Figure 2a, patients #1, #2, #4, #8 and #11). Three of four IMCs did not show 
chromosomal CNVs (patient #12, #13 and #16; patient #12 and #13 had stable 
disease and patient #16 died of non-disease related illness. Of note, patient #12 
could only be evaluated for 1p, 3p, 3q and 6p). One IMC showed gain of chromosome 
6 confirmed by OncoScan analysis (Figure 3a, Online Resource 3, patient #14). This 
was a GNAQ-mutated IMC showing local recurrence and leptomeningeal seeding at 
follow-up. With the OncoScan analysis, no other gross chromosomal CNVs were 
detected in this sample. Of the two LMMs that were evaluated using MLPA, one 
Table 1  Continued
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
18 *, & F 59 LMM S2 Mx 1+ Distant metastases 
(bone, lungs). Deceased.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - loss& loss& - - gain&
19 F 32 LMM Th10-11 Mx 1+ LM seeding. No extradural 
disease. Deceased.
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - gain loss -
20 M 55 LMM L1-L2 Mx 1+ LM seeding. No distant 
metastases. Deceased.
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
F female, M male, MC melanocytoma, IMC intermediate-grade melanocytoma, LMM  leptomeningeal 
melanoma, CPA cerebello-pontine angle, EM extramedullary, ID intradural, LM leptomeningeal, S spindle, E 
epithelioid, Mx mixed; 
* cases of which results of mutation analysis were in part described previously (9), - no copy number 
changes with MLPA, na not available (sex, age, location, follow-up) or not assessable (MLPA and/or 
mutation analysis), # cases with 100bp-amplicon in the BIOMED-2 gene control PCR (n=7). 
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GNA11-mutated LMM showed gain of 6p, and loss of 6q (Figure 2b, patient #19). 
The patient with this LMM suffered from leptomeningeal seeding at presentation but 
had no extradural melanoma dissemination. The second case was a GNAQ-mutated 
LMM that demonstrated monosomy 3 and gain of 8q, confirmed by OncoScan 
analysis (patient #18) (Figure 3b). In addition, the OncoScan data revealed the 
following CNVs for this LMM: loss of chromosome 1p, loss of chromosome 2p, loss 
of chromosome 8p, loss of chromosomes 10, 11 and 18, and gains of chromosomes 
4p, 17 and 22 (Figure 3b, Online Resource 4). 
Table 1  Continued
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
18 *, & F 59 LMM S2 Mx 1+ Distant metastases 
(bone, lungs). Deceased.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - loss& loss& - - gain&
19 F 32 LMM Th10-11 Mx 1+ LM seeding. No extradural 
disease. Deceased.
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - gain loss -
20 M 55 LMM L1-L2 Mx 1+ LM seeding. No distant 
metastases. Deceased.
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
The remaining cases (n=13) allowed amplification of the 200bp-amplicon, minimally, & copy number alterations 
of two cases confirmed by use of OncoScan analysis (Affymetrix); 
Cases not assessable in the mutational analysis (data not further shown): case 6 for GNA11 and NRAS, case 
7 for HRAS, case 10 and 18 for NRAS ex 2, case 15 for GNA11, NRAS and HRAS, case 17 for GNA11 exon 4; 
Nine cases not assessable with MLPA (na), possibly due to the combination of low quality DNA (100bp-
amplicon in the BIOMED-2 gene control PCR, marked with #) and/or heavily pigmentation, marked with +.
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Figure 1  The GNA11Q209L mutation was present in patient #16 (IMC) and patient #19 (LMM)
a. Forward sequence tracing for GNA11 surrounding codon 209 of exon 5, showing the mutation 
c.626 A>T (p.(Gln209Leu)) for patient #16 (IMC).
b. GNA11-mutated IMC in the cerebellar tentorium (magnification 400x) showing an epithelioid 
cell type and increased mitotic activity (arrow) (patient #16).
c. GNA11-mutated melanoma in a 32-year-old female (magnification 200x) located at the spinal 
region Th10-11 (patient #19), showing a mixed cell type, nuclear pleomorphism and mitotic 
activity (arrow).
a
b
c
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Figure 2  MLPA results for patient #8 (GNAQ-mutated MC) and patient #19 (GNA11-mutated LMM)
a. MLPA results of a GNAQ-mutated MC located in the spinal canal at level of the 11th thoracic 
vertebrae (patient #8), without evident copy number changes. The ratio of 1.3 at 8p12 (probe 27) 
and the ratio of 1.2-1.3 at 8q24.12 (probes 29 and 30) were considered within the normal range.
b. GNA11-mutated primary leptomeningeal melanoma showing gain of 6p and loss of 6q by 
MLPA (patient #19). The ratio of 1.3 at 8q24.12 (probe 30) was considered within the normal 
range.
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DISCUSSION 
We previously demonstrated the presence of oncogenic mutations in Q209 of GNAQ 
in a series of LMNs (37%) (9). In the present study, we broadened our sequencing 
analysis and tested a series of 20 LMNs for the presence of  “hotspot” mutations in 
Figure 3  Copy number variation plots obtained by OncoScan SNP-analysis for patient #14 
(a) (IMC) and patient #18 (b) (LMM), using the NEXUS 5.1 software package.
The normalized and log2-transformed patient-over-reference intensity ratios (2Log(T/R)) for 
each array probe are displayed (blue dots) according to their chromosomal position (from 1pter 
– Yqter), with each chromosome separated with a dotted vertical line. The results of a statistical 
copy number algorithm are shown by the black horizontal lines, with a normal copy number 
(n=2) at the 0-line, a loss (deletion) going down (negative probe values) and a gain (duplication/
amplification) going up (positive probe values). The corresponding allelic frequency plots, 
which are also obtained by the OncoScan SNP-analysis, are shown in the Supplementary 
Figures. The information regarding the CNVs and the corresponding allele frequency plots is 
needed for a correct interpretation of the copy number results (see Online Resources 3 and 4).
The genome profile of the IMC (patient #14) is depicted in panel (a) and demonstrates gain of 
chromosome 6 and (normal) male hemizygosity for chromosome X. The genome profile of the 
LMM in patient #18 is depicted in panel (b), and demonstrates losses of chromosome 1p, 2p, 
3, 8p, 10, 11 and 18. Clear gains are present of chromosome 4p, 8q, chromosome 17 (loss of 
17q21.22q25.3) and 22.
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Q209 and R183 of GNA11 and GNAQ, as these “hotspots” were more recently shown 
to be mutated in cases of LMNs as well (10, 19, 20). We identified two LMNs harboring 
a GNA11 mutation at codon 209 (Q209L) (10%). This result is very similar to the study 
of Gessi et al. who detected a GNA11Q209L mutation in two out of 16 LMNs (13%) (10). 
Our study thus confirms that GNA11Q209 mutations are a rare event in LMNs (~10%). 
A similarly low GNA11Q209 mutational frequency has been reported in blue nevi (7%) 
while in UMs this frequency is higher (32%) (14). Furthermore, the MC cases in our 
series did not show any GNA11Q209 mutations (n=11) and this was also the case in the 
six MCs in the series of Gessi et al. (10). However, GNA11Q209 mutations do occur in 
MCs, as two MC cases have been reported to harbor such mutation (Q209P and 
Q209L, respectively) (19, 20). In 55% of LMNs, we detected mutations in codon 209 
of GNAQ, which is in the range of Gessi et al. (43%) and similar to the GNAQQ209 
mutational frequency in UMs (45%) and blue nevi (55%) (9, 10, 14). 
In UMs and blue nevi, mutations at codon 183 of both GNAQ and GNA11 are rare 
(1-3% in either gene, tested in >200 cases) (14). In contrast, little is known about the 
GNAQR183 and GNA11R183 mutational frequency in LMNs. Up to now, only one smaller 
case series searched for mutations in this codon of both genes and detected one 
activating GNAQR183 mutation in five LMN cases (19). In our study, however, mutations 
in codon 183 of GNAQ and GNA11 were absent, suggesting that these mutations are 
a rare event in LMNs. 
At the moment, it is unclear whether GNAQ or GNA11 mutations in LMNs have any 
association with histological characteristics or clinical behavior. In UM, such an 
association has not been found (14, 25, 26). Furthermore, although inhibition of the 
GNAQ/GNA11-dependent MAPK signaling pathway is now under investigation for 
UMs, it remains to be determined whether a similar approach would be effective in 
LMNs (27-33).
In our present series of adult LMN cases, we did not find any BRAF, NRAS or HRAS 
mutations. Similar results were obtained by Wang et al. (34). Of note, in contrast to the 
adult setting, we and others recently showed that mutations at Q61of NRAS rather 
than GNAQ or GNA11 are involved in the development of LMNs in children (10, 35, 36). 
The incidence of CNS metastasis in patients with melanoma ranges from 10% to 40% 
in clinical studies (37). This high frequency of CNS metastasis in melanoma patients 
is in contrast to the very low incidence of primary melanoma of the CNS (1). Still, the 
discrimination between a primary versus metastatic melanocytic tumor in or around 
the CNS is relevant because of different patient work-up and the substantially better 
prognosis of patients with a primary neoplasm, even when the tumor is malignant 
(38-41). In contrast to primary LMNs, mutations in GNAQ and GNA11 are absent or 
very rare in cutaneous melanoma (CM) (1.4%, tested in > 150 cases), acral melanoma 
(0%) and mucosal melanoma (0%) (14, 32). As a consequence, molecular testing of 
these genes could be helpful for elucidating the origin of a melanocytic tumor in or 
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around the CNS. For instance, demonstration of a GNAQ or GNA11 mutation in a CNS 
melanocytic tumor favors a primary LMN, although a metastasis from a UM or 
malignant blue nevus still needs to be excluded. Conversely, the demonstration of a 
BRAF mutation favors a metastasis from a CM as these melanomas show a high 
frequency of BRAF mutations (50%) (42, 43) (Figure 4). 
Based on the presence of GNAQ and GNA11 mutations in both LMNs and UMs, we 
postulated that UMs and especially aggressive LMNs might share chromosomal 
copy number variations. The strong association of monosomy 3 and gain of 8q with 
poor UM patient prognosis is well documented (21, 22, 44). Gain of 6p in UMs is often 
mutually exclusive with monosomy 3 and correlates with a better prognosis (21, 22, 
45). However, in our study, only two lesions carried the common gross chromosomal 
abnormalities seen in UM: one GNAQ-mutated LMM showed monosomy 3 and gain 
of 8q; and one GNA11-mutated LMM showed gain of 6p and loss of 6q. The former 
patient developed metastases in the bone and lungs two years after initial diagnosis, 
Figure 4  Frequency of GNAQ, GNA11 and BRAF “hotspot” mutations for LMNs, UMs and CMs.
Demonstration of a GNAQ or GNA11 mutation in a CNS melanocytic tumor may be helpful in 
discriminating a primary LMN from a CM metastasis in/around the CNS, as CMs only very rarely 
harbor GNAQ or GNA11 mutations. Vice versa, the demonstration of a BRAF mutation strongly 
favors a metastasis from a CM, as CMs show a high frequency of BRAF mutations. Note: the 
mutation frequencies include the hotspot mutations at codon 209 of GNAQ and GNA11, and 
codon 600 of BRAF, and were based on the following series, including the present study: (9, 10, 
13, 14, 34, 46-49).
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but no liver metastases were demonstrated. The latter patient showed leptomeningeal 
seeding but no distant metastases. In addition, one GNAQ-mutated IMC, presenting 
with local recurrence and leptomeningeal seeding, also showed gain of chromosome 
6. Due to the limited number of patients that could be tested, however, it is still unclear 
if the gross chromosomal changes in LMNs have any prognostic implications.
We conclude that LMNs share some genetic aberrations with UMs, especially 
GNAQQ209 and GNA11Q209 mutations, although the latter are, in contrast to UMs, an 
infrequent event in LMNs. Mutations in GNAQR183 and GNA11R183 were absent in our 
series, suggesting that these mutations are rare in LMNs, as in UMs. The demonstration 
of a GNAQ or GNA11 mutation in a LMN may have diagnostic value, allowing the 
discrimination of a primary CNS melanocytic tumor from a cutaneous melanoma 
metastasis. Copy number variations in some aggressive LMNs resemble those 
present in UMs including monosomy 3 and gain of 8q but their exact prognostic 
significance is so far unclear.
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ELECTRONIC SUPPLEMENTARY MATERIAL
Supplementary Table 1  Primers used for mutational analysis  
Gene Exon Forward (Fw)  
Reverse (Rv)
Primer sequence 5’- 3’
GNA11 5 Fw GGTGGGAGCCGTCCTGGGATTGC
Rv CCCACCTCGTTGTCCGAC
GNA11 4 Fw GTGCTGTGTCCCTGTCCTG
Rv GGCAAATGAGCCTCTCAGTG
GNAQ 5 Fw TTCCCTAAGTTTGTAAGTAGTGC
Rv TCCATTTTCTTCTCTCTGACC
GNAQ 4 Fw TTCTCATTGTGTCTTCCCTCCT
Rv AAGGCATAAAAGCTGGGAAAT
BRAF 15 Fw CCTTTACTTACTACACCTCAG
Rv AAAAATAGCCTCAATTCTTAC
NRAS 2 Fw GGTTTCCAACAGGTTCTTGC
Rv CCACTGGGCCTCACCTCTATG
NRAS 3 Fw GATTCTTACAGAAAACAAGTGG
Rv TAATGCTCCTAGTACCTGTAGAG
HRAS 3 Fw CTGCAGGATTCCTACCGGA
Rv ACTTGGTGTTGTTGATGGCA
All primers except for the GNAQ reverse primer contained a M13 forward or reverse consensus sequence 
enabling standardized sequencing of different exons     
Online Resource 2. MLPA data analysis
Data analysis was performed in Microsoft Excel as follows: 1) the “average control 
probe fraction” of the control samples is calculated by dividing the peak value of each 
probe amplification product by the combined value of all the probes of the control 
samples (n=3), and subsequently to calculate the average of the obtained values, 2) 
the “average patient probe fraction” is calculated by dividing the peak value of the 
patient probe amplification by the combined value of all patient probes, and, 
subsequently to divide this value by the “average control probe fraction”, 3) next, the 
obtained value is divided by the average of the reference probes of the patient 
sample, and 4) is corrected for tumor load. A normal or disomy copy number was 
determined from a signal of 0.8-1.2; above 1.2 was indicated an amplification and 
below 0.8 indicated a deletion.
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Online Resource 3 CNV plot and allelic frequency plot obtained by OncoScan 
SNP-analysis for patient #14 (IMC)
Online Resource 4 CNV plot and allelic frequency plot obtained by OncoScan 
SNP-analysis for patient #18 (LMM)
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ABSTRACT
The histological differential diagnosis between melanotic schwannoma, primary 
leptomeningeal melanocytic lesions and cellular blue nevus can be challenging. 
Correct diagnosis of melanotic schwannoma is important to select patients who 
need clinical evaluation for possible association with Carney Complex. Recently, we 
described the presence of activating codon 209 mutations in the GNAQ gene in 
primary leptomeningeal melanocytic lesions. Identical codon 209 mutations have 
been described in blue nevi. The aim of the present study was to (1) perform a 
histological review of a series of lesions (initially) diagnosed as melanotic schwannoma 
and analyze them for GNAQ mutations, and (2) test the diagnostic value of GNAQ 
mutational analysis in the differential diagnosis with leptomeningeal melanocytic 
lesions. We retrieved 25 cases that were initially diagnosed as melanotic schwannoma. 
All cases were reviewed using established criteria and analyzed for GNAQ codon 209 
mutations. After review, nine cases were classified as melanotic schwannoma. GNAQ 
mutations were absent in these nine cases. The remaining cases were reclassified as 
conventional schwannoma (n=9), melanocytoma (n=4), blue nevus (n=1) and 
lesions that could not be classified with certainty as melanotic schwannoma or 
melanocytoma (n=2). GNAQ codon 209 mutations were present in 3/4 melanocytomas 
and the blue nevus. Including results from our previous study in leptomeningeal 
melanocytic lesions, GNAQ mutations were highly specific (100%) for leptomeningeal 
melanocytic lesions compared to melanotic schwannoma (sensitivity 43%). We conclude 
that a detailed analysis of morphology combined with GNAQ mutational analysis can 
aid in the differential diagnosis of melanotic schwannoma with leptomeningeal 
melanocytic lesions.
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INTRODUCTION
Melanotic schwannoma is a rare variant of schwannoma composed of cells having 
the ultrastructure and immunophenotype of Schwann cells but containing melanosomes 
in varying stages of maturation (24,25). They show a peak incidence in the fourth decade, 
and affect males and females equally. About half of these tumors arise in close 
proximity to the neural axis. These neoplasms are often associated with spinal nerve 
roots, cranial nerves or arising from the paraspinal sympathetic chain (5,15). The other half 
arises in a wide variety of sites including the gastrointestinal tract, soft tissues, skin, 
heart and liver (3,8,10,13,25). The biological behavior of melanotic schwannomas can 
be unpredictable with metastasis reported in up to 10% of cases, sometimes even in 
absence of histological features suggestive of aggressive behavior (5,27).
A specific subgroup of melanotic schwannomas contain psammoma calcifications. 
About half of these so-called psammomatous melanotic schwannomas occur in the 
setting of the autosomal dominant Carney complex, a multiple neoplasia syndrome 
characterized by a markedly increased risk to develop myxomas, mucocutaneous 
lentigines and blue nevi, endocrine hyperactivity and/or psammomatous melanotic 
schwannomas (5). Isolated cases of non-psammomatous melanotic schwannomas 
have been associated with Carney complex as well (6). Nearly two thirds of patients 
with Carney complex have mutations spread over the PRKAR1A gene, which encodes 
the R1α regulatory subunit of cyclic-AMP-dependent protein kinase A (14,29).
The differential diagnosis between melanotic schwannomas and pigmented melanocytic 
lesions can be difficult, especially in small biopsy specimens. It includes primary or 
metastatic melanoma, a diagnosis with obvious prognostic and therapeutic relevance. 
In addition, melanotic schwannomas may histologically closely resemble leptomeningeal 
melanocytomas and cellular blue nevi (20). Immunohistochemical stains are not 
always useful  in sorting out this differential diagnosis. All these lesions generally 
express S-100 (which can be explained by their common neural crest origin) and one 
or more melanocytic markers. Although stains for components of the basement 
membrane can be useful in discriminating tumors with schwannian differentiation 
from tumors with melanocytic differentiation, overlap in staining patterns has been 
noted and can impair interpretation, especially in small biopsy specimens (4,12,21,26).
Recently, we reported the presence of activating mutations in the GNAQ gene at 
codon 209 in primary leptomeningeal melanocytomas (50%) and melanomas (25%) 
(16). The GNAQ gene maps on chromosome 9q21, and encodes the α-subunit of a 
heterotrimeric GTP-binding protein that couples G protein coupled receptor signalling 
to the MAP kinase pathway (22). GNAQ codon 209 mutations form an alternative 
route to MAP kinase activation (28). Identical oncogenic mutations in the GNAQ gene 
have been reported in blue nevi (83%) and uveal melanomas (UMs) (46%) (17,28).
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The aims of the present study were (1) to perform a thorough histological review of a 
series of lesions that were (initially) diagnosed as melanotic schwannoma and to 
analyze these cases for mutations in the GNAQ gene, and (2) to assess the diagnostic 
value of GNAQ mutational analysis in the differential diagnosis of melanotic schwannoma 
with primary leptomeningeal melanocytic lesions by including data from our previous 
study on GNAQ mutations in leptomeningeal melanocytic lesions (16).
MATERIALS AND METHODS
Patients and histopathology
For this retrospective study, formalin-fixed and paraffin-embedded (FFPE) tissues of 
melanotic schwannomas were retrieved from archives of various Departments of 
Pathology in The Netherlands. The cases were obtained through the Dutch nationwide 
histopathology and cytopathology data network and archive (PALGA) (7). All cases 
(n=25) were initially diagnosed as melanotic schwannomas.
FFPE tissues were sectioned at 4 µm, deparaffinized, and subjected to antigen 
retrieval by limited protein digestion or citrate (CC1) and microwave treatment. Slides 
were then incubated at room temperature with antibodies to S-100 protein (polyclonal, 
1:800, Dako Co. , Lot 00060051), Melan-A (Mart-1, 1:800, Neomarkers, Lot 799P807C), 
HMB-45 (1:50, Neomarkers, Lot 23068), MIB-1 (Ki-67, 1:200, Dako Co., Lot 00045312), 
EMA (E-29, 1:50, Dako Co., Lot 00051982), Collagen type IV (monoclonal, 1: 1250, 
Sigma, Lot 062K4819) and Laminin (polyclonal, 1:100, Thermo, Lot 82H907B). Amino- 
ethylcarbazole served as chromogen. Reticulin stains (Laguesse) were performed on 
each case. Schmorl and Perl´ s (iron) stains were performed to confirm melanin 
pigmentation.
Histology was revised independently by two pathologists (HK, BK) without knowledge 
of molecular results. Revision of the slides included scoring of histological criteria 
and immunohistochemical stains.
The deposition of basement membrane material in the reticulin, Collagen type IV and 
Laminin stains was categorized into three staining patterns. The pericellular pattern 
was represented by an extensive network of basement membrane material around 
individual tumor cells, consistent with schwannian differentiation (12,24). The nested/
perilobular pattern consisted of deposition of basement membrane material around 
nests of tumor cells (rather than around individual tumor cells), and is typically seen 
in melanocytic lesions (26). The biphasic staining pattern was characterized by areas 
with nested staining as well as areas with pericellular staining, and has been 
described in melanotic schwannomas (12,24).
After revision, the cases were reclassified as: (1) melanotic schwannoma, with or without 
psammoma bodies and/or fat, (2) conventional schwannoma, (3) melanocytoma, (4) 
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lesion not further classified with certainty as melanotic schwannoma or melanocytoma, 
or (5) blue nevus.
Criteria used for classification are presented in Table 1. The diagnosis of `melanotic 
schwannoma`  and c`onventional schwannoma`  was based on WHO criteria (24). 
Additional detailed histological criteria of melanotic schwannoma were retrieved from 
Mooi (20), and included circumscribed, often encapsulated tumors consisting of 
spindle to epithelioid cells, with or without psammoma bodies and/or fat, variable 
melanin pigmentation, S-100 positivity and expression of Melan-A and/or HMB-45. 
Schwannomas lacking positivity for both HMB-45 and Melan-A were classified as 
conventional schwannomas. A pericellular staining pattern in the basement membrane 
stains served as an additional criterion for conventional schwannoma, while in 
melanotic schwannomas also a biphasic staining pattern can be present (12,24). The 
diagnosis of ` melanocytoma`  was based on histological criteria as described by Brat 
et al. (1,2). This included circumscribed, non-encapsulated lesions consisting of 
nests or fascicles of spindle and/or epithelioid cells with little nuclear atypia and 
variable melanin pigmentation. Immunohistochemical criteria included S-100 
positivity, expression of Melan-A and/or HMB-45, and a nested staining pattern in the 
basement membrane stains. Lesions with increased mitotic activity or invasion of 
neuroglial tissue were classified as ´intermediate-grade´ melanocytomas.
The diagnosis of ‘cellular blue nevus’ was based on histological criteria described by 
Mooi (19). This included a primary location of the lesion within the dermis with a 
biphasic architecture, especially at the base of the lesion, consisting of nodules and 
sheets of pale, oval melanocytes intermingled with pigmented dendritic melanocytes 
diffusely arranged in sclerotic stroma.
For statistical evaluation, 19 leptomeningeal melanocytic lesions from our previous 
study were included (16).
DNA extraction
About five manually dissected sections of 10 µm FFPE tissue with an estimated tumor 
cell percentage of at least 60% were used for DNA extraction. After heating in ATL 
buffer, the tissue sections were incubated in proteinase K for one hour, followed by 
subsequent purification of the DNA according to the manufacturer (QIAamp DNA 
Mini Kit, QIAGEN GmbH, Germany). DNA sample concentration was assessed spec-
trophotometrically (Varian Cary 50 spectrophotometer, Agilent Technologies).
Mutational analysis
Direct sequence analysis of GNAQ exon 5 was performed on DNA-specimens from 
25 l pigmented lesions of schwannian or melanocytic origin. PCR amplification was 
performed in a total volume of 25 µL, containing 50 ng DNA, PCR-buffer IV (Integro), 
37 mM MgCl2, 250 µM of dNTPs, 37.5 µg bovine serum albumin (Sigma), 10 pmol of 
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forward primer (p740, sequence: 5’ TGTAAAACGACGGCCAGTTTCCCTAAGTTTG-
TAAGTAGTGC 3’) and reverse primer (p 705, sequence: 5’ CAGGAAACAGCTAT-
GACCCTTACCTCATTGTCTGAC 3’, or p695, sequence: 5’ TCCATTTTCTTCTCTCT-
GACC 3’) and 0.05 units of thermostable DNA polymerase (Sigma). Primers p740 and 
p705 contained a M13 forward and a M13 reverse consensus sequence, respectively, 
enabling standardized sequencing of different exons.
DNA amplification was performed in duplicate in a PTC 200 Thermal Cycler (MJ 
Research). The PCR was started with 5 min at 92°C and followed with 35 cycles of 
denaturation 45 s at 94°C, annealing at 62°C for 45 s and extension at 72°C for 45 s, 
followed by a final extension at 72°C for 20 min and cooling down for 5 min at 20°C. 
PCR products were purified with MinElute plates (Qiagen). After analysis of the PCR 
products by agarose gel electrophoresis (2%; Invitrogen) , 1-4 µl of the PCR products 
were sent in for sequence analysis using an ABI PRISM 3700 DNA analyzer (Applied 
Biosystems).
Because the DNA-quality of some specimens was suboptimal, different primer 
combinations were used in the PCR. The DNA-samples of cases 1, 2, 3, 5, 6, 13, 14, 
22 and 23 were of sufficient quality and the primer combination p740 and p705, 
yielding a PCR product of 224 basepairs (bp), was used for DNA-amplification. 
Sequence analysis was performed using the M13 forward primer and reverse primer 
on duplicate DNA-amplifications of the same specimen. For the DNA-samples that 
were strongly degraded (cases 4, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 20, 21, 24, 25) 
the primer combination p740 and p695, yielding a PCR product of 134 bp, was used. 
Sequence analysis (in duplicate) of these samples was performed using the forward 
primer only, since the reverse primer p695 is closely flanking the mutation hotspot. By 
sequence analysis of the entire PCR products, it was shown that the primers used 
specifically amplified the GNAQ gene (accession nr: NM_002072.2) and not its 
pseudogene (GNAQP1; accession nr: NG_000862.4v). The amplified gene sequence 
was specific for the GNAQ gene, and nucleotides that are present in the pseudogene 
were not detected (9).
Statistical analysis
The diagnostic value of GNAQ mutational analysis in the differential diagnosis of 
melanotic schwannoma with primary leptomeningeal melanocytic lesions was tested 
using additional data from our previous study on GNAQ mutations in primary 
leptomeningeal melanocytic lesions (16). Sensitivity and specificity of GNAQ 
mutational analysis was calculated. To assess whether the difference in GNAQ 
mutational status between melanotic schwannoma and leptomeningeal melanocytic 
lesions was statistically significant, we performed Fisher’s exact test (SPSS 16.0 for 
Windows).
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RESULTS
Patient and histopathological characteristics
We retrieved 25 lesions initially diagnosed as melanotic schwannomas from the 
archives of various Departments of Pathology in The Netherlands. After revision, the 
lesions were reclassified using the above-mentioned criteria into nine melanotic 
schwannomas, nine conventional schwannomas, four melanocytomas, one blue 
nevus and finally two lesions that could not be further classified with certainty as 
melanotic schwannoma or melanocytoma. Patient and histopathological characteris-
tics are summarized in Table 2. 
As far as data were available, the melanotic schwannomas had an equal sex 
distribution and the mean age was 37.2 years. Most melanotic schwannomas were 
located around the spinal cord (7/9), while 2 lesions were located in the extremities 
(lower arm and lower leg). As far as was assessable, melanotic schwannomas were 
circumscribed, encapsulated tumors (6/9) (Figure 1a) with variably but mostly 
intense melanin pigmentation (6/9) (Figure 1b). Eight of nine melanotic schwannomas 
contained psammoma bodies (Figure 1a, b) and, in addition, one melanotic 
schwannoma contained large, empty vacuoles resembling fat (case 8) (Figure 1c). 
Tumor cells were arranged in sheets and fascicles and varied from spindle to 
epithelioid, often with  nuclear pseudoinclusions (Figure 1c) and conspicuous 
nucleoli. In some cases there was nuclear palissading and one case showed Antoni 
A and B areas together with Verocay bodies (case 4). Marked nuclear pleomorphism, 
necrosis, and invasion in surrounding structures was absent. These tumors were all 
negative in the EMA stains (excluding meningeoma). MIB-1 staining was less than 1 
percent. S-100 stains showed a diffuse and strong expression in all melanotic 
schwannomas (Figure 1d). In addition, all lesions showed positivity for Melan-A and 
HMB-45 (Figure 1e). Reticulin, Collagen type IV and Laminin stains showed in four of 
nine cases an extensive network of basement membrane material around individual 
tumor cells (pericellular pattern), consistent with schwannian differentiation (Figure 1f). 
In five melanotic schwannomas, a biphasic staining pattern was present consisting 
of areas with pericellular deposition of basement membrane material next to areas 
with deposition around nests of tumor cells (nested/perilobular pattern). One lesion 
initially diagnosed elsewhere as a ` peripherally located melanotic schwannoma`  was 
reclassified as a cellular blue nevus (case 19) (19).
Nine lesions initially diagnosed elsewhere as melanotic schwannoma were reclassified 
as conventional schwannomas. These lesions showed the typical histological features 
of schwannomas with frequent Antoni A and B areas, nuclear palissading, blood 
vessel hyalinization and wavy nuclei. We did not classify them as melanotic 
schwannoma because positivity for both Melan-A and HMB-45 was lacking. They all 
contained focally some fine intracytoplasmic grayish pigment in tumor cells (Schmorl 
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positive). Furthermore, extensive areas with deposition of basement membrane 
material around individual tumor cells in the basement membrane stains was present.
Based on the criteria described by Brat et al. (1,2), four lesions located around the 
spinal cord were reclassified as melanocytomas. Three of them showed an infiltrative 
growth pattern in the neuroglial tissues and were classified as intermediate-grade 
melanocytomas (Figure 2a). All lesions consisted of fascicles and nests of spindle 
and/or epithelioid cells with variable melanin pigment. Nuclei were round to oval and 
uniform in size, with mostly small nucleoli (Figure 2b). Prominent nuclear atypia was 
absent. In contrast to the melanotic and conventional schwannomas, S-100 was only 
focally positive (Figure 2c), while Melan-A and HMB-45 were more diffusely positive 
(Figure 2d, e). MIB-1 staining was less than 1 percent in all cases. Reticulin, Collagen 
type IV and Laminin stains showed deposition of basement membrane material 
around vascular structures and nests of tumor cells (nested/perilobular), but not 
around individual tumor cells (Figure 2f).
Finally, two lesions could not be classified with certainty into melanotic schwannoma 
or melanocytoma (case 24 and 25). Case 24 was a variably, partly heavily pigmented 
lesion  consisting of spindle to pleiomorphic cells (Figure 3a, c). The lesion showed 
infiltrative growth in or from a ganglion at the lumbar spinal region (Figure 3b). The 
nuclei showed moderate to strong atypia with conspicuous nucleoli (Figure 3c). 
MIB-1 staining was less than 10%. Psammoma bodies were absent. S-100, Melan-A 
and HMB-45 stains were diffusely positive. The reticulin, Collagen type IV and Laminin 
stains showed a biphasic pattern (Figure 3d,e). Based on these histological features 
we favored the diagnosis of melanotic schwannoma with atypical features suggestive 
of aggressive behavior. For case 25, only limited biopsy material was available which 
impaired unequivocal histological assessment. It concerned a heavily pigmented 
lesion located at the cerebellopontine angle consisting of spindle cells with mild 
cytonuclear atypia and small nucleoli. S-100 was focally positive while the Melan-A 
and HMB-45 stains were diffusely positive. A nested/perilobulated staining pattern 
was present in the reticulin, Collagen type IV and Laminin stains. In this case, we 
favored the diagnosis of melanocytoma.
Results of GNAQ mutational analysis
All lesions were tested for mutations in exon 5 of the GNAQ gene. The results are 
presented in Table 2. We detected mutations in exon 5 of GNAQ in 3 of 4 
melanocytomas and the blue nevus (c.626A>T (p.(Gln209Leu))). No mutations were 
detected in melanotic or conventional schwannomas. In the two lesions which we 
could not classify with certainty as melanotic schwannoma or melanocytoma (case 
24 and 25), only case 25 (the probable melanocytoma case) had a mutation in codon 
209 of exon 5 (c.626A>T (p.(Gln209Leu))).
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Table 2   Patient and histopathological characteristics and results of mutational analysis
Patient Sex Age Diagnosis Localization Origin 
from nerve / 
ganglion
Circumscribed, 
capsule
Pigmentation Psammoma 
bodies
Cell 
type
Schwannian 
features
Nuclear 
pleomorphism
S-100 HMB-45 Melan- A Basement 
membrane 
staining
GNAQ exon 5 
mutation
1 F 75 MS L1-L2 na + 1+ + S Pa mi 2+ 1+ 1+ B -
2 F 35 MS L1-5 + + 3+ + E,S Pa mi 2+ 1+ 2+ B -
3 M 42 MS L2 na + 3+ - S - mi 2+ 2+ 1+ B -
4 na na MS C2 + + 3+ + E,S A, V mi 2+ 2+ 1+ P -
5 na na MS C1 na na 3+ + S - mi 2+ 1+ 2+ P -
6 na na MS C4 na na 3+ + E, S - mi 2+ 2+ 2+ B -
7 M 35 MS Lumbal + na 3+ + S Pa mi 2+ 1+ 2+ B -
8 F 23 MS Lower arm na + Focal 1+ +,  fat E - mi 2+ 1+ 1+ P -
9 M 13 MS Lower leg + + Focal 1+ + E, S - mi 2+ 1+ 1+ P -
10 M 72 Sw Vestibular nerve na na 2+ - S Pa mi 2+ neg neg P -
11 F 60 Sw Th11 na na Focal 1+ - S Pa, V mi 2+ neg neg P -
12 F 32 Sw Retroperitoneum na + Focal 1+ - S Pa, A mi 2+ neg neg P -
13 M 42 Sw Sacrum na + Focal 1+ - S Pa mi 2+ neg neg P -
14 na na Sw Intercostal nerve na + 1+ - S Pa, A mi 2+ neg neg P -
15 M 49 Sw S1 na na Focal 1+ - S Pa, A mi 2+ neg neg P -
16 F 74 Sw S2 + na Focal 1+ - S Pa mi 2+ neg neg P -
17 F 74 Sw Groin na na Focal 1+ - S Pa, A mi 2+ neg neg P -
18 M 44 Sw Sacral na + Focal 1+ - S Pa, A mi 2+ neg neg P -
19 na na blue nevus Foot na + 2+ - S,O - mi Focal 1+ 2+ Foc. 1+ N c.626A>T 
(p.(Gln209Leu))
20 na na IMC Cauda na No, invasion of 
CNS
1+ - S - mi Focal 1+ 2+ 2+ N c.626A>T 
(p.(Gln209Leu))
21 na na IMC IM na No, invasion of 
CNS
3+ - E,S - mi Focal 1+ 2+ 1+ N -
22 na na IMC IM na No, invasion of 
CNS
1+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
23 na na MC EM na na 3+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
24 F 41 NOS L5 + na 3+ - E,S - mo, sev 1 + 1+ 2+ B -
25 na na NOS CPA na na 3+ - S - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
na data not available, MS melanotic schwannoma, Sw conventional schwannoma with limited pigment 
(neuromelanin, lipofuscin), IMC intermediate-grade melanocytoma, MC melanocytoma, NOS lesion not further 
classified with certainty as melanotic schwannoma or melanocytoma, IM intramedullary, EM extramedullary,  
CPA cerebellopontine angle, S spindle cell phenotype, E epithelioid cell phenotype, O ovoid, Pa palissading 
of nuclei, V Verocay bodies, A Antoni A and B pattern, mi mild,  mo moderate, sev severe, B biphasic,  
P pericellular, N nested.
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10 M 72 Sw Vestibular nerve na na 2+ - S Pa mi 2+ neg neg P -
11 F 60 Sw Th11 na na Focal 1+ - S Pa, V mi 2+ neg neg P -
12 F 32 Sw Retroperitoneum na + Focal 1+ - S Pa, A mi 2+ neg neg P -
13 M 42 Sw Sacrum na + Focal 1+ - S Pa mi 2+ neg neg P -
14 na na Sw Intercostal nerve na + 1+ - S Pa, A mi 2+ neg neg P -
15 M 49 Sw S1 na na Focal 1+ - S Pa, A mi 2+ neg neg P -
16 F 74 Sw S2 + na Focal 1+ - S Pa mi 2+ neg neg P -
17 F 74 Sw Groin na na Focal 1+ - S Pa, A mi 2+ neg neg P -
18 M 44 Sw Sacral na + Focal 1+ - S Pa, A mi 2+ neg neg P -
19 na na blue nevus Foot na + 2+ - S,O - mi Focal 1+ 2+ Foc. 1+ N c.626A>T 
(p.(Gln209Leu))
20 na na IMC Cauda na No, invasion of 
CNS
1+ - S - mi Focal 1+ 2+ 2+ N c.626A>T 
(p.(Gln209Leu))
21 na na IMC IM na No, invasion of 
CNS
3+ - E,S - mi Focal 1+ 2+ 1+ N -
22 na na IMC IM na No, invasion of 
CNS
1+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
23 na na MC EM na na 3+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
24 F 41 NOS L5 + na 3+ - E,S - mo, sev 1 + 1+ 2+ B -
25 na na NOS CPA na na 3+ - S - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
na data not available, MS melanotic schwannoma, Sw conventional schwannoma with limited pigment 
(neuromelanin, lipofuscin), IMC intermediate-grade melanocytoma, MC melanocytoma, NOS lesion not further 
classified with certainty as melanotic schwannoma or melanocytoma, IM intramedullary, EM extramedullary,  
CPA cerebellopontine angle, S spindle cell phenotype, E epithelioid cell phenotype, O ovoid, Pa palissading 
of nuclei, V Verocay bodies, A Antoni A and B pattern, mi mild,  mo moderate, sev severe, B biphasic,  
P pericellular, N nested.
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Diagnostic value of GNAQ mutational analysis
In our previous study on GNAQ mutations in primary leptomeningeal melanocytic 
lesions (16), codon 209 mutations of GNAQ were present in seven of 19 lesions. 
Taking these previous results into account, a total GNAQ mutation frequency of 43% 
(10/23) in primary leptomeningeal melanocytic lesions was detected. No GNAQ 
Figure 1  Melanotic schwannoma (case 4) showing a circumscribed tumor, covered by a fibrous 
capsule and containing several psammoma bodies (a) (x50). Detail of the same lesion showing 
spindle cell morphology, an ample amount of melanin pigment and a psammoma body (case 
4) (b) (x200). Melanotic schwannoma (case 8) with more epithelioid cell morphology, nuclear 
pseudoinclusions (arrow) and large vacuoles resembling fat (c) (x400). Strong and diffuse 
positivity for respectively S-100 and HMB-45 in a melanotic schwanomma (case 4) (d, e) (x25, 
x100). Same lesion with pericellular deposition of basement membrane material (case 4) (f) 
(Laguesse stain, x400).
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mutations were detected in the melanotic schwannomas. The mutational status between 
melanotic schwannoma and leptomeningeal melanocytic lesions was significantly 
different (P = 0.030). GNAQ mutations were highly specific for leptomeningeal melano - 
cytic lesions compared to melanotic schwannoma (100%), however, sensitivity for 
leptomeningeal melanocytic lesions was low (43%).
Figure 2  Intermediate-grade melanocytoma (case 20) with invasion of neuroglial tissue; note 
the Rosenthal fibers (arrow) in the surrounding neuropil (a) (x200). Epithelioid cell morphology 
with bland nuclei and small nucleoli in a melanocytoma (case 22) (b) (x400). Focal positivity for 
S-100 in the same lesion (case 22) (c) (x200). Diffuse positivity for HMB-45 and Melan-A, 
respectively, in the same lesion (d, e) and a nested staining pattern in the reticulin stain (f) (case 
22) (Laguesse stain, x200).
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DISCUSSION
Especially on biopsy material, the differential diagnosis of melanotic schwannoma 
with primary leptomeningeal melanocytic lesions and, in case of peripherally located 
lesions, cellular blue nevi can pose a problem to pathologists since these lesions 
have overlapping histological features and immunohistochemical stains are not 
always useful. All these lesions are variably pigmented, spindle and/or epithelioid cell 
tumors, expressing S-100 (owing to their common neural crest origin) and one or 
more melanocytic markers. However, some histological features favor the diagnosis 
of melanotic schwannoma, such as circumscribed, often encapsulated growth, and/
or the presence of psammoma bodies. Psammoma bodies are generally absent in 
melanocytic tumors, although one case of a psammomatous melanoma arising in an 
intradermal nevus has been described (18). Stains for components of the basement 
Figure 3  Case 24 was a variably, partly heavily pigmented lesion consisting of spindle to 
pleomorphic cells (a, c) (x200), showing infiltrative growth in a ganglion at the lumbar spinal 
region with dispersed incorporated ganglion cells (arrow) (b) (x400). The nuclei showed marked 
atypia with conspicuous nucleoli (c) (x200). In the reticulin stain, both a pericellular (d) and 
nested staining pattern was seen (e) (Laguesse, x100). We, therefore, favored the diagnosis of 
a melanotic schwannoma with atypical features suggestive of aggressive behavior. Molecular 
analysis of this case did not reveal mutations in the GNAQ gene.
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membrane can be useful in discriminating tumors with schwannian differentiation 
from tumors with melanocytic differentiation (12). Deposition of basement membrane 
material around individual tumor cells (`pericellular`  pattern) is a feature of tumors 
with schwannian differentiation, and is generally not pronounced in melanocytic 
tumors (23,26). However, stains for basement membrane in melanin producing 
tumors should be interpreted with caution. First, in melanotic schwannomas a 
biphasic staining pattern has been described with deposition of basement membrane 
material around both individual tumor cells as well as around nests of tumor cells (12), 
as was the case in five of nine melanotic schwannomas in our study. On biopsy 
material, with only limited tissue to evaluate, this might result in misinterpreting the 
lesion as a melanocytic tumor. Secondly, most melanomas show absence of 
basement membrane material around individual tumor cells (26), except for spindle 
cell melanomas and desmoplastic neurotropic melanomas in which also a biphasic 
staining pattern has been described (4,21,26).
Recently, we reported the presence of activating mutations in codon 209 of the GNAQ 
gene in primary leptomeningeal melanocytic lesions (16). This gene encodes the 
α-subunit of q class heterotrimeric GTP-binding proteins which couple G protein 
coupled receptors to the MAP kinase pathway. Identical codon 209 mutations have 
been reported in UMs (46%) and blue nevi (83%) (28). These codon 209 mutations 
occur in the ras-like domain turning GNAQ into a dominant acting oncogene (28).
The aim of the present study was to perform a thorough histological review of a series 
of lesions that were initially diagnosed as melanotic schwannoma and analyze these 
cases for mutations in the GNAQ gene. In addition, we evaluated the diagnostic value 
of GNAQ mutational analysis in the sometimes difficult differential diagnosis with 
primary leptomeningeal melanocytic lesions. Twenty five cases initially diagnosed as 
melanotic schwannoma were reviewed and reclassified using established criteria into 
nine melanotic schwannomas, nine conventional schwannomas, four melanocytomas, 
one blue nevus and two lesions that could not be further classified with certainty as 
melanotic schwannoma or melanocytoma. The fact that in only nine of 25 cases the 
initial diagnosis melanotic schwannoma remained unchanged after review illustrates 
the difficult differential diagnosis with esp. conventional schwannoma and lepto-
meningeal melanocytic lesions. Including results from our previous study (16), a total 
GNAQ mutation frequency of 43% was present in leptomeningeal melanocytic lesions 
(10/23). No GNAQ mutations were detected in the melanotic schwannomas (0/9). 
These results show that GNAQ mutations are highly specific for leptomeningeal 
melanocytic lesions compared to melanotic schwannoma (100%). Thus, GNAQ 
mutational analysis can have diagnostic value: in case a GNAQ mutation is present 
this supports the diagnosis of a melanocytic lesion. It is important to note here that 
lack of a GNAQ mutation does not rule out the diagnosis of a melanocytic lesion. 
Correct diagnosis of melanotic schwannoma has clinical relevance as melanotic 
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schwannoma can occur in the setting of the autosomal dominant Carney complex 
and may require additional clinical investigations.
GNAQ codon 209 mutations in blue nevi have been reported in up to 83% (28). This 
high mutation frequency suggests that GNAQ mutational analysis can also be useful 
in the differential diagnosis of peripherally located melanotic schwannoma with blue 
nevus. Noteworthy, we reclassified a substantial number of lesions initially diagnosed 
as melanotic schwannoma into conventional schwannoma (n=9), based on absence 
of staining for Melan-A and HMB-45. These lesions all contained some areas with 
fine intracytoplasmic grayish Schmorl positive pigment in tumor cells. However, the 
absence of staining for Melan-A and HMB-45 contradicts the presence of true 
melanosomes in these cells and suggests that the pigment is rather autophagosome- 
related (e.g. neuromelanin, lipofuscin) (11). Care should thus be taken not to 
over-diagnose melanotic schwannoma in order to prevent unnecessary clinical 
work-up for Carney Complex.
At the moment, it is unclear why mutations in the GNAQ gene are especially found in 
a subgroup of melanocytic lesions, including leptomeningeal melanocytic lesions, 
UMs and blue nevi but not in CM (16,17,28). The fact that these GNAQ-mutated 
melanocytic lesions seem to be derived from non-epithelium related melanocytes 
may indicate that GNAQ mutations preferentially occur in melanocytes present in 
extra-epithelial structures such as leptomeninges, dermis and uvea. However, 
whether the site-specific occurrence of GNAQ mutations is a consequence of the 
mutations themselves or represents different target cell populations needs to be 
further determined. GNAQ codon 209 mutations seem to be an early event in the 
pathogenesis since they occur in benign as well as malignant melanocytic lesions. 
These activating codon 209 mutations form an alternative route for MAP kinase 
activation and probably represent an initial stimulus for melanocytes to proliferate 
(22,28). Inhibition of GNAQ-dependent MAP kinase signalling may form a novel 
option for targeted therapy of these tumors.
In conclusion, this study illustrates the difficult differential diagnosis of melanotic 
schwannoma with leptomeningeal melanocytoma, and shows that a detailed analysis 
of morphology combined with molecular analysis of the GNAQ hotspot mutation can 
aid herein. Correct diagnosis of melanotic schwannoma is important to select those 
patients who need further clinical evaluation for possible association with Carney 
Complex.
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ABSTRACT 
Neurocutaneous melanosis (NCM) is a rare congenital syndrome characterized by 
the presence of large or multiple congenital melanocytic nevi (CMN) of the skin and 
melanotic and nonmelanotic lesions in the central nervous system (CNS). It is hard to 
predict which patients with large or multiple CMN will develop symptomatic NCM. 
The prognosis for patients with diffuse leptomeningeal melanocytic deposits or CZS 
melanoma is currently poor as there is no effective treatment.
We studied central nervous system melanocytic tumors (CNS-MTs) from five NCM 
patients and corresponding CMN from three of these patients by genome-wide 
analysis of copy number variations and analysis of (hotspot) mutations in a panel of 
genes.
All CNS-MTs and CMN harbored a heterozygous NRASQ61 mutation, confirming a central 
role for NRAS mutations in NCM-associated melanocytic neoplasms. Additionally, in the 
CNS-MTs, but not in the CMN, multiple large copy number variations were present. 
Focal LOH at 6p22.1 and focal genomic aberrations (copy neutral LOH and or copy 
number loss) at 10q22.1 were found in all CMN and all CNS-MTs of the pediatric 
patients and may thus indicate underlying NCM when found in CMN.
Our findings provide clues for diagnosis and prognosis for patients with NCM. 
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INTRODUCTION
Neurocutaneous melanosis (NCM) is a rare, congenital syndrome characterized by 
the association of large or multiple congenital melanocytic nevi (CMN) of the skin and 
central nervous system (CNS) abnormalities (1-4). The CNS abnormalities in NCM are 
broad and include both melanocytic as well as non-melanocytic lesions with widely 
varying clinical outcomes (5-7). The CNS melanocytic lesions in NCM range from 
mere melanin deposits in the brain parenchyma to proliferations of melanocytic cells 
in the CNS, mostly in or along the leptomeninges. These melanocytic cells can be 
cytologically benign or malignant, called melanocytosis or melanoma, respectively. 
Diffuse leptomeningeal melanocytic deposits are associated with poor survival (7). 
Neurological manifestations in NCM patients usually occur before the age of two 
years, and less frequently, later on in the second or third decade of life (4, 8-11). 
Relatively little is known about the exact risk that patients with large or multiple CMN 
have of developing neurological manifestations. The prevalence of radiological CNS 
abnormalities although increases with the severity of cutaneous phenotype, i.e. size 
of largest CMN and total number of nevi (4, 12, 13).  Bittencourt et al. (14) prospectively 
followed 160 patients with large CMN. Four patients developed manifest NCM (2,5%). 
DeDavid et al. (15) found a higher incidence, with manifest NCM in 33 patients among 
a population of 289 patients with large cutaneous melanocytic nevi (11%). Recently, 
Bekiesinska et al. (16) reported an even higher incidence of NCM (29.2 %) in a series 
of 24 children with giant CMN. CNS magnetic resonance imaging has recently been 
proposed as a screening instrument in children with multiple CMN (6). The histologic 
features of the congenital nevi in NCM are the same as in congenital nevi found in 
patients who never develop neurologic symptoms. 
Acquisition of post-zygotic somatic NRAS mutations occurring during early embryonic 
migration of melanocytes is thought to underlie the pathogenesis of NCM (17). These 
mutations mainly affect codon 61 of NRAS. In a recent series, twelve of sixteen 
patients with NCM were shown to harbor a somatic NRASQ61 mutation in their CMN 
(75%) (18). Kinsler et al. found mutations in codon 61 of NRAS in affected neurological 
and cutaneous tissues of 12 out of 15 patients (80%). Mutations were absent in 
unaffected tissues and blood consistent with NRAS mutation mosaicism (5). Other 
studies have also shown the presence of NRASQ61 mutations in both the CMN and the 
central nervous system melanocytic tumors (CNS-MT) of NCM patients (19, 20). It is 
currently unclear whether BRAF mutations are also involved in the pathogenesis of 
NCM. 
Knowledge on copy number variations (CNVs) in CNS-MTs is largely lacking. In the 
single study that has been published on this subject, Kinsler et  al. reported absence 
of large gains or losses in one case of NRAS-mutated melanocytosis in an 8-year-old 
boy with NCM (using array CGH) (5). In contrast, they detected multiple gains and 
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losses in a primary NRAS-mutated melanoma in the cerebellum of a 10-year-old child 
with NCM that developed liver metastases. The aberrations in this melanoma 
included, among others, loss of whole chromosome 3, gain of chromosome 8 and 
loss of 9p24.3–p21.1, the latter including the CDKN2A locus (5). However, given the 
small number of cases studied, the diagnostic and prognostic significance of these 
CNVs is unclear.
The aim of our study was to further elucidate the genetic alterations in melanocytic 
nevi and CNS melanocytic tumors of patients with NCM. Paired samples of skin nevi 
and CNS melanocytic tumors of five NCM patients were investigated by genome 
wide CNV analysis and next-generation sequencing to detect mutations in a panel of 
cancer genes. Results were correlated with clinical characteristics including survival.
MATERIALS AND METHODS 
Patients
Formalin-fixed, paraffin-embedded (FFPE) tissue was obtained from two NCM 
patients from our own hospital (Radboud UMC) and from three NCM patients through 
PALGA (the Dutch nationwide histopathology and cytopathology data network and 
archive)  (31). Main patient characteristics are summarized in Table 1. Patients 1-4 are 
children with an age ranging from four to nineteen at the time of pathological diagnosis 
of the CNS-MT. All these children died of disease. Patient 5 is a 30-year-old woman 
alive two years after diagnosis of melanomatosis. None of the patients had clinical 
evidence of primary melanoma outside the CNS.
Histology of all lesions was revised by WB and HK. Patients 1 and 5 had a histological 
diagnosis of diffuse melanomatosis, patients 2 and 4 were diagnosed with CNS 
melanoma, and patient 3 with melanocytosis. From three patients (cases 2, 3 and 5) 
FFPE tissue from both a CMN and the CNS melanocytic tumor was available. From 
patient 3 we had FFPE material from different stages of disease. Some data from 
patient 3 has been published before (20). 
DNA extraction 
For DNA extraction, areas with an estimated neoplastic cell percentage of at least 
50% were selected and manually dissected. DNA was extracted by digestion in a 
proteinase K/Chelex-100 solution. After proteinase K inactivation, the mixture was 
spun for five minutes and the supernatant containing the DNA was used for DNA 
purification with the QIAamp DNA micro kit 50 (Qiagen, Stanford, CA, USA). DNA 
concentration was determined with a Qubit 2.0 Fluorometer (Life Technologies, 
Carsbad, CA, USA). Quality control of the extracted DNA was performed with size 
ladder PCR.
129
Genomic analysis of melanocytic tumors in neurocutaneous melanosis
7
Ta
b
le
 1
  P
at
ie
nt
 c
ha
ra
ct
er
is
tic
s 
an
d 
ge
no
m
ic
 te
st
s 
Pa
tie
nt
A
ge
 a
t 
di
ag
no
si
s 
S
ex
S
am
pl
e
S
am
pl
e 
co
lle
ct
io
n
E
st
im
at
ed
 %
 
of
 n
eo
pl
as
tic
 
ce
lls
M
ut
at
io
ns
O
nc
oS
ca
n
Fo
llo
w
-u
p
1
4
M
B
ra
in
: m
el
an
om
at
os
is
B
io
ps
y 
at
 4
y
65
-7
0
N
R
AS
c.
18
2A
>
G
 (p
.(G
ln
61
Ar
g)
); 
Q
61
R
; 4
1%
 m
ut
an
t a
lle
le
+
D
O
D
2
7
M
Sk
in
: c
on
ge
ni
ta
l n
ev
us
B
io
ps
y 
at
 3
y
80
-9
0
N
R
AS
 c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
Q
61
K
; 4
2%
 m
ut
an
t a
lle
le
+
D
O
D
B
ra
in
: m
el
an
om
a
B
io
ps
y 
at
 7
y
>
 8
0
N
R
AS
  c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
Q
61
K
; 4
0%
 m
ut
an
t a
lle
le
+
3
13
M
Sk
in
: c
on
ge
ni
ta
l n
ev
us
B
io
ps
y 
at
 2
 m
on
th
s
80
N
R
AS
  c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
 
Q
61
K
; 3
5%
 m
ut
an
t a
lle
le
  
+
D
O
D
B
ra
in
: m
el
an
oc
yt
os
is
 
be
fo
re
 tr
ea
tm
en
t
B
io
ps
y 
at
 1
3y
50
N
R
AS
 c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
Q
61
K
; 3
4%
 m
ut
an
t a
lle
le
 
+
B
ra
in
: m
el
an
oc
yt
os
is
 
af
te
r t
re
at
m
en
t
Au
to
ps
y
80
N
R
AS
 c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
Q
61
K
; 4
6%
 m
ut
an
t a
lle
le
  
+
Sk
in
: c
on
ge
ni
ta
l n
ev
us
 
af
te
r t
re
at
m
en
t
Au
to
ps
y
80
N
R
AS
 c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
Q
61
K
; 2
5%
 m
ut
an
t a
lle
le
  
-
4
19
M
B
ra
in
: m
el
an
om
a
Au
to
ps
y
80
N
R
AS
 c
.1
81
C
>
A 
(p
.(G
ln
61
Ly
s)
); 
Q
61
K
; 2
3%
 m
ut
an
t a
lle
le
  
+
D
O
D
5
30
F
Sk
in
: c
on
ge
ni
ta
l n
ev
us
 
B
io
ps
y 
at
 2
4y
90
.N
R
AS
 c
.1
82
A>
G
 (p
.(G
ln
61
Ar
g)
); 
Q
61
R
; 5
1%
 m
ut
an
t a
lle
le
+
al
iv
e
B
ra
in
: m
el
an
om
at
os
is
B
io
ps
y 
at
 3
0y
70
N
R
AS
.c
.1
82
A>
G
 (p
.(G
ln
61
Ar
g)
); 
Q
61
R
; 3
0%
 m
ut
an
t a
lle
le
+
M
ut
at
io
n 
an
al
ys
is
 b
y 
N
G
S
 w
as
 p
er
fo
rm
ed
 in
 d
up
lic
at
e.
 F
or
 e
ac
h 
sa
m
pl
e,
 th
e 
id
en
tifi
ed
 m
ut
at
io
n 
w
as
 d
et
ec
te
d 
in
 d
up
lic
at
e 
w
ith
 s
im
ila
r m
ut
an
t a
lle
le
. O
nc
oS
ca
n 
+
 o
r -
: 
O
nc
oS
ca
n 
ha
s 
(+
) o
r h
as
 n
ot
 (-
) b
ee
n 
p
er
fo
rm
ed
 o
n 
th
e 
sa
m
pl
e;
 D
O
D
 d
ie
d 
of
 d
is
ea
se
. C
as
e 
3 
ha
s 
ha
d 
ex
p
er
im
en
ta
l t
re
at
m
en
t w
ith
 a
 M
E
K
-in
hi
bi
to
r; 
se
e 
da
ta
 p
ub
lis
he
d 
be
fo
re
 (2
0)
. D
N
A
 fr
om
 u
na
ffe
ct
ed
 s
ki
n 
of
 p
at
ie
nt
 3
 a
nd
 D
N
A
 fr
om
 to
ns
ill
ar
 ti
ss
ue
 fr
om
 a
 h
ea
lth
y 
p
er
so
n 
w
er
e 
us
ed
 a
s 
co
nt
ro
l s
am
pl
es
.
130
Chapter 7
Mutation analysis
Mutation analysis of a panel of genes was performed by next-generation sequencing 
using single molecule Molecular Inversion Probes (smMIP) (A. Eijkelenboom et al., 
Reliable Next Generation Sequencing of FFPE tissue using single molecule tags. 
Journal of Molecular Diagnostics, In press.) (21). The cancer hotspot gene panel 
includes the following  genes and hotspot regions:AKT1 (NM_005163.2): codon 17, 
BRAF (NM_004333.4): codon 582-615, CTNNB1 (NM_001904.3): codon 19-48, 
EGFR (NM_005228.3): codon 465-499, 688-823, 849-875, ERBB2 (NM_004448.3): 
codon 770-785, GNA11 (NM_002067.4): codon 183 en 209, GNAQ (NM_002072.3): 
codon 183 en 209, GNAS (NM_000516.4): codon 201 en 227, H3F3A (NM_002107.4): 
codon 28 en 35, H3F3B (NM_005324.4): codon 37, HRAS (NM_005343.2): codon 12, 
13, 59 en 61, IDH1 (NM_005896.3): codon 132, IDH2 (NM_002168.3): codon 140 en 
172, JAK2 (NM_004972.3): codon 617, KIT (NM_000222.2): codon 412-513, 550-591, 
628-713, 799-828, KRAS (NM_004985.4): codon 12, 13, 59, 61, 117 en 146, MPL 
(NM_005373.2): codon 515, MYD88 (NM_002468.4): codon 265, NRAS 
(NM_002524.4): codon 12, 13, 59, 61, 117 en 146, PDGFRA (NM_006206.4): codon 
552-596, 632-667, 814-848, PIK3CA (NM_006218.2): codon 520-554, 1020-1069. 
Using the ‘TP53/CDKN2A gene panel’ sequence analysis more than>95% of the 
coding regions of  TP53 (NM_000546.4) and CDKN2A (P14: NM_058195.1 en P16: 
NM_000077.3) was performed.
Analysis of copy-number variations by OncoScan analysis
Copy-number alterations were determined by OncoScan array analysis (molecular 
inversion probe (MIP) technology) (22) as we have described before (23). Due to 
limited amounts of material and DNA and/or limited quality of the DNA, it was not 
possible to analyze all the collected specimens by OncoScan analysis as can be 
seen in Table 1. DNA from unaffected skin from patient 3 and DNA from tonsillar 
tissue from a healthy person were used as control samples. Data were analyzed 
using Nexus Copy Number 7.5 genomic software (BioDiscovery, El Segundo, CA, 
USA). A copy number of 2 per individual is considered normal. CNVs were identified 
with the SNP-Fast Adaptive States Segmentation Technique 2 (SNP-FASST2) 
segmentation algorithm. Copy gains were defined with log2ratio values between 0.3 
and 1.2, copy losses were defined with log2ratio values between -0.3 and -1.2. 
Log2ratio values exceeding 1.2 and -1.2 were defined as high gains and big losses, 
respectively. To rule out that the found aberrations do occur in the general population, 
they were compared to known CNVs reported in the Database of Genomic Variants 
(DGV), Toronto (http://projects.tcag.ca/variation/), comprising more than 2.5 million 
entries identified in more than 22,300 genomes (24). 
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RESULTS
Mutation analysis
Main patient characteristics are summarized in Table 1. Mutation analysis could be 
performed for all samples. All samples harbored a NRASQ61 mutation; two patients 
had a NRASQ61R and three had a NRASQ61K mutation. Based upon comparison of the 
mutated allele frequency with the estimated neoplastic cell percentage, all NRAS 
mutations were heterozygous mutations.  Remarkably, all samples of patient 3, 
including a sample of normal tissue, harbored a concomitant PDGFRA c.1895C>T 
(p.(Thr632Met)) variant with approximately 50% variant allele frequency in the tissues 
examined. This variant is described as an infrequently occurring single nucleotide 
polymorphism (SNP, rs572964298 in exac, broadinstitute.org). No other mutations in 
the regions of the genes investigated were found.
Copy number variations
Figure 1 shows an overview of all genome wide CNVs that were found. Table 2 
provides information on the larger gains and losses (defined as ≥ 30Mb) per sample. 
In contrast to the CMN, all CNS melanocytic tumors showed various relatively large 
CNVs. The CMN contained only focal aberrations, mostly copy neutral loss of 
heterozygosity (cnLOHs). Compared to the malignant CNS-MTs of patients 1, 2 and 
4, the leptomeningeal melanomatosis of the adult female patient (patient 5) had a 
relative low number of large aberrations. Interestingly, this patient presented relatively 
late in life with neurological symptoms and has shown only slow progression of the 
disease so far.
Patient 4 showed a loss of 1p including NRAS (located at 1p13.2). The other samples 
did not show any CNVs in this region. None of the samples showed CNVs in the 
region of CDKN2A (9p21). In all CNS-MT samples copy number gain and allelic 
imbalance of 6p was present. Gain of 8q was present in all CNS-MT samples as well, 
except for the melanomatosis of patient 1. These CNVs were absent in the nevi. 
From patient 3 DNA was available from different lesions at different stages of disease 
(i.e. brain biopsy at the time of diagnosis and brain tissue from autopsy performed 
five months later). Compared to the findings in the brain biopsy material, the CNVs in 
the autopsy material were more extensive with involvement of whole (arms of) 
chromosomes. In the autopsy material there was loss of 8p and gain of 8q, 13q, 15q 
and the entire chromosome 20 and LOH of 8p (see Figure 1 and Table 2). Some of 
these aberrations occurred specifically in this patient while others were also (partially) 
detected in CNS-MTs of the other patients. The latter comprise copy number gain 
and allelic imbalance of 13q and 15q, copy number loss and LOH of 8p as well as 
copy number gain and allelic imbalance of 8q, including MYC. In contrast to the long 
arms of chromosome 13 and 15, aberrations of chromosome 8 have frequently been 
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Table 2   All gains and losses ≥ 30Mb
Patient/ sample Large copy number 
changes (>30Mb)
Coordinates
1 melanomatosis Gain 1q21.2 - q32.1* chr1:149,039,031-206,944,465
Gain 1q32.1 - q44* chr1:207,013,396-249,250,621
Gain 6p25.3 - p12.1* chr6:0-54,670,464
Loss 6q16.1 - q27 chr6:93,921,636-171,115,067
Gain 20q11.21 - q13.33 chr20:29,445,644-63,025,520
2 melanoma Gain 1q21.3 - q32.1* chr1:151,549,259-201,458,099
Gain 1q32.1 - q43* chr1:201,709,694-241,573,334
Gain 6p25.3 - p21.31* chr6:0-35,406,385
Loss 6q12 - q27 chr6:63,869,874-171,115,067
Gain 8q11.1 - q24.3 chr8:46,950,145-146,364,022
Loss 10p15.3 - p11.1 chr10:0-39,087,061
Loss 10q11.21 - q26.3 chr10:42,365,676-135,534,747
Loss 11q14.1 - q25 chr11:85,459,252-135,006,516
Loss 16q12.1 - q24.3 chr16:49,514,255-90,354,753
2 congenital nevus - -
3 melanocytosis before treatment - -
3 melanocytosis after treatment Loss 8p23.3 - p11.21 chr8:0-40,514,039
Gain 8q11.1 - q24.3 chr8:46,950,145-146,364,022
Gain 13q14.2 - q34 chr13:49,183,989-115,169,878
Gain 15q11.2 - q26.3 chr15:21,308,314-102,531,392
Gain 20q11.21 - q13.33 chr20:29,445,644-63,025,520
3 congenital nevus - -
4 melanoma Gain 6p25.3 - p21.31* chr6:0-35,390,085
Gain 8p23.3 - p11.1 chr8:0-43,749,726
Loss 10p15.3 - p11.1 chr10:0-39,087,061
Gain 20q11.21 - q13.33 chr20:29,445,644-63,025,520
5 melanomatosis Gain 2q31.2 - q37.3 chr2:179,652,455-243,199,373
Gain 6p25.3 - p12.3* chr6:0-50,006,716
Gain 8q13.3 - q24.3 chr8:72,068,938-146,364,022
Control skin case 3 - -
Control tonsil - -
A list of all large gains and losses (defined as ≥ 30Mb) found with the OncoScan analysis.
 – = large losses absent. * CNVs also found by Kinsler et al. (5)
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described in various melanoma types. Aberration of 8q was present in all CNS-MT 
samples in our series except for case 1. Aberrations of 8q are frequent in uveal and 
skin melanomas we have analyzed before ((23) and unpublished data). 
Focal LOH at 6p22.1 was found in both the CNS-MTs and CMN of all pediatric patients 
but not in the lesions of the adult patient in our series. Copy neutral LOH at 10q22.1 
was found in all cases except for the melanoma of patient 4 (which showed copy 
number loss) and the melanoma of patient 2 (which showed LOH and copy number 
loss).
DISCUSSION
Here we provide the results of whole-genome analyses of CNVs and of mutation 
analysis of melanocytic lesions from both the skin and the CNS of NCM patients. Our 
findings may help to identify genetic factors associated with the oncogenesis and 
progression of these lesions and to identify new targets for treatment.
All melanocytic lesions from both the skin and the CNS harbored an activating NRAS 
codon 61 mutation, which is fully in line with data from the literature (5). The presence 
of NRAS mutations in most NCM cases could be helpful in future targeted treatment 
of NCM patients with neurological symptoms or melanoma development (20, 25, 26). 
While none of the samples in our study harbored a BRAF mutation, others have 
presented data indicating that BRAF mutations may occasionally be involved in the 
pathogenesis of NCM as well. Salgado et  al. reported a BRAFV600E mutation in the 
CMN of two NCM patients (2/16, 12.5%) but the CNS-MTs of these patients were not 
investigated (18). Also, a minority of patients with large or giant CMN outside the 
context of NCM may harbor BRAFV600E instead of NRASQ61 mutations (27), but data 
are contradictory since other studies have not found BRAF mutations in these CMN 
(28, 29). Obviously, demonstration of a BRAF mutation in the melanocytic tumors of 
patients with NCM may have therapeutic consequences and needs further 
investigation. Saldago et al. (30) have described  amplification of mutated NRAS 
(p.Q61R) in a patient with NCM who died at 17 months of age due to disseminated 
disease. They have hypothesized that amplification of mutated NRAS may be a 
genetic mechanism leading to melanoma development in the context of NCM. We 
did not see amplification of mutated NRAS in our series.
One of our patients harbored an infrequently found single nucleotide polymorphism 
in platelet derived growth factor receptor alpha (PDGFRA), the relevance of which in 
the context of the developed melanocytic lesion is unknown. Of note, gene mutations 
in PDGFRA have been described in other melanoma subtypes (31, 32). 
Knowledge on CNVs in NCM has been largely lacking. OncoScan analysis revealed 
substantial differences in the number of aberrations between the CNS-MTs and the 
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CMN in our series. The nevi had very few and small aberrations, mostly cnLOHs 
whereas the CNS-MTs had a high number of various large copy number variations 
(defined as ≥ 30Mb) (see Figure 1 and Table 2). This finding is in line with the 
previously described, highly significant differences in CNVs between cutaneous 
melanoma and nevi, with only Spitz nevi having some form of aberration (33). 
In the only previously published study on genomic and mutational aberrations in 
NCM associated neoplasms, Kinsler et al. reported multiple losses and gains in a 
primary melanoma in the cerebellum of a 10-year old child (5). The large aberrations 
(like in our own study defined as ≥ 30Mb) they described were gain of 1q21.1-q44, 
loss of chromosome 3, loss of 5p15.33-q11.2, gain of 6p25.3-p11.2, gain of whole 
chromosome 8 and loss of 9p24.3-p21.1, loss of 11p15.5-p13 and loss of chromosome 
18 (5). We detected a gain in nearly exactly the same region of 1q in two of our 
CNS-MT cases (case 1 and 2; see Table 2). The gain of 6p described by Kinsler et al. 
was present in all malignant CNS-MTs of our series (cases 1, 2, 4 and 5- see Table 2). 
In our series, gain of 8q was detected in four of the CNS-MTs (cases 2, 3, 4 and 5- see 
Table 2). Gain of the short arm of chromosome 8 was seen in case 4. However, we 
did not see gain of whole chromosome 8. Furthermore, we describe allelic imbalance 
or cnLOH of 9p24.3-p13.1 in case 3 but no loss in this region, whereas Kinsler et al. 
reported a loss of a larger region in 9p. We did not find loss of chromosome 3, 5, 11p or 
18 in our cases. The different CNS-MT samples of patient 3, obtained in different 
phases of the disease (i.e. brain biopsy at time of diagnosis and brain tissue from 
autopsy performed five months later), enabled us to also study potential markers of 
progression. This patient received experimental treatment with a MEK-inhibitor shortly 
before he died as has been published (20). We did not find a significant change in 
mutant allele frequency in the context of the estimated percentage of neoplastic cells 
of the NRASQ61k mutation in the samples before and after treatment. Kinsler et al. 
reported progression from heterozygosity to homozygosity for a NRAS Q61K mutation 
in samples of a cutaneous lesion before and after malignant progression of this 
lesion (5). Our case differed from the case of Kinsler et al. as in our patient no apparent 
change from histologically benign to malignant occurred. In addition, the only NRAS 
homozygous melanoma case described by Kinsler et al. was a cutaneous melanoma 
developing in a congenital nevus. They did not find loss of heterozygosity for NRAS 
mutations in malignant CNS tumors. We also did not find homozygosity for NRAS in 
our malignant cases in the CNS. It could be hypothesized that malignant progression 
in NCM might be different in cutaneous and leptomeningeal locations. OncoScan 
analysis of the CNS-MT in this case did show that the aberrations occurring at an 
earlier stage of disease were more focal and only small (defined as <30Mb), whereas 
they were more pronounced and sometimes extended over whole chromosome 
arms or even whole chromosomes after progression (see Figure 1 and Table 2). This 
supports the presumption that additional aberrations occur during progression. In 
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the material of this patient, five CNVs may be associated with malignant progression: 
loss of 8p, and gain of 8q, 13q, 15q and 20 (see Table 2). As these regions harbor 
hundreds of genes it is not possible to indicate one or a few genes likely to be involved 
in the more aggressive behavior of the tumor cells.
Copy number mean gains of 6p and 8q were detected as common aberrations in the 
CNS-MTs (see Table 2). Both aberrations have frequently been described in 
melanomas of different origin (23, 33-37). The 8q copy number gain was detected in 
all the CNS-MTs except for the melanomatosis of case 1. It was relatively high in both 
circumscribed lesions (case 2 and 4). Notably, regions with copy number gain of 8q 
were only focally observed, in short stretches of the genome, in the melanocytosis of 
case 3 before treatment. After treatment, copy number gain of the entire 8q arm was 
seen.
LOH at 6p22.1 was found in both the CNS-MTs and CMN of all pediatric patients but 
not in the lesions of the adult patient in our series. Copy neutral LOH at 10q22.1 was 
found in the CMN of all the patients and in most of the CNS-MTs except for the 
melanoma of patient 4 (who showed copy number loss at 10q22.1) and the melanoma 
of case 2 (which showed LOH and copy number loss of 10q22.1). Using our in house 
database including 1400 samples (DNA from saliva of 1400 students), we have not 
detected common aberrations in these regions. For future research, it would be very 
interesting to test large CMN of children without NCM in order to know whether these 
aberrations are specifically associated with NCM. If so, testing CMN of children for 
these aberrations could potentially be a diagnostic test that helps to determine 
whether a patient has NCM with the risk of developing neurologic manifestations.
In conclusion, all CMN and CNS-MT obtained from 5 NCM patients harbored an 
activating NRAS mutation, which may provide a potential target for therapy. The CMN 
had relatively few CNVs compared to the CNS-MTs. Five CNVs (loss of 8p, and gain 
of 8q, 13q, 15q and 20) may be associated with more aggressive behavior in the 
CNS-MTs. In addition, LOH at 6p22.1 and copy neutral LOH at 10q22.1 may serve as 
an indicator of underlying NCM when found in large congenital nevi.
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ABSTRACT 
Objective. The aim of this study was to evaluate a series of primary melanomas of 
the female urogenital tract for oncogenic mutations in KIT, NRAS and BRAF in order 
to identify patients who may be amenable to targeted therapy.
Methods. We reviewed twenty-four cases of female urogenital tract melanomas and 
used Sanger sequencing analysis for the detection of oncogenic mutations in exons 
9, 11, 13, and 17 of KIT; exons 2 and 3 of NRAS; and exon 15 of BRAF.  
Results. Twenty-four patients were included: fourteen vaginal melanomas, four 
cervical melanomas, five urethral melanomas and one vulvar melanoma. NRAS 
mutations (4/24, 21%) were more prevalent than KIT mutations (1/24, 4%), while BRAF 
mutations were absent. Three of four NRAS mutations were present in vaginal 
melanomas (21%), mainly affecting codon 61 (3/4). They were mutually exclusive with 
the KIT mutation. The KIT mutation was present in a vaginal melanoma and affected 
exon 17.
Conclusions. Melanomas of the female urogenital tract relatively commonly harbor 
mutations in NRAS; this makes NRAS an interesting therapeutic target for these 
patients in the advanced setting. KIT mutations were rare in our study in contrast to 
some previous reports. We cannot exclude that anatomical site-related differences 
and/or population related differences in KIT mutation frequency exist within urogenital 
tract melanomas.
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INTRODUCTION
Primary melanomas of the female urogenital tract are rare and account for 
approximately 20% of all mucosal melanomas (1). They comprise melanoma of the 
vulva, vagina, uterine cervix and urethra/ureter/urinary bladder, and originate from 
melanocytes present in the epithelium of mucosal membranes that cover the 
urogenital tract. They carry a poor prognosis with a 5-year survival of approximately 
11% (1). Diagnosis often occurs at advanced stage (1, 2). In case of vaginal melanoma, 
about 50% of patients have positive regional lymph nodes, and nearly 20% have 
distant metastases at time of diagnosis (3). Locoregional control might be obtained 
by surgery and/or radiation therapy but in case of metastatic disease, few effective 
treatment options exist (2).  
It has been shown that melanomas arising from mucosa are genetically distinct from 
the common cutaneous melanoma. While oncogenic mutations in BRAF are present 
in approximately 50% of cutaneous melanoma, these mutations are very rare in 
mucosal melanoma (0-10%) (4, 5). Activating BRAF mutations lead to constitutive 
activation of the mitogen-activated protein kinase (MAPK) pathway (6), and are an 
effective target in the treatment of metastatic BRAF-mutated melanomas using 
selective BRAF inhibitors (such as vemurafenib) (7, 8). 
Mucosal melanomas commonly harbor activating KIT mutations (approximately 20%) 
(4, 9-11), that result in activation of several downstream pathways including the MAPK 
and PI3K/AKT pathways (12). Several case reports and Phase II trials have reported 
objective responses to the KIT inhibitors imatinib and sorafenib in advanced 
KIT-mutated melanoma (11, 13-15). Another major oncogene in melanoma is NRAS, 
which is mutated in approximately 20% of cutaneous melanomas and in varying 
frequencies in mucosal melanomas (16-19). Activating NRAS mutations cause 
aberrant signaling in the MAPK and the PI3K/AKT pathways, and are an interesting 
target for molecular therapy in advanced melanoma patients carrying these mutations 
(20). 
The KIT and NRAS mutation frequencies in mucosal melanomas seem to relate to 
specific mucosal sites. KIT mutations are relatively frequent in melanomas of the 
urogenital tract (up to 45%) compared to sinonasal melanomas (7-12.5%) (10, 21-25), 
while NRAS mutations are rare in anal melanomas (5%) compared to sinonasal (22%) 
and esophageal melanomas (38%) (25-27). For urogenital tract melanomas only 
limited numbers of cases have been studied for presence of oncogenic NRAS 
mutations. As knowledge of molecular subtypes of melanoma is important for 
selection of patients amenable to targeted therapy, the aim of our study was to search 
for oncogenic mutations in KIT, NRAS and BRAF in a series of primary melanomas of 
the female urogenital tract in The Netherlands (n=24).
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MATERIALS AND METHODS
Patient selection
For this retrospective study, formalin fixed and paraffin embedded (FFPE) tissues of 
twenty-four primary melanomas of the female urogenital tract were retrieved from five 
pathology archives in The Netherlands in an anonymized way (between 1995 and 
2013). Histological diagnosis was revised by two experienced pathologists (WB, 
HKV). Tissue handling and data-assessment were performed according to the Code 
Proper Secondary Use of Human Tissue (http://www.federa.org/code-goed-gebruik- 
van-lichaamsmateriaal-2011). 
DNA isolation and mutation analysis
Five 10μm sections were used for DNA extraction. The first and last slide of the 
paraffin blocks were stained with hematoxylin and eosin and reviewed by a pathologist 
for determination of representativity and estimation of percentage of neoplastic cells 
(at least 70  %, as specified in Table 1). DNA extraction was performed using a 
proteinase K treatment followed by affinity-purification using the QIAamp DNA Mini 
Kit (QIAGEN) according to the manufacturer’s instructions. The concentration of the 
DNA samples was quantified by NanoDrop ND-1000 (Nanodrop). Testing for 
mutations in NRAS (exons 3 and 2), KIT (exons 9, 11, 13, and 17), and BRAF (exon 15) 
was carried out by PCR and Sanger sequencing. Genomic DNA (20-100 ng) was 
amplified in a reaction volume of 25 μL containing 12.5 μL AmpliTaq Gold® 360 PCR 
Master Mix (Applied Biosystems). Primer sequences used are listed in Table 2. 
All primers contained a M13 forward or reverse consensus sequence for sequencing 
the different exons. The PCR conditions were 95⁰C for 10 minutes, 38 cycles of 95⁰C 
for 30 seconds, 58⁰C for 30 seconds, and 72⁰C for 1 minute followed by an extension 
step of 72⁰C for 7 minutes. The PCR products were purified by using Multiscreen-HTS 
PCF Filter Plates (Merck, Millipore). One micro liter of the PCR product was used per 
sequence analysis (forward and reverse), using an ABI PRISM 3700 DNA analyzer 
(Life Technologies, Foster City, USA).
RESULTS
Clinicopathologic characteristics 
Twenty-four cases were collected (mean age of the patients 68 years): fourteen vaginal 
melanomas, four cervical melanomas, five urethral melanomas and one vulvar 
melanoma (see Table 1). The diagnosis was confirmed in all cases by an experienced 
dermatopathologist (WB). Mean tumor diameter was 30.5 mm and mean tumor 
thickness was 12.1 mm (biopsies excluded). 
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Since mutation analysis was the primary goal of the research described in this article 
and the material was collected in an anonymized way, we could not collect information 
on clinical stage and/or survival. 
Mutation analysis 
All cases were screened for mutations in exons 9, 11, 13, and 17 of KIT (Table 1). A 
KIT exon 17 mutation c.2458G>T (p.(Asp820Tyr)) was detected in one of the fourteen 
vaginal melanomas; this mutation (also described as pD820Y) has previously been 
reported in other mucosal melanomas (21, 24, 28) (see Figure 1A for the chromatogram 
traces). None of the  other cases showed a KIT mutation. In four cases NRAS 
mutations were identified of which three were present in vaginal melanomas and one 
in a melanoma of the urethra (see Table 1 and Figure 1B and 1C).  Three mutations 
occurred in codon 61 and one in codon 12 of NRAS. They were mutually exclusive 
with the KIT mutation. BRAF exon 15 mutations were absent. 
Case 15 showed an unusual growth pattern with mainly spindle cells and partly a 
nested growth pattern and no epidermal component. This case was also tested for 
EWSR1-CREB and EWSR1-ATF1 translocations to exclude the possibility of the lesion 
being a clear cell sarcoma. No translocations were found (data not shown).
Table 2   Primers used for mutation analysis
Gene Exon Direction Primer sequence (5’-3’)
KIT 9a Forward GTATGCCACATCCCAAGTG
Reverse CCTTACATTCAACCGTGCC
9b Forward CAGTGGATGTGCAGACAC
Reverse GATATGGTAGACAGAGCC
11 Forward CCAGAGTGCTCTAATGAC
Reverse CATGGAAAGCCCCTGTTTC
13 Forward CGCTTGACATCAGTTTGCC
Reverse CAGACAATAAAAGGCAGC
17 Forward GGTTTTCTTTTCTCCTCC
Reverse CTGTCAAGCAGAGAATGGG
BRAF 15 Forward CTTCATAATGCTTGCTCTG
Reverse GCCTCAATTCTTACCATCC
NRAS 2 Forward ATTACTGGTTTCCAACAGG
Reverse CTGGATTGTCAGTGCGCTTT
3 Forward CCCCAGGATTCTTACAGAAAA
Reverse TCGCCTGTCCTCATGTATTG
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DISCUSSION 
In the past years, important progression has been made in the treatment of patients 
with advanced stage cutaneous melanoma by using targeted therapy directed against 
mutated signal transduction molecules. Targeted therapy might also importantly attribute 
to prognosis and survival in the rare group of urogenital tract melanomas. Genetic 
alterations in these melanomas have however not been extensively studied yet.  
To our knowledge, only a limited number of studies have searched for oncogenic 
NRAS mutations in urogenital tract melanomas (see Table 3 for an overview). In our 
Figure 1  Chromatogram traces showing a KIT c.2458G>T (p.(Asp820Tyr)) mutation in case 13 (A), 
a NRAS c.35G>T (p.(Gly12Val)) mutation in case 8 (B) and a NRAS c.181C>A (p.(Gln61Lys)) 
mutation in case 3 (C).
A
B
C
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series of 24 urogenital melanomas, we detected four NRAS mutations (4/24, 16%): 
three in vaginal melanomas (3/14, 21%) and one in an urethral melanoma (1/5, 20%). 
Aulmann et al. found NRAS mutations in both vulvar (5/42, 12%) and vaginal (2/15, 
13%) melanomas (41). Omholt and colleagues reported an even higher NRAS 
mutation frequency in vaginal melanomas (43%), which was significantly higher than 
in mucosal melanomas of other sites in their series (24). In our study, mutations 
mainly involved codon 61 and were mutually exclusive with KIT mutations. The latter 
is in accordance with previous studies, although rarely coexistent (pre- and post 
treatment) KIT and NRAS mutations have been detected in samples of melanoma 
patients (28, 29, 41).  Of note, as oncogenic NRAS mutations are an early event in 
melanomagenesis and frequently present in benign congenital melanocytic nevi 
(80%) (30), we could not identify any precursor lesions in the slides of our cases. 
Also, the cases with mutations did not show any histological characteristics different 
from those without a mutation.  The relatively high frequency of NRAS mutations in 
our study, especially in the vaginal melanomas (21%), makes NRAS an interesting 
therapeutic target for these patients in the advanced setting. One strategy in targeting 
the mutant NRAS protein is the use of inhibitors that target downstream-activated 
cascades such as the MAPK pathway and the PI3K/AKT/mTOR pathway (31). 
Melanoma cell lines harboring NRAS gene mutations were shown to be sensitive to a 
MEK inhibitor. A recent clinical trial with MEK162, a potent MEK inhibitor, has revealed 
some response in patients with NRAS-mutant melanoma (32, 33). As NRAS activates 
multiple downstream pathways, combination of inhibitors such as MEK and PI3K/
mTOR inhibitors might be more effective, and clinical trials with such combinatorial 
approaches are currently underway (31, 34). 
We detected only one KIT mutation, p.D820Y, which was in a vaginal melanoma (1/24, 
4%). KIT encodes a type III transmembrane receptor tyrosine kinase that consists of 
five distinct domains, including the juxtamembrane region encoded by exon 11 that 
is most often affected by mutations in both gastrointestinal stromal tumor (GIST) and 
melanoma (12). Recently, three phase II studies have shown that imatinib mesylate 
(Gleevec®) is effective in patients with advanced KIT-mutated melanomas, in addition 
to case reports of KIT-mutated urogenital melanoma patients showing response to 
KIT inhibition (11, 21, 28, 29, 35, 36). Response to imatinib mesylate depends on the 
region of the protein affected by mutation (12). For melanomas, mutations in exon 11 
and exon 13 are sensitive to KIT tyrosine kinase inhibitors (11, 12, 28). The p.D820Y 
KIT mutation in our series is associated with secondary resistance to imatinib 
mesylate in GIST (11, 37) and is also predictive of a lower probability of response to 
imatinib mesylate in KIT-mutated melanoma (11, 35); although recently a partial 
response to imatinib mesylate has been noted in a mucosal melanoma (location not 
further specified) harboring this specific KIT mutation (28).
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The low frequency of KIT mutations (4%) in our study is in contrast to several studies 
that have reported a higher frequency of KIT mutations in urogenital melanomas 
(range up to 45%) (See Table 3 for an overview)(10, 21-24, 38-41). However, most of 
these studies investigated a relatively low number of patients with exception of two 
larger studies by Omholt et al. (24) and Aulmann et al. (41). Furthermore, most of 
these studies did not specify for anatomic location, e.g. vulvar versus vaginal, so it 
cannot be assessed whether differences exist in the frequency of KIT mutations 
between vaginal and vulvar melanomas, while there are indications that this might be 
the case. In our study mainly vaginal melanomas were included (n=14) and only one 
of these harbored a KIT mutation (7%), suggesting that vaginal melanomas only 
rarely harbor KIT mutations. This is supported by the study of Omholt et al. who 
detected no KIT mutations in seven vaginal melanomas and a relatively high frequency 
of KIT mutations in vulvar melanomas (8/23, 35%), accounting for the relatively high 
KIT mutation frequency of 27% in thirty vulvovaginal melanomas in their study (24). 
Very recently, Aulmann et al. also described KIT mutations in seven out of thirty-nine 
(7/39, 18%) vulvar melanomas, but none in fifteen vaginal melanomas (41). In line with 
this, Handolias et al. reported two KIT mutations in five vulvar melanomas (40%), and 
Torres-Cabala et al. reported three KIT mutations in eleven vulvar melanomas (27%) 
(See Table 3) (21, 40). Obviously, further investigation in larger series is needed to 
determine whether true differences exist in KIT mutation frequency between vulvar 
and vaginal melanomas. This could reflect different pathways for tumor genesis, and 
could have potential clinical implications for testing and treatment of patients with 
advanced disease.    
Several studies have shown that BRAF mutations are uncommon in mucosal 
melanomas, with reported frequencies ranging from 0 to approximately 10% (11, 25, 
26, 39, 41). In line with this, we did not detect BRAF mutations in our series of female 
urogenital tract melanomas. However, BRAF exon 15  mutations have been reported 
in some cases of vulvar melanomas (9%) (Table 3) (24). Therefore molecular testing 
for BRAF mutations in urogenital tract melanomas should be encouraged as selected 
patients might have a mutation and benefit from anti-BRAF therapy.
In conclusion, NRAS mutations were more prevalent than KIT mutations in our series 
of melanomas arising from the female urogenital tract. This is important as these 
patients might benefit from MEK inhibition. As the present study mainly investigated 
vaginal melanomas and only patients from the Netherlands, it cannot be excluded 
that site- and population specific differences in KIT mutation frequency exist among 
female urogenital tract melanomas. The absence of BRAF mutations in our study is in 
line with results from other studies and also with the reported mutation frequency in 
other types of mucosal melanomas. Testing for BRAF mutations is however still 
encouraged as selected patients might have a mutation and might benefit from 
anti-BRAF therapy. To our opinion, urogenital melanomas should be tested for NRAS, 
151
Mutation analysis in melanoma of the female urogenital tract
8
KIT and BRAF mutations in the advanced setting as patients might benefit from 
targeted therapy.
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SUMMARIZING DISCUSSION AND FUTURE PERSPECTIVES
Melanocytic neoplasms include several tumor types that are characterized by distinct 
clinical features, histopathological appearances, genetic aberrations, and biological 
behavior (1). Cutaneous melanocytic neoplasms are by far the most common type of 
melanocytic neoplasms and in the past decades much knowledge has been gained 
on the molecular mechanisms underlying the most frequent cutaneous melanocytic 
lesions. Much less is known about the molecular mechanism in less frequent 
melanocytic tumor subtypes in the skin or in melanocytic tumors developing in 
non-cutaneous sites. The main goal of the research described in this thesis was to 
learn more about the genetic aberrations present in different less frequent melanocytic 
neoplasms, including Spitz tumors, primary leptomeningeal melanocytic tumors, 
uveal melanomas, and melanomas of the female urogenital tract, in order to gain 
knowledge on pathogenesis, improve diagnostics and to search for treatment 
targets. In order to facilitate the reading of the rest of this chapter, an overview of the 
different genes and pathways involved is given in figure 1 (2).
SPITZ TUMORS
Spitz tumors are uncommon skin tumors that mainly arise in children and adolescents, 
but may also occur in older individuals and constitute diagnostic problems for 
 dermatopathologists on a regular basis (3-5). Under-diagnosis as a nevus, over- 
diagnosis as a melanoma, and an uncertain diagnosis of Spitzoid tumor of unknown 
malignant potential (STUMP) all occur in this specific subset of melanocytic skin 
tumors. Currently, three subgroups of spitzoid melanocytic tumors have been 
described with specific genetic characteristics partly associated with a typical 
phenotype: the HRAS-mutated Spitz tumors (chapter 3), the melanocytic BAP1- 
associated intradermal tumors (MBAITs), and the spitzoid lesions with kinase fusions 
(see also chapter 2).
HRAS-mutated Spitz tumors
HRAS-mutated Spitz tumors are characterized by a typical phenotype. In chapter 3 
twenty-four cases are described which we identified while studying a large group of 
Spitz tumors (93 Spitz nevi and 77 STUMPs). HRAS-mutated Spitz tumors are 
dermal-based tumors with a relatively low cellularity, desmoplasia and an infiltrative 
base. They can be easily misdiagnosed as a melanoma especially when dermal 
mitoses are present and when the lesions present in older patients. In our series 
of twenty-four HRAS-mutated Spitz tumors, seven (29%) were initially diagnosed as 
a melanoma or melanoma was an important differential diagnostic consideration. 
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Figure 1  Main intracellular pathways that are implicated in different subtypes of melanoma. 
Mutations in KIT are relatively frequent in mucosal melanoma (~20%) and acrolentiginous 
melanoma, result in activation of the MAPK and PI3/AKT/mTOR pathways, and can be treated 
with KIT inhibitors. Approximately 50% of cutaneous melanomas (CM) harbor mutations in 
BRAF at codon 600, which provide a therapeutic target for selective BRAF inhibitors. Mutations 
in NRAS (~20% of CM) signal to MEK/ERK through CRAF, but also to the PI3/AKT/mTOR 
pathway. MEK inhibitors have shown activity in some patients with NRAS mutant melanoma. 
Signaling pathways downstream of GNAQ/GNA11 (~80% of uveal melanomas (UMs)) include 
activation of PKC through the release of diacylglycerol (DAG) by β‐PLC, which can activate the 
MAPK pathway. Another downstream pathway is the Hippo‐YAP pathway resulting in activation 
and translocation of the transcriptional coactivator YAP into the nucleus through a mechanism 
of actin polymerization regulated by the GTPases Rho and Rac. Metastatic UMs frequently 
harbor inactivating mutations in BAP1, which is involved in multiple functions including 
regulation of the cell cycle and epigenetic modulation. Inhibition of downstream components 
such as MEK, PKC, BAP1 and YAP are now under (pre) clinical investigation for treatment of 
GNAQ/GNA11‐mutated UM.
MAPK = mitogen‐activated protein kinase; PKC = protein kinase C; PLC = phospholipase C; 
UM = uveal melanoma; ERK = extracellular signal‐regulated kinase; MEK = mitogen‐activated 
ERK kinase; PI3K/AKT/mTOR = phosphatidylinositol 3‐kinase/protein kinase AKT/mammalian 
target of rapamycin. Adapted from (2). 
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A correct distinction with a melanoma is clinically relevant since prognosis is different; 
none of the patients with a HRAS-mutated Spitz tumor in our series developed 
recurrences or metastases (mean and median follow-up of 10.5 y) which is in 
accordance with findings in most other studies. HRAS mutations are encountered in 
<1% of cutaneous melanomas (6). The HRAS-mutated Spitz tumors account for 
~15% of Spitz tumors. The typical morphology of the HRAS-mutated Spitz tumors 
is probably a consequence of the HRAS mutation. It has been demonstrated that 
overexpression of HRAS in normal human melanocytes causes increase in cell size 
and massive intracellular vacuolization (7). It is currently unclear why HRAS mutations 
occur almost exclusively in Spitz tumors and not in spitzoid melanoma. 
Melanocytic BAP1-associated intradermal tumors
The melanocytic BAP1-associated intradermal tumors (MBAITs) (8), ~5% of Spitz 
tumors, are often polypoid, dermal based tumors consisting of large epithelioid “spitzoid- 
looking” cells and can have a small compound nevus component (especially in 
BAP1-germline mutated lesions). In one-third of cases tumor-infiltrating lymphocytes 
are prominent. MBAITs can occur in the setting of a BAP1 germline mutation (8), but 
also sporadically (9, 10). The majority of lesions carry a concomitant BRAF mutation 
(9, 11) and, much less frequently, a concomitant NRAS mutation (12, 13). No HRAS 
mutations have been described in MBAITs. The prognosis of MBAITs seems favorable 
without recurrences and infrequent progression to melanoma and very rarely 
metastases (14). At present, the most important reason for recognition of a MBAIT is 
that they can be a marker of an underlying BAP1-associated germline mutation. The 
BAP1 tumor predisposition syndrome predisposes to cutaneous and uveal melanoma 
(8, 15), mesothelioma (14, 16), renal cell cancer (17), and possibly several other types 
of cancer (18). The cutaneous melanocytic tumors in the setting of germline BAP1 
mutations do not differ in histological appearance from those with sporadic mutations 
(12). In addition, recognition of a melanocytic tumor as a MBAIT is important to 
prevent overdiagnosis of melanoma. In the past, but even nowadays, not all (general) 
pathologists are familiar with these tumors and they are still diagnosed as melanoma 
or consultated to exclude melanoma. Of note, several other terms have been 
proposed for MBAITs, especially BAPoma and naevoid melanoma-like melanocytic 
proliferation (19) and Wiesner tumor. 
Spitz tumors with genomic rearrangements involving kinases
The third group of Spitz tumors, up to 50%, are those with genomic rearrangements 
(translocations, fusions) of various receptor tyrosine kinases, including ALK (~10% of 
Spitz tumors), ROS (~10%), NTRK1 (~10%), RET (<5%) and MET (rare), or the serine- 
threonine kinase BRAF (~5%) (19-21). Fusion-positive Spitz tumors generally occur 
in patients that are younger than those with tumors without a translocation (20). 
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The genomic rearrangements cause fusion of the kinase domain to a wide range of 
partner genes, which leads to high expression of fusion genes that subsequently 
causes ligand independent dimerisation and auto-phosphorylation of the kinase 
domain. These kinases subsequently activate multiple oncogenic signaling pathways 
like the MAPK/ERK, P13K/AKT/mTOR, and JAK-STAT pathways resulting in increased 
cell proliferation, and cell survival (8). In these tumors, kinase fusions are mutually 
exclusive; no combinations with BAP1 inactivation or HRAS mutations have been 
observed. Furthermore, these kinase fusions are present along the entire spectrum 
of the Spitz tumors (55% in Spitz nevi; 56% in atypical spitzoid tumors and 39% in 
spitzoid melanomas). Most have no specific histologic features and are difficult to 
identify. An in-depth description of the clinicopathological features of the different 
types of Spitz tumors with genomic rearrangements involving kinases is beyond the 
scope of this thesis, but are described in detail  by Wiesner et al. (19). Recognition of 
Spitz tumors that carry a kinase fusion might be mainly important for therapy of 
malignant lesions in the advanced setting. Thus far no reports on treatment of these 
lesions as such are available. Metastatic spitzoid melanomas harboring kinase 
fusions might be candidates for treatment with kinase inhibitors, just like for instance 
lung cancers with ALK or ROS1 fusions (22, 23), and medullary thyroid carcinoma 
with RET fusions (24-26). 
Implications for the pathologist
Thorough histopathological examination remains the gold standard for the diagnosis 
of Spitz tumors, but in certain cases additional molecular analysis can be useful. To our 
opinion, in daily pathological practice, Spitz tumors that are hard to classify should 
be tested for mutations in HRAS, BRAF and NRAS. BRAF and NRAS should be tested 
for as these are frequently mutated in adult cutaneous melanomas (see chapter 1). 
The presence of a BRAF or NRAS mutation therefore favors the diagnosis of a 
melanoma whereas the presence of a HRAS mutation indicates an indolent biological 
behavior. When based on morphological findings a MBAIT is considered, we 
advocate that BAP1 protein expression analysis is performed. In case of inconclusive 
BAP1 immunostaining results (a staining that is difficult to interpret) or unexpected 
positive protein expression, while histological suspicion for a MBAIT is high, we 
advise to perform additional BAP1 mutation analysis. Immunostaining for BAP1 is 
sometimes positive despite an underlying BAP1 mutation (own observation and (27)). 
In the past, also in the setting of spitzoid tumors, mutation analysis by conventional 
techniques such as Sanger sequencing was often hampered due to a limited amount 
of material or because of the presence of a low percentage (i.e. less than 30%) of 
neoplastic cells. Often spitzoid lesions have inflammation or are relatively small or 
superficial; all these factors can lead to a low neoplastic cell percentage in a specimen. 
By mutation detection via next-generation sequencing (NGS), the sensitivity of a 
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molecular test is greatly improved enabling mutation detection in tissues with a lower 
percentage of neoplastic cells. 
Spitzoid melanomas with metastases, in which targeted treatment is considered, 
should -if negative for BRAF, NRAS, or KIT, be tested for genomic rearrangements 
involving kinases as patients with those harboring kinase fusions (of ALK, ROS, or 
RET), might benefit from treatment with kinase inhibitors. In many laboratories the 
gene fusions are currently interrogated using in situ hybridization. Detection of gene 
fusions by NGS technology accompanied by robust data analysis will soon make its 
entrance in molecular laboratories. 
The classification of Spitz tumors will probably be more refined in the future due to 
progress of our understanding of tumor pathogenesis. By integration of clinical, 
pathological, and genetic criteria, more subsets of Spitz tumors will probably be 
defined which will lead to improved diagnosis, treatment and prognosis.
UVEAL MELANOMAS
Uveal melanomas (UMs) are derived from melanocytes in the choroid coat, ciliary 
body, and iris of the eye. Despite local control, up to 50% of patients develop 
metastases, with average survival less than one year after the diagnosis of metastatic 
disease. At the moment there is no effective treatment for metastatic disease. 
Chromosome 3 loss, which is often associated with a BAP1 mutation on the remaining 
chromosome, is strongly correlated with metastatic disease as is, to a lesser extent, 
gain of chromosome 8q (15, 28-30). Disomy of chromosome 3, gain of chromosome 
6p, and mutations in EIF1AX and SF3B1 have been reported to be associated with a 
relatively good prognosis (28, 30-33). However, in a recently published series of 151 
UMs, the tumors with disomy 3 and a SF3B1 mutation carried an increased risk of 
metastatic spread compared to those with wild type SF3B1. Metastases in patients 
with mutated SF3B1 occurred late whereas those in patients with BAP1 mutations 
occurred early (34). UMs frequently carry mutations in the G protein encoding genes 
GNAQ and GNA11 (45% and 32% respectively) (35-37) (see figure 2). 
The results of whole genome copy-number analysis of twenty-five UMs as well as 
mutation and MLPA analysis of these tumors, are described in chapter 4. Our study 
confirms previously reported GNAQ and GNA11 mutation frequencies in UMs, as well 
as the presence of monosomy 3 as the most relevant genetic prognostic factor 
indicating a poor prognosis. We demonstrated that analysis of monosomy 3 by the 
described MLPA assay was efficient and robust. Soon, this MPLA assay will be 
replaced by NGS technologies to detect copy number alterations. Our study indicates 
that chromothripsis (a single catastrophic genetic event leading to a genomic 
landscape with multiple chromosomal rearrangements), and chromosome 8q gain 
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may play a role in initiation of UMs lacking a GNAQ or GNA11 mutation, while loss of 
chromosome 2p may be involved in metastatic disease in UMs without monosomy 3. 
These latter findings need to be corroborated in a larger series of tumors. There was no 
correlation between the various chromosomal abnormalities and histologic features. 
PRIMARY LEPTOMENINGEAL MELANOCYTIC NEOPLASMS
In the adult setting, primary leptomeningeal melanocytic neoplasms (LMNs) generally 
lack mutations in BRAF, HRAS and NRAS that are commonly found in cutaneous 
melanocytic neoplasms, but, like UMs, frequently harbor oncogenic mutations in 
GNAQ and GNA11 (see figure 2 and chapter 5). 
We have tested twenty LMNs (eleven melanocytomas (MC), five intermediate grade 
melanocytomas (IMCs) and four leptomeningeal melanomas (LMM)) for hotspot 
mutations in GNAQ, GNA11, BRAF, NRAS and HRAS. GNAQQ209 mutations were found 
in eleven neoplasms (in total 11/20 (55%); 7/11 MCs (64%); 2/5 IMCs (40%), 2/4 LMMs 
(50%)), and two neoplasms carried a GNA11Q209 mutation (in total 2/20 (10%); 1/5 
IMCs (20%) and 1/4 LMMs (25%)). 
GNA11Q209 mutations were less frequent in the LMNs than GNAQQ209 mutations, as 
has been reported (38, 39). This is in contrast to UMs where there is a more even 
distribution of GNAQ and GNA11 mutations, but in accordance with the reported 
distribution in blue nevi (35). 
In the reported series within this thesis, no GNAQR183, GNA11R183, BRAF, HRAS or 
NRAS mutations were found. In another more recent unpublished melanocytoma 
case we did, however, find a GNA11R183 mutation, and a GNAQR183 mutation has been 
reported in a melanocytoma in literature as well (40). Mutations at codon 183 of 
GNAQ and GNA11 thus do occur, but, as is also the case for UMs, at a much lower 
frequency than those at codon 209. 
GNA11 mutations might be associated with a more aggressive behavior
There was no significant association between GNAQ/ GNA11 mutational status and 
cell type, location of the lesion, disease-related death, or clinical behavior. However, 
GNA11Q209 mutations might have a more potent oncogenic effect than GNAQQ209 
mutations. All cases in our series harboring a GNA11 mutation were melanocytomas 
of intermediate grade or a melanoma (chapter 5). Recently, van de Nes et al. (39) 
reported comparable findings. In a series of seventeen primary LMNs, they found two 
GNA11 mutated cases (12%) compared to twelve cases with a GNAQ mutation (71%). 
Both GNA11 mutated cases were melanocytomas of intermediate grade that recurred. 
In UMs, GNA11 mutations also seem to be associated with a more aggressive 
behavior as UM metastases carry a higher frequency of GNA11 (57-60%) to GNAQ 
165
Summarizing discussion and future perspectives
9
(20-22%) mutations (35, 41), whereas primary UMs carry slightly more GNAQ 
(45-47%) than GNA11 (32-44%) mutations (35, 42). Moreover, GNA11 mutations are 
relatively infrequent in blue nevi compared to UMs. However, in UM patients, no 
significant association has been found between GNAQ or GNA11 mutational status 
and survival (35, 37, 43). Future studies are needed to determine whether GNA11 
mutations are associated with a more aggressive behavior in primary LMNs as well 
as in UMs. 
Figure 2  Relative frequency of oncogenic mutations in primary LMNs in adults vs. frequencies 
in uveal and cutaneous melanomas.
Primary leptomeningeal melanocytic neoplasms (LMNs) in adults frequently harbor oncogenic 
mutations in GNAQ and to a lesser extent in GNA11. The mutation profile is comparable with 
that of uveal melanoma, but distinct from cutaneous melanoma. GNAQ/GNA11/BRAF mutation 
analysis can be used as a diagnostic tool in the differential diagnosis of primary LMNs vs. 
metastasis of cutaneous melanoma to the central nervous system (CNS). Adapted from (2).
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Genetic resemblance of primary leptomeningeal melanocytic 
neoplasms with uveal melanomas
LMNs and UMs not only carry the same type of mutations. In chapter 5 we show with 
multiplex-ligation dependent probe analysis (MLPA) and OncoScan analysis, that 
they have more genetic aberrations in common (chapter 5). Detailed study of one 
intermediate grade melanocytoma and two leptomeningeal melanomas showed 
copy number variations resembling those found in UMs (i.e. gain of chromosome 6, 
gain of chromosome 8q and monosomy of chromosome 3) (28, 44). While these 
copy number variations have prognostic relevance in UMs, the prognostic relevance 
in LMNs still needs further investigation.
Recently, we have described another similarity between LMNs and UMs (45). 
Mutations in either SF3B1 or EIF1AX, which are frequently mutated in UMs (31-33), 
were detected in eight out of twenty-four primary LMNs (8/24, 33%). This underscores 
even more that UMs and LMNs resemble each other genetically. Immunohistochemical 
nuclear staining for BAP1, which was used as a surrogate marker for the detection of 
inactivating mutations in the BAP1 gene, was present in all cases in our series, 
suggesting absence of underlying BAP1 mutations in these tumors. However, there 
may have been a selection bias in our case series as it mainly concerned (relatively) 
low-grade tumors with disomy of chromosome 3. Recently, in a series of seventeen 
primary LMNs, one intermediate grade melanocytoma was reported to carry an 
inactivating BAP1 c.178C>T (p.R60*) mutation as well as a GNAQQ209 mutation and 
monosomy of chromosome 3 (39). Detailed follow-up data was not available, but the 
tumor did recur. De la Fourchadière et al. (46) reported a case of a primary 
leptomeningeal melanoma with a GNAQR183 mutation and complete absence of 
nuclear BAP1 staining. Array comparative genomic hybridization analysis revealed 
an altered profile, including a loss at the 3p2.1 BAP1 locus. The patient had a family 
history of uveal melanomas and meningeomas, and both sisters of the patient turned 
out to have a germline BAP1 mutation. These findings suggest that BAP1 mutations 
may play a role in LMNs, and that these tumors might need to be added to the list of 
tumors associated with germline BAP1 mutations. The prognostic significance of 
SF3B1, EIF1AX and BAP1 mutations in LMNs is presently unclear and needs to be 
further elucidated. 
Mutation analysis in the differential diagnosis of a primary 
leptomeningeal melanocytic neoplasm and a melanoma metastasis 
Mutation analysis of BRAF, GNAQ and GNA11 can be of aid in the differential diagnosis 
of a primary CNS melanoma versus a melanoma metastasis in the CNS in an adult 
patient. In contrast to primary LMNs, mutations in GNAQ or GNA11 are absent or very 
rare in cutaneous melanoma (1.4%, tested in >150 cases), acral melanoma (0%) and 
mucosal melanoma (0% in most studies), whereas cutaneous melanomas frequently 
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(50%) harbor BRAF mutations which are absent or rare in LMNs, see figure 2 (2). 
A melanoma in the CNS is much more likely a metastasis than a primary CNS 
melanoma, as primary melanocytic LMNs are very rare and cutaneous melanomas 
are relatively frequent and frequently metastasize to the CNS. In autopsy studies up 
to 2/3 of patients who died of a cutaneous melanoma had a CNS metastasis, whereas 
in clinical studies 10-40% of patients develop CNS metastases (47-49). Presence of a 
GNAQ or GNA11 mutation in a CNS melanoma, favors a primary LMN, whereas 
demonstration of a BRAF or NRAS mutation in adults, favors a metastasis from a 
cutaneous melanoma. Of note, this is different in children where primary LMNs harbor 
NRAS mutations (see chapter 7).
Differentiating a primary LMN from a metastasis is important because of its implications 
for further patient work-up, and the better prognosis of patients with a primary CNS 
melanoma compared to those with a melanoma metastasis in the CNS (47-54).
Mutation analysis in the differential diagnosis of a primary 
leptomeningeal melanocytic neoplasm and a melanotic schwannoma 
Histologically, melanotic schwannoma can closely resemble LMNs and blue nevi 
(55). Additional stainings are not always of help as there is overlap in staining patterns 
and they can be hard to interpret, especially in small biopsies (56-59). The difficulty 
of the diagnosis of a melanotic schwannoma, is illustrated by the fact that in our 
series of twenty-five cases initially diagnosed as a melanotic schwannoma, sixteen 
were reclassified based on criteria from the literature (55, 60-63) (as conventional 
schwannoma, n= 9; melanocytoma, n= 4; lesion not further classified with certainty 
as melanotic schwannoma or melanocytoma, n= 2 or blue nevus, n= 1) (see chapter 6).
All twenty-five cases were tested for GNAQQ209 mutations. No mutations were found 
in the nine melanotic schwannomas. However, GNAQQ209 mutations were found in 
one case reclassified as a blue nevus, in three cases reclassified as melanocytoma, 
and in one case that could not be reclassified with certainty as melanotic schwannoma 
or melanocytoma. Of note, all melanotic schwannomas were also tested for GNAQR183, 
GNA11Q209 and GNA11R183 mutations; none were found (data not published).
Combining these data with our previous findings in nineteen LMNs where seven 
contained a GNAQQ209 mutation (64), we concluded that GNAQ mutations are very 
helpful for discriminating primary LMNs from melanotic schwannomas. Correct 
diagnosis of the latter is important to select those patients who need further evaluation 
for possible underlying Carney Complex, an autosomal dominant syndrome associated 
with myxoid tumors (especially myxomas of the heart which can be lethal), endocrine 
overactivity and pigmented skin lesions (65, 66). 
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NEUROCUTANEOUS MELANOSIS
Primary LMNs can occur sporadically, mainly in adults, but they can also occur in the 
setting of neurocutaneous melanosis (NCM), mainly in children. NCM is a rare, 
congenital syndrome characterized by the association of large or multiple congenital 
melanocytic nevi (CMN) of the skin and central nervous system (CNS) abnormalities. 
The CNS abnormalities in NCM are diverse and include both melanocytic as well as 
non-melanocytic lesions with widely varying clinical outcomes. Once diffuse lepto- 
meningeal melanocytic growth or CNS melanoma is present, prognosis is very poor 
and there is no effective treatment.
Patients with large and/or multiple CMN, are at risk for having neurocutaneous melanosis, 
but it is currently hard to predict which patients will develop symptomatic NCM. Recently, 
magnetic resonance imaging (MRI) has been proposed as a screening instrument for 
congenital neurological lesions in children with more than one CMN at birth (67), but to 
our opinion there are several disadvantages: many often very young children need to 
be scanned (under general anesthesia) in order to find a rare case of NCM. In the 
reported study (67), twenty-one percent of the children had an abnormal MRI. A negative 
MRI, however, does not exclude NCM developing at a later stage. Furthermore, there 
can be subtle changes of which the relevance is currently unknown but nevertheless 
cause a lot of anxiety for parents. Currently, there is only very limited knowledge on 
the genetic aberrations in the melanocytic lesions of patients with NCM. 
Chapter 7 describes whole genome copy-number variation analysis as well as 
mutation analysis in paired samples of primary LMNs and CMN of five patients with 
NCM. Results were correlated with clinical characteristics including survival.
All primary LMNs and CMN harbored a heterozygous NRASQ61 mutation, confirming a 
central role for NRAS mutations in NCM-associated melanocytic neoplasms. No additional 
mutations were found. 
Our study supports the current hypothesis that both skin and leptomeningeal 
melanocytic lesions in NCM are caused by an early post-embryonic NRAS mutation 
in precursors of melanocytes. Depending on the timing of this NRAS mutation during 
development, this leads to NCM (in case of early mutation) or “only” a congenital 
nevus (in case of a later mutation). Additionally, in the LMNs, but not in the CMN, we 
found multiple large copy number variations. This indicates that additional genetic 
aberrations cause proliferation of the leptomenigeal melanocytes.
A potentially very interesting finding was focal loss of heterozygosity (LOH) at 6p22.1 
and focal genomic aberrations (copy neutral LOH and or copy number loss) at 
10q22.1 in all CMN and all primary LMNs of the four pediatric patients in our series. 
This recurrent and characteristic genetic alteration might be indicative of an underlying 
NCM when found in CMN, and might be a predictive marker for development of 
subsequent neurological disease. Such a marker is currently lacking; in patients with 
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large or several congenital nevi it is currently unclear which patients are going to 
develop neurological disease because of melanocytic proliferation. It would be very 
interesting to compare a series of CMNs from patients who have never developed 
NCM with a set of CMN and primary LMNs from patients with NCM for these 
aberrations in order to know if information on 6p22.1 and 10q22.1 can indeed be used 
as a diagnostic test. Due to the rarity of NCM, collection of sufficient numbers of 
patients and tumor tissues for systematic study however requires more time. 
MELANOMAS OF THE FEMALE UROGENITAL TRACT
Urogenital melanomas are rare and belong to the subgroup of the mucosal 
melanomas. They often get diagnosed at advanced stage with little treatment options, 
and are associated with a poor outcome. A recent study from our hospital showed 
that 6% of all vulvar cancers are melanomas and that they carry a more-worse 
prognosis than cutaneous melanomas. The five year survival for vulvar melanoma 
patients was 35% (95% CI 26,7-44.4%) compared to 50% (95% CI 40.5-59.1) for 
cutaneous melanoma patients with the same age, tumor ulceration stage, Breslow 
thickness, lymph node status and distant metastases diagnosed in the same time 
period (135 vulvar melanoma patients between 2004 and 2012) (log rank test: p = 0.002) 
(68). This difference may be caused by a difference in biological behavior, impact of 
tumor environment, or a combination thereof. In mucosal melanomas mainly KIT and 
NRAS mutations are found with frequencies varying between different mucosal sites, 
while oncogenic mutations in BRAF are very rare (69-76). 
In the study described in chapter 8 we investigated a series of twenty-four primary 
female urogenital tract melanomas. More precisely, fourteen vaginal melanomas, 
four cervical melanomas, five urethral melanomas and one vulvar melanoma were 
tested for mutations in KIT, NRAS and BRAF. NRAS mutations were detected in four of 
these tumors (4/24, 16%): three in vaginal melanomas (3/14, 21%) and one in an 
urethral melanoma (1/5, 20%). Only one KIT mutation was found: in a vaginal 
melanoma (1/24, 4%). No BRAF mutations were present. The low frequency of KIT 
mutations is in contrast to some other studies (for an overview see table 1 in chapter 8). 
However, in previous studies the number of patients was generally low. Also, the 
exact anatomic location (e.g. vulvar or vaginal) was often not specified in previous 
studies, but may well have had an impact, as KIT mutations seem more prevalent in 
vulvar melanomas compared to vaginal melanomas (our present study, (74, 77, 78)). 
Based on our results, we advocate that mutation analysis (KIT, NRAS and BRAF) 
should be performed in patients with metastatic urogenital tract melanoma since this 
may provide treatment options.
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CONCLUDING REMARKS
Melanomas originating from epithelia-associated vs non-epithelia-
associated melanocytes
Melanocytic neoplasms range from benign to malignant lesions and represent a 
group of distinct tumor types. At present, different melanocytic neoplasms are considered 
to arise from different types of melanocytes. These different types may be intrinsically 
different and/or the different microenvironments may change their function and 
response to stimuli. 
One way to subgroup melanocytic neoplasms is to discriminate between those 
originating from epithelia-associated versus non-epithelia-associated melanocytes 
(1, 70, 79-81).  
Cutaneous melanomas, acral melanomas (originating from the glabrous skin of the 
palms, soles and the nail apparatus) and the mucosal melanomas belong to the first 
and by far largest group. For cutaneous melanomas, there is a clear difference 
between melanomas occurring in skin with chronic sun damage (CSD; the tumors 
are generally characterized by a higher mutation burden, relatively late age of onset, 
and mutations mainly in NRAS, NF1, KIT, and in BRAF but not the most frequent BRAF 
V600E mutation) versus melanomas occurring in skin with intermittent sun exposure 
(non-CSD; these present earlier in life, are often associated with nevi, having a 
comparatively low mutation burden, and frequently harboring the most frequent 
V600E BRAF mutation). In acral melanomas UV-radiation is probably not a causal 
factor as they occur at similar incidences across the world. The frequency of BRAF 
mutations is lower than in non-CSD melanomas and approximately 20% have 
mutations in KIT. Mucosal melanomas, as described in chapter 8, harbor frequent 
mutations in NRAS and KIT, but less frequently in BRAF.
The melanomas originating from melanocytes not associated with epithelia are those 
arising in the dermis, uvea and CZS. As mentioned in chapters 4-7, melanomas 
belonging to this group mainly carry GNAQ or GNA11 mutations whereas those are 
virtually absent in the melanocytic neoplasms originating from epithelia-associated 
melanocytes.
In contradiction with previously published literature and the above mentioned 
hypothesis, Sheng et al. (82) very recently have described the presence of GNAQ and 
GNA11 mutations in mucosal melanomas. In a series of 284 primary mucosal 
melanoma samples from different primary anatomic sites (head and neck, anorectum, 
genitourinary and esophagus), they found GNAQ mutations in 4.6% of cases and 
GNA11 mutations in 4.9% of cases. GNAQ/GNA11 mutations were not significantly 
associated with age, gender, or primary anatomic site. The GNAQ mutations involved 
only exon 5 codon 209 whereas the GNA11 mutations involved both exon 5 (79%) and 
exon 4 (21%). Mutation types were mostly the same as described for UMs, but at 
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other frequencies (i.e. GNAQ Q209L mutations were found in 92% of the GNAQ 
mutated mucosal melanomas and Q209P in 8% whereas mutation frequencies in 
GNAQ mutated primary UMs are 33% and 66% respectively (www.mycancergenome.
org). GNA11 Q209L mutations were found in 43% of the GNA11 mutated mucosal 
melanomas and Q209R in 36% and R183C in 21% whereas mutation frequencies in 
GNA11 mutated primary UMs are 92%, 0% and 2-5% respectively (www.
mycancergenome.org)). Van Raamsdonk et al. did not find any GNAQ or GNA11 
mutation in 62 mucosal melanoma samples they tested (35). Maybe there is a 
difference between races as the study by Sheng et al. has been performed among a 
Chinese population whereas the study from van Raamsdonk et al. has been 
performed in the United States. It is remarkable that there was no difference in 
mutation types and frequencies between the different primary anatomical sites, 
as this seems to be true for NRAS and KIT mutations as has been mentioned in 
chapter 8. Most samples were also tested for mutations in KIT, BRAF and NRAS. 
Ten BRAFV600E mutations were found in the 188 samples tested for a BRAF mutation 
(5%), and only 17 KIT mutations in the 259 samples tested for a KIT mutation (7%), 
and only 14 NRAS mutations in the 192 tested for a NRAS mutation 7%). This makes 
it questionable whether all melanomas were truly primary mucosal. 
Systemic therapy in locally advanced or metastatic melanomas
Traditional cytotoxic agents like Dacabarzine have had none to limited impact on 
overall survival in patients with locally advanced or metastatic melanoma. Dacabarzine 
has been the only chemotherapeutic agent that has been approved for the treatment 
of metastatic melanoma, but is associated with a low response rate (approximately 
10%) and limited influence on median overall survival. The discovery that the pathways 
involved by mutated oncogenes can be more specifically targeted, has drastically 
improved therapeutic efficacy in a subset of these patients; mainly in those with a 
BRAF mutated cutaneous melanoma. The response rate to the first BRAF inhibitor 
vemurafenib (approved by the European Medicines Agency (EMA) since 2011) in 
patients with a BRAF-mutated metastatic cutaneous melanoma is 50%. The median 
overall survival in patients with advanced cutaneous melanoma treated with 
vemurafenib is fourteen to sixteen months whereas it is six to nine months in those 
treated with dacabarzine. Unfortunately, progression occurs in the vast majority of 
the patients after a median progression-free survival of five to seven months due to 
acquired resistance (83-85). The predominant pattern of resistance involves BRAF- 
independent reactivation of the mitogen-activated protein kinase (MAPK) pathway. 
However, MAPK pathway independent mechanisms may also be important (86, 87). 
The combined inhibition of both BRAF and MEK has been shown to improve clinical 
outcome by preventing or delaying the onset of resistance. Moreover, combined 
therapy decreases the number of secondary cutaneous cancers that occur due to 
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paradoxical activation of the MAPK pathway in keratinocytes. In a trial with 495 
patients with previously untreated unresectable locally advanced or metastatic 
BRAFV600 mutation-positive melanoma, the median progression-free survival was 
almost ten months in the group treated with the BRAF inhibitor vemurafenib in 
combination with the MEK inhibitor cobimetinib versus six months in the control 
group treated with vemurafenib and placebo. The rate of complete or partial response 
in the combination group was 68%, as compared with 45% in the control group, 
including rates of complete response of 10% in the combination group and 4% in the 
control group (88). In a more recent trail, 423 patients with previously untreated 
unresectable locally advanced or metastatic BRAF Val600Glu or BRAF Val600Lys 
mutation-positive melanoma were treated with BRAF inhibitor dabrafenib in 
combination with the MEK inhibitor trametinib or dabrafenib only. Median progres-
sion-free survival was eleven months in the combination group and almost nine 
months in the dabrafenib only group. Median overall survival was twenty-five months 
and almost nineteen months respectively (89).
While the research described in this thesis has focused on finding genetic aberrations 
that could be used for targeted therapy, others have identified a variety of targets for 
immunotherapeutic approaches. In the context of immunotherapy, cutaneous 
melanoma is studied very extensively as it appears to be one of the most immunogenic 
cancers witnessing occurrence of spontaneous regression and the presence of tu-
mor-infiltrating T-lymphocytes in primary tumors and metastases (90). In the recent 
years, immunotherapy has emerged and for metastatic cutaneous melanoma there 
has been a shift towards immunotherapy as first-line treatment. The currently most 
used immunotherapies in melanoma, target immune checkpoint receptors. 
Ipilimumab has been approved by the EMA for unresectable stage III and IV cutaneous 
melanoma since 2011. Ipilimumab is a monoclonal antibody that harnesses the 
immune system by blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). 
Blocking of CTLA-4 by ipilimumab augments T-cell activation and proliferation. 
Treatment with ipilimumab can provide durable tumor control and long-term survival 
benefits. A disease control rate of 28.5% has been reported. However, a high rate of 
severe adverse effects have been observed (fatigue, skin toxicity, diarrhea, colitis 
etc.) (90). Anti-PD1 immune checkpoint inhibitors nivolumab and prembolizumab 
have been approved by the EMA since 2015 for unresectable stage III and IV 
cutaneous melanoma. Programmed death-1 (PD1) is another cell-surface small 
receptor on T-cells that, like CTLA-4, is inhibitory to the immune response of T-cells. 
In normal tissues, binding of PD-1 to its ligand PD-L1 prevents an excessive immune 
response and regulates tolerance to self-antigens. First results in patients with 
advanced melanoma have been promising and trials are ongoing (90, 91). 
In a recent trial, 418 patients who had a previously untreated unresectable locally 
advanced or metastatic melanoma without a BRAF mutation, were treated with PD-1 
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immune-checkpoint–inhibitor antibody nivolumab or dacarbazine chemotherapy. At 
1 year, the overall rate of survival was 72.9% in the nivolumab group, as compared 
with 42.1% in the dacarbazine group. The median progression-free survival was 5.1 
months in the nivolumab group versus 2.2 months in the dacarbazine group. The 
objective response rate was 40.0% in the nivolumab group versus 13.9% in the 
dacarbazine group (92). Treatment with a combination of both immune checkpoint 
inhibitor antibodies seems even more effective. The objective-response rate and the 
progression-free survival among patients with advanced melanoma who had not 
previously received treatment were significantly greater with nivolumab combined 
with ipilimumab than with ipilimumab monotherapy (93). 
Although treatment with immune checkpoint inhibitors has led to major improvements 
in the survival of patients with advanced metastatic BRAF mutation-negative 
cutaneous melanoma, there are still several challenges. Treatment induces toxicity, is 
very expensive, and still only effective in a subset of patients while currently there are 
no biomarkers to select those patients who will benefit from therapy. Several other 
types of immunotherapy are under investigation like dendritic cell vaccination (which 
has recently shown improved overall survival when used in the adjuvant setting in 
cutaneous melanoma patients with regional lymph node metastases (94)), stimulation 
of the immune system with the use of vaccines to induce melanoma-specific 
responses, adoptive T cell transfer therapy, and others (91). 
Summarizing, the advantage of immunotherapy is the fact that more durable 
responses are achieved in comparison to targeted treatment and resistance does not 
occur. Disadvantage is that the effects are of later onset while targeted treatment 
often gives very rapid response. In rapidly progressive patients, therefore, 
immunotherapy is not applicable, and targeted treatment is still the treatment of first 
choice. For the future, combination of immunotherapy and targeted treatments 
(combined or sequential, depending on disease progression) are expected to 
combine the best of both treatments. 
There are not much data on the effectiveness of targeted therapy or immunotherapy 
in the less frequent melanoma subtypes this thesis focuses on. 
A few series have been published on the use of immune checkpoint inhibitors in 
patients with mucosal melanoma. These have shown that it is effective in a subset of 
patients and warrant further investigation. In a small case series of four female 
patients with large mucosal melanomas of the lower genital tract (three vaginal and 
one cervical), Ipilimumab has shown promising results in combination with radiation 
therapy in the initial treatment. One of the patients achieved complete pathological 
response (95). In a series of 71 Italian patients with metastatic mucosal melanoma 
from different primary sites treated with Ipilimumab, the response rate was 12% (i.e. 
partial or complete remission) and the immune-mediated disease control-rate was 
36% (i.e. stable disease). Median progression-free survival and overall survival were 
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4.3 and 6.4 months, respectively (96). In a recent retrospective multicenter cohort of 
35 patients with advanced mucosal melanoma, anti-PD-1 agents nivolumab or 
pembrolizumab showed an objective response rate of 23% and a median progres-
sion-free survival of 3.9 months. There was no detectable difference between subsites 
(twelve mucosal melanomas were from anorectal origin, fourteen primary vulvovaginal 
and nine originated from the head/ neck region). Response rates in this study were 
comparable to the published rates in patients with cutaneous melanoma (97). 
Several studies have implicated the efficiency of KIT inhibitors in the treatment of 
patients with advanced mucosal melanomas with KIT aberrations. In a phase II trial 
conducted by Carvajal et al. (98), 28 patients with mutations in or amplification of KIT, 
who had advanced unresectable melanoma arising from acral (10/28), mucosal 
(13/28) or chronically sun-damaged (5/ 28) sites, were treated with KIT inhibitor imatinib. 
Overall durable response rate was 16%, with a median time to progression of 
12 weeks, and a median overall survival of 46.3 weeks. Two patients achieved durable 
complete response (lasting 94 (ongoing) and 95 weeks), two achieved durable 
partial response (lasting 53 and 89 (ongoing) weeks), two achieved transient partial 
response (lasting 12 and 18 weeks), and five achieved stable disease lasting for 12 
weeks or longer. Guo et al. (99) have published a phase II trial of imatinib in 43 patients 
with metastatic melanoma harboring KIT aberrations, including 11 cases with 
mucosal melanoma. The median progression free survival was 3.5 months, and the 
6-month progression free survival rate was 36.6%. 10 patients achieved partial response 
(23.3%), and 13 patients achieved stable disease. An overall response rate of 29% 
has been reported by Hodi et al. (100) among 25 patients with metastatic melanomas 
harboring mutationally activated or amplified KIT (17 mucosal melanomas). 
Response rates were higher in the patients with a KIT mutation compared to those 
with amplification only, and seemed more effective when the mutant allele was 
relatively abundant compared to the wild-type allele (98, 100). Mutations in KIT are 
widely distributed over the coding region, and the modest results from the studies 
might indicate that only select KIT alterations are truly oncogenic and indicative of an 
effective therapeutic target. The effectiveness of newer-generation KIT inhibitors is 
under investigation. Treatment with MEK inhibitors has not been proven effective in 
mucosal melanomas.
In contrast to mutant BRAF and c-KIT, at the moment, small molecules that selectively 
inhibit mutant NRAS, GNAQ or GNA11 are not available.
For UMs, adjuvant therapy, including both targeted therapy as well as treatment with 
immune-checkpoint inhibitors has not been very effective with at most only limited 
clinical activity in small subset of patients (101-104). Maybe immunotherapy is not 
effective in uveal melanomas because the eye is an immune privileged site. Histo-
pathologically, uveal melanomas lack inflammatory cells in contrast to most of the 
cutaneous melanomas. 
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Some in vitro data have suggested that MEK inhibitors might be able to target 
NRAS-mutated LMNs. Experience in the use of targeted therapy in LMNs, however, is 
largely lacking (2).
The knowledge on the pathogenesis of melanoma as well as the treatment options of 
advanced melanoma are evolving rapidly. With the perspective discovery of more 
targets, the development of new drugs and the discovery of biomarkers, we are 
entering a new era being able to develop a more personalized approach. The use of 
combined therapies seems most promising. Hopefully, in the near future, advanced 
melanoma can be cured in a larger subset of patients, and therapeutic options will 
also improve for the less frequent melanoma subtypes.
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Melanocytaire tumoren zijn tumoren die ontstaan uit melanocyten, dat zijn melanine-
pigment-vormende cellen. Melanocyten komen in grote aantallen voor in de huid en 
zorgen hier voor bescherming tegen de schadelijke effecten van de zon. Maar 
melanocyten komen ook voor in andere organen zoals het oog, de zachte vliezen die 
de hersenen en het ruggenmerg omgeven (leptomeningen) en de slijmvliezen van 
bijvoorbeeld de vrouwelijke geslachtsorganen. Melanocytaire tumoren komen het 
meest frequent voor in de huid, maar ze kunnen overal in het lichaam ontstaan waar 
melanocyten aanwezig zijn. Deze tumoren kunnen zowel goedaardig (in de huid 
bijvoorbeeld nevus oftewel moedervlek) als kwaadaardig (melanoom) zijn. De diverse 
typen melanocytaire tumoren verschillen wat betreft klinisch en histopathologisch 
beeld, onderliggende genetische veranderingen en biologisch gedrag. 
De afgelopen jaren is de kennis over de onderliggende genetische veranderingen bij 
de meest voorkomende nevi en melanomen van de huid enorm toegenomen. Veel 
minder is bekend over de genetische veranderingen in de niet in de huid gelokaliseerde 
melanocytaire tumoren en de minder vaak voorkomende typen melanocytaire 
tumoren van de huid. Het doel van het onderzoek beschreven in dit proefschrift was 
om meer te weten te komen over de genetische veranderingen in een aantal zeldzame 
typen melanocytaire tumoren, in het bijzonder Spitz tumoren in de huid, primaire 
leptomeningeale melanocytaire tumoren, melanomen in het oog en melanomen van 
de vrouwelijke urinewegen en geslachtsorganen. Het streven is om op basis van de 
opgedane kennis het begrip over de moleculaire ontstaanswijze (pathogenese) te 
doen toenemen, de diagnostiek te verbeteren en om aangrijpingspunten te vinden 
voor meer effectieve therapie. 
In hoofdstuk 2 wordt een overzicht gegeven van de huidige kennis van de genetische 
veranderingen in verschillende typen melanocytaire tumoren en van de toegevoegde 
waarde van moleculair onderzoek in de diagnostiek van deze tumoren.
In hoofdstuk 3 worden de HRAS-gemuteerde Spitz tumoren beschreven. Spitz 
tumoren zijn zeldzame melanocytaire huidtumoren die voornamelijk voorkomen bij 
kinderen en jongvolwassenen, maar soms ook bij ouderen. De diagnostiek van deze 
Spitz tumoren leidt vaak tot diagnostische dilemma’s. Dit kan leiden tot onderdiagnose 
als een “gewone” nevus, overdiagnose als een melanoom of tot een onzekere 
diagnose van atypische spitzoide tumor met onvoorspelbaar biologisch gedrag. 
Op dit moment zijn drie subtypen Spitz tumoren beschreven met specifieke 
genetische veranderingen waaronder de HRAS-gemuteerde Spitz tumoren. Deze 
hebben een typisch histologisch beeld dat wordt gekenmerkt door een dermale 
ligging, desmoplasie en een infiltratieve basis en ze zijn relatief celarm. Het risico op 
overdiagnose als een melanoom is vrij groot, met name als er celdelingen aanwezig 
zijn en als de patiënt een volwassene is. In onze serie was 29% van de gevallen in 
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eerste instantie gediagnosticeerd als een melanoom of stond melanoom in de 
differentiaal diagnose. Onderscheid met een melanoom is klinisch relevant vanwege 
het grote verschil in prognose. Uit meerdere studies is namelijk gebleken dat HRAS 
gemuteerde Spitz tumoren een goede prognose hebben. Ook in onze serie heeft 
geen van de patiënten een recidief of metastasen ontwikkeld (gemiddelde en mediane 
follow-up in onze serie 10.5 jaar).
Nauwkeurige histopathologische beoordeling is de gouden standaard in de diagnostiek 
van Spitz tumoren. In het geval van niet goed te classificeren atypische Spitz tumoren 
kan aanvullende moleculaire diagnostiek naar mutaties in de oncogenen HRAS, 
BRAF en NRAS behulpzaam zijn. HRAS mutaties worden vrijwel nooit gevonden in 
melanomen van de huid (<1%) en het vinden van deze mutatie in een melanocytaire 
tumor van de huid met een beeld (ook) passend bij een Spitz tumor duidt op een 
gunstig biologisch gedrag. BRAF en NRAS  zijn daarentegen vaak gemuteerd in 
melanomen van de huid (zie hoofdstuk 2); een mutatie in een van deze genen in een 
atypische Spitz tumor pleit derhalve voor de diagnose melanoom.
In hoofdstuk 4 worden de resultaten getoond van genetische analyse van 25 primaire 
uveale melanomen. Uveale melanomen zijn melanomen uitgaand van de melanocyten 
in choroidea, corpus ciliare of iris van het oog. Ons onderzoek bevestigt dat uveale 
melanomen frequent GNAQ of GNA11 mutaties hebben en geen mutaties in BRAF of 
NRAS (dit in tegenstelling tot melanomen van de huid) en dat monosomie van 
chromosoom 3 een belangrijke, prognostisch ongunstige factor is. Onze bevindingen 
suggereren dat chromothripsis (een extreme vorm van structurele verandering van 
chromosomen waarbij één of meerdere chromosomen uiteen vallen om vervolgens 
schijnbaar vrij willekeurig weer ‘in elkaar gezet’ te worden) en toename van chromosoom 
8q een rol spelen bij het ontstaan van uveale melanomen zonder een GNAQ of GNA11 
mutatie en dat verlies van chromosoom 2p geassocieerd is met gemetastaseerde 
ziekte in het geval van disomie van chromosoom 3. 
Het onderzoek beschreven in hoofdstuk 5 toont aan dat primaire leptomeningeale 
melanocytaire tumoren bij volwassenen geen mutaties in BRAF, HRAS en NRAS 
hebben zoals melanocytaire tumoren van de huid, maar dikwijls mutaties in GNAQ en 
GNA11 zoals uveale melanomen. Bovendien blijken de genetische veranderingen in 
primaire leptomeningeale melanocytaire tumoren en uveale melanomen nog meer 
overeenkomsten te vertonen, met name op het gebied van veranderingen in aantal 
kopieën van (delen van) chromosomen (copy number variations). Verder onderzoek 
zal moeten uitwijzen of deze genetische veranderingen in primaire leptomeningeale 
melanocytaire tumoren dezelfde prognostische betekenis hebben als in uveale 
melanomen.
Hoofdstuk 6 laat zien dat GNAQ en GNA11 mutatie analyse kan bijdragen in de soms 
lastige differentiaaldiagnose van gepigmenteerde tumoren in het centraal zenuw -
stelsel. Naast strikte morfologische criteria helpt mutatie analyse om een onderscheid 
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te maken tussen onder andere een primaire leptomeningeale melanocytaire tumor 
en een melanotisch schwannoom hetgeen klinische consequenties heeft. 
In hoofdstuk 7 wordt de genetische analyse beschreven van melanocytaire tumoren 
van de huid en leptomeningen in vijf patiënten met neurocutane melanosis. Dit is een 
hele zeldzame, aangeboren aandoening die wordt gekenmerkt door een combinatie 
van grote moedervlekken en abnormale aggregaties van melanocyten in het centrale 
zenuwstelsel. Bij een groot deel van deze patiënten ontstaan in de loop van het leven 
(meestal vroeg) leptomeningeale melanocytaire tumoren. In tegenstelling tot bij 
volwassenen die meestal een GNAQ of GNA11 mutatie in de tumor hebben (zie 
hoofdstuk 5), hebben de primaire leptomeningeale melanocytaire tumoren en ook de 
grote moedervlekken bij kinderen vaak NRAS mutaties. Ons onderzoek toont aan dat 
in de leptomeningeale melanocytaire lesies daarnaast vaak meerdere, relatief grote 
chromosomale afwijkingen aanwezig zijn, dit laatste in tegenstelling tot in de 
moedervlekken van dezelfde patiënten. Wel worden in de grote moedervlekken 
bepaalde andere chromosomale afwijkingen gevonden die mogelijk gebruikt kunnen 
worden als indicator voor neurocutane melanonosis en zo kunnen helpen de 
diagnose neurocutane melanosis te stellen. Op dit moment is namelijk nog niet goed 
genoeg te voorspellen of een kind met een grote moedervlek ook neurocutane 
melanosis heeft. 
Onze studie naar de typen mutaties in melanomen van de vrouwelijke geslachtsor-
ganen en urinewegen wordt beschreven in hoofdstuk 8. Melanomen van de 
vrouwelijke geslachtsorganen en urinewegen behoren tot de groep van de mucosale 
melanomen oftewel de slijmvliesmelanomen. In mucosale melanomen zijn met name 
mutaties in NRAS en KIT aanwezig en slechts zelden BRAF mutaties, dit in tegenstelling 
tot de huidmelanomen. Vergeleken met andere studies werden in onze studie relatief 
weinig KIT mutaties en relatief veel NRAS mutaties in deze slijmvliesmelanomen 
gevonden. Mogelijk heeft de specifieke anatomische lokalisatie (bijvoorbeeld vulva 
versus vagina) invloed op het type mutatie. Het type mutatie is relevant bij de keuze 
voor aanvullende gerichte therapie bij gemetastaseerde ziekte.
De laatste jaren is de kennis van de genetische afwijkingen bij melanocytaire huid - 
tumoren enorm toegenomen. Dit heeft geleid tot de ontwikkeling van therapieën 
gericht op de moleculaire afwijking of het gevolg daarvan. Hiermee wordt in een deel 
van de patiënten indrukwekkend effect bereikt bij de behandeling van gemetastaseerd 
huidmelanoom. Daarnaast zijn de behandelopties voor gemetastaseerd huidmelanoom 
sterk toegenomen door de toepassing van immuuntherapie. In tegenstelling hiermee 
is de kennis van de onderliggende genetische afwijkingen bij de zeldzamere typen 
melanocytaire tumoren relatief beperkt en zijn er vaak weinig of geen behandelopties 
bij gemetastaseerde ziekte. 
Het onderzoek beschreven in dit proefschrift richtte zich op het vergroten van de 
kennis over de genetische veranderingen in enkele van de meer zeldzame typen 
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melanocytaire tumoren. De kennis die is opgedaan met dit onderzoek heeft geleid tot 
verbetering in de diagnostiek en tot verdieping van de kennis over de pathogenese 
van deze tumoren. Daarmee biedt dit onderzoek enkele aangrijpingspunten voor 
meer gerichte therapie en voor vervolgstudies aan deze relatief zeldzame categorieën 
van melanocytaire tumoren. 
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